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Abstract
Controlled drug delivery via biodegradable polymeric carriers is acknowledged as a
means to deliver drugs at desired rates to the target sites in the human body with
reduced drug toxicity and longer drug half lives. Although a few polymers have federal
drug agency (FDA) approval for such applications, their use is limited as various drugs
have individual properties and require different polymeric carriers for optimal
encapsulation and release. The aim of the project was to develop a versatile polymeric
system with adaptable properties which can be readily tuned to the characteristics of the
drug for better encapsulation and improved control over the drug release.
Poly(glycerol adipate) (PGA) and poly(glycerol adipate-co-pentadecalactone) (PGA-co-
PDL) were synthesised via enzyme catalysed esterification, using glycerol, divinyl
adipate and co-pentadecalactone as monomers. The evaluation of these polymers for
drug delivery applications has previously been reported. In this work incremental
changes were introduced in these polymers to alter their physicochemical properties.
Various reaction parameters were investigated to understand their effects on the
polymer synthesis and a set of reaction conditions were obtained which were applied for
the reproducible synthesis of a polyester library in a good yield at a useful scale of
IOOg.
Functionalised and non-functionalised FDA approved monomeric units were used to
impart different physicochemical properties to the polymers, such as, molecular weight,
hydrophilicity, melting temperature (Tm), glass transition temperature (Tg) and
degradability. It was observed that functionalised monomers such as glycerol, sorbitol
and dithiothreitol altered the polymer properties, such as their physical state at room
temperature, solubility, hydrophilicity, Tm and Tg values. Additionally these
functionalised monomers also provide a site of attachment for post-synthetic
modifications of the polymer backbone. Stearic acid and ibuprofen were successfully
conjugated to the backbone hydroxyl (-OH) groups, altering the hydrophobicity of the
polymer and also considerably slowing the drug release.
The synthesised polymers were formulated into microparticles and evaluated for the
encapsulation of drugs via an oil-in-water (o/w) emulsion solvent evaporation
technique. Four drugs from different therapeutic classes bearing a wide range of
chemistries and properties were encapsulated, namely indomethacin, ibuprofen,
rifampicin and levofloxacin (listed in order of increasing water solubilities). It was
VlII
observed that minor changes in polymer chemistry, such as the incorporation of glycerol
in place of 1,3-propanediol or altering the ratio of monomers, did not show any
significant effect on drug encapsulation and release. However, altering the polymer
properties by using monomers such as triethylene glycol, polyethylene glycol (PEG) or
stearic acid resulted in a considerable improvement in the encapsulation of poorly
water-soluble drugs (ibuprofen, indomethacin) and watersoluble drug (levofloxacin).
However, the rifampicin, failed to be encapsulated in any of the synthesised polymers
via this o/w solvent emulsion technique. The resulting micropartic1esizes ranged from 5
to lOllm, which is within the range required for pulmonary drug delivery.
The developed polymeric system was stable under storage in dry conditions and low
temperatures with a good shelf life (longer than one year), but degraded completely
within six weeks under simulated physiological conditions as required for a degradable
drug delivery system.
The results obtained in this study were compared with the most commonly used FDA
approved polymer, poly(lactic acid-co-glycolic acid) (PLGA) and it was observed that
most polymers in the library exhibited comparable encapsulation efficiency but with
better control over the release of the drugs from micropartic1es. Depending on the
polymer and drug chemistry, the drug release profiles showed an initial burst followed
by steady release.
In conclusion, a biodegradable polyester-based drug delivery system was developed,
which is capable of controlled delivery of three of the drugs tested. Hence, it is
potentially a good alternative to the currently available FDA approved polymers.
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General Introduction
1.0 BACKGROUND
In pharmaceutical and scientific research, the development of drug delivery systems is
an area of interest for researchers around the globe. The reason behind this growing
interest lies in the fact that by the end of the last century, the use of antibiotics and other
drugs increased several fold, which resulted in an increase in various unwanted side
effects such as drug toxicity and the development of drug-resistance. To meet these
challenges researchers put more effort into the development of either novel drugs or
new drug delivery strategies. There are multiple extensive stages in the development of
a new drug molecule, including the clinical trials requirements for the legal or FDA
approval before marketing (Carpenter 2002). Hence, this process suffers the drawback
of being very tedious and expensive, and so does not always meet the rising challenges
and issues described above. Therefore, researchers have focused on the development of
alternative drug delivery strategies to overcome issues such as drug toxicity by
controlling the release of drugs in the human body. Such approaches involve the design,
synthesis and application of materials that deliver the drugs to a targeted site in a safe
and efficient manner. This made drug delivery research a broader scientific area,
covering various stages of drug delivery, such as the synthesis of new materials,
encapsulation and loading of therapeutic agents, targeted delivery and controlled drug
release as well as, degradation and elimination of drug carriers from the human body.
1.1 DRUG DELIVERY
Drug delivery covers a broad and very significant area of research. It is defined as a
method or process to administer drugs or pharmaceutical compounds in humans or
animals to achieve a therapeutic effect. The most common routes of administration of
therapeutic agents are oral, intravenous, intramuscular, inhalation and spinal. The main
advantages of delivering drugs via these routes are to use a simple method to achieve
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the targeted level of therapeutic agent in the subject's body and to get a fast response.
Although these methods have been used in practice for a long time, there are some
problems associated with these approaches, such as:
• Reduced efficacy of drugs because of partial degradation or shorter half lives
• Drug induced toxicity (by administration of higher doses of drug to overcome
the drug loses in the human body)
• Increased costs and patient compliance issues
To solve the inherent disadvantages of classical drug delivery methods, targeted and
controlled drug delivery approaches were developed and adapted with many benefits
(Langer 1990), such as:
• Targeted delivery of the drug in the amount required to prevent overdosing and
to diminish the drug toxicity and increase the drug efficacy
• Delivery of drugs without in vivo degradation
• Sustained release of a drug to keep a minimum therapeuticlblood drug level for
longer durations without the need for repeated administrations
• Control of the release rates for reduced dosing frequency and increased patient
compliance
Controlled drug delivery was first introduced in 1949, when the Wurster technique was
developed for the coating of edible tablets (Wurster 1957). Further advances were then
made by the development of new methods, such as coacervation (liquid encapsulation
technique) (De Jong 1949), microencapsulation (Veis & Aranyi 1960) and
pharmaceutical implants (Lilla & Vistnes 1976). Drug targeting was developed in the
1980s by the successful development of transdermal patches and this lead to the
development of targeted (site specific) delivery of drugs in the 1990s. Out of all these
techniques, microencapsulation received the most recognition and application in the
3
pharmaceutical industry. Nowadays more than 65% of all current drugs are delivered
using some form of micro-encapsulation (Whateley 1992).
Polymeric drug encapsulation or entrapment works by surrounding or suspending the
drug molecules in a polymer matrix, and the resulting particles are known as core-shell
structures where the core consists of the drug and the shell is made up of polymer
(Figure 1.1). This way the polymeric shell interacts with the surrounding physiological
environment, while preventing unnecessary exposure of the drug.
-0\---- Polymeric Shell
~_-+- Core - (drug)
Figure 1.1: Schematic of a drug loaded microparticie
Different types of polymers can be used as the matrix for drug encapsulation and
entrapment in micro/nanopartic1es but biodegradable polymers are generally preferred
for such applications.
1.1.1 Polymeric drug delivery
The use of biodegradable polymers in drug delivery applications is advantageous
because of their biocompatibility, biodegradability and non-toxicity (Jain 2000). One of
the world's first successful, commercial polymer-based controlled drug delivery devices
was Ocusert® for the treatment of glaucoma. Ocusert® delivers pilocarpine
continuously for 1 week with less side effects than the directly administered drug
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(Armaly & Rao 1973). In addition, the anticancer agent doxorubicin was successfully
delivered using N-(2-hydroxypropyl)methacrylamide polymer, resulting in reduced
cardiac toxicity and side effects such as alopecia and nausea, by altering its
pharmacokinetics (Zheng et al ; Patil et al 1991;Kline et al 1998).
Applications of polymeric drug delivery systems are not limited to small drug
molecules; tetracycline was incorporated into ethylene-vinyl acetate copolymer and
other different polymers for the treatment of periodontal disease (Kenawy et al 2002).
Successful applications of these polymer-based drug delivery systems opened the door
for researchers to investigate the delivery of a range of drugs for the treatment of more
complicated diseases, such as bethanecol for Alzheimer's disease, diphosphonates to
prevent heart valve calcification, dopamine and bromocriptine for the treatment of
Parkinson's disease and nitrosoureas for the treatment of brain tumours (Levy et al
1985).
Many researchers used similar strategies for the delivery of larger and more complicated
molecules such as proteins. Initially it was thought that very large molecules could not
diffuse out of the polymeric system in a controlled fashion but different animal studies
showed that proteins such as insulin (Hu et al 2006) and peptides can be delivered via
polymers. The first successful demonstration of this principal was the FDA approval of
the Lupron Depot'", This is a poly lactic acid-co-glycolic acid (PLGA) based system for
the delivery of leuprolide acetate to treat prostate cancer (Farokhzad & Langer 2006).
Applications of these polymers became more widespread and reached the extent where
they were used for the delivery of lysozyme (Chang-Moon Lee 2005), genes (Bivas-
Benita et al 2004; Convertine et al 2009), DNA (Bivas-Benita et al 2004; Bilati et al
2005), vaccines and antigens (Kirby et al 2008). Hepatitis B surface antigens were also
delivered using PLGA (Carpenter 2002). This approach was further exploited by
Hershfield et al (1993) to reduce the immunogenic response to certain therapeutic
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enzymes by the attachment of polyethylene glycol (PEG) to the enzymes, for example,
PEG-uricase, PEG-asparaginase and PEG-adenosine deaminase were all prepared.
Some polymers, such as amphiphilic polymers, respond to different physiological
signals such as temperature or pH. Hence, these materials received attention for drug
encapsulation or release upon an external trigger, which led to improved targeting and
controlled delivery of therapeutics (Schmaljohann 2006).
In the last decade, researchers around the globe have attempted the controlled delivery
of various drugs, such as ibuprofen, flurbiprofen, c1oricromene, diclofenac diethyl
ammonium, piroxicam, methylprednisolone, cyclosporine A, orzolamide, pilocarpine,
metipronolol, amikacin sulphate, betaxolol chlorohydrate, progesterone, carteolol,
hydrocortisone, ganciclovir, gatifloxacin, acyclovir and betamethasone phosphate
(Nagarwal et al). Drug molecules have a wide range of physicochemical properties,
such as water solubility, hydrophilicity, molecular weight, molecular size and charge.
Therefore, depending on the application, their encapsulation in a polymer matrix
requires the use of different polymers and various specialised techniques to control the
morphology and properties of the resulting microparticles.
1.1.2 Formulation and encapsulation of micro particles
The advantage of using microparticles for the targeted delivery of therapeutics includes
their ability to reduce drug diffusion from the targeted site. For example, the controlled
release of insulin (Liu et al 2007) and protein delivery for bone growth (Kempen et al
2008). Protecting the sensitive drug substances from the external environment results in
increased halflives of the drug molecules. It is well established that for such
applications microparticles of sizes ranging from 10-200Jlm are suitable (Anderson &
Shive 1997) because smaller particles would either diffuse away from the site or can be
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taken away from the targeted site by phagocytes. The precise properties of polymeric
microparticles are usually modified according to the nature of their application. This can
be achieved by varying certain variables, such as the:
1. Well-defined core-shell architecture: This allows the encapsulation of both freely
and poorly water soluble drugs and therapeutic agents that are otherwise difficult to
administer to the body. The polymeric matrix provides colloidal stability to the
whole microparticle structure.
2. Size range « 150nm or 1-200J...lm):Depending upon the application the particles can
be formulated in various size ranges. For example for intravenous delivery, particles
of about 200nm are formulated to move freely in blood vessels, while for pulmonary
delivery particles of sizes greater than IOf.Lmare used.
3. Surface area: By controlling the size and morphology of microparticles the surface
area can be changed which helps to control the rate of drug release.
4. Targeting: This is also known as the enhanced retention and permeation (EPR)
effect which provides some level of selectivity in drug targeting from the size and
surface properties (charges) of particles.
1.1.3 Techniques for microparticle preparation
Different techniques can be employed for the encapsulation of therapeutics into
biomaterials depending on the nature of the drug and polymer. Table 1.1 summarises
the most commonly employed techniques for microencapsulation which can be used
depending on the type of polymer, physical state of the matrix and the desired particle
sizes. These techniques can be used for encapsulation of either liquid or solid
therapeutic agents in the microparticle cores.
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Table 1.1
Common techniques for the encapsulation of drugs in polymeric matrices (Gosh 2006)
Physico-mechanical processes are commonly used commercially because of the lower
cost and less time consuming factors. For example, spray drying (Figure 1.2a) is already
being used for fragrances, oils and flavours while fluid bed coating is the most common
technique in the pharmaceutical industry.
Solvent evaporation or solvent emulsion methods are extensively used, along with other
physicochemical methods, in drug encapsulation and microparticulate formation
studies. Based on the application, the solubility of the drugs and the core material, the
solvent evaporation method can be further categorised into the following procedures:
a) Oil-in-water emulsion (o/w)
b) Water-in-oil-in-water emulsion (w/o/w)
c) Water-in-oil-in-oil emulsion (w/%)
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g) Salting-out
d) Interfacial disposition
e) Solvent enhanced dispersion
f) Nanoprecipitation
The most common emulsion system used for the encapsulation of hydrophobic drugs is
oil-in-water (o/w) (Figure 1.2b), with the micro spheres being produced by the emulsion
solvent evaporation method. Various surfactants, such as Eudragit'" and PVA, can be
used for improved encapsulation and to stabilise the core-shell architecture. Drug
loading is achieved by dissolving the polymer and the drug in an organic solvent
followed by subsequent dilution in water and then evaporation of the solvent.
Hot air Cnntinous phase
(controlling surfactant)
•• -
o o oo 0
o
Drying chamb er .
o 0
o 0 o
• •••
Microp article
Core particle
a) b)
Dispersed phase (centaining
polymer and drng)
Figure 1.2: Schematic illustration of a) spray drying technique b) oil-in-water emulsion
solvent technique.
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Solvent emulsion is not limited to the encapsulation of small drug molecules, but can
also be used for enzyme and protein encapsulation inmicroparticles. Hydrophilic drugs,
proteins and enzymes, being more soluble in water, cannot be effectively encapsulated
in polymers via the o/w solvent-emulsion method. To overcome this problem, a double
emulsion system, w/o/w solvent-emulsion or spray-drying technique (Figure 1.2a) is
usually used.
Factors effecting particle morphology and encapsulation
There are a number of formulation parameters which can affect morphology (size, shape,
surface texture) and drug encapsulation in microparticles. These parameters do not only
include experimental parameters such as mixing speed, type of solvent and
polymer/drug concentration but also cover the effect of polymer/drug chemistry
(molecular weight, hydrophilicity) and choice of surfactant. All of these factors playa
pivotal role in determining the particle morphology and drug encapsulation efficiency.
1.1.4 Drug release
After administration to the human body, encapsulated drugs are released by two
common mechanisms; diffusion and/or surface erosion (Figure 1.3). Diffusion is the
early mechanism, responsible for the release of drug from the surface or core of the
particle. Once the drug molecules have released from the particle through channels or
pores, allowing water to penetrate, the subsequent hydrolysis or degradation of the
polymer matrix causing surface erosion occurs. This surface erosion is a slower process
and results in further release of the drug at a steady rate over a longer period. To control
the release of the drug various physical and chemical properties of both the drug and
polymer can be considered; for example their hydrophobic character, lipophilicity,
molecular weight, size, pharmacokinetics and biodistribution.
10
Diffusion
Surface erosion
Drug loaded microparticle
Figure 1.3: Schematic mechanism of drug release from microparticles.
FDA approved polymers, poly lactic acid (PLA) and poly lactic-eo-glycolic acid
(PLGA), are well studied and commonly used in microencapsulation as both polymers
are biocompatible and degrade quite easily and quickly (Jain 2000). Another FDA-
approved biodegradable polymer used for drug delivery applications IS
polycaprolactone (PCL), which is quite stable and has comparatively slower
degradation rates (Sinha et al 2004). Hence this polymer is also used in controlled
release drug delivery applications. Depending on drug chemistry, the drug loading is
often low for these FDA-approved polymers (Govender et al 1999). Apart from the low
drug loading and encapsulation efficiencies, control over the release of drugs from these
polymers is not consistent, as drug release occurs rapidly (known as burst release) with
PLA and PLGA while it is much slower with PCL.
A major challenge for researchers in this area is to control the burst release of drugs
from microparticles. The drug release from microparticles depends on multiple factors
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such as polymer molecular weight, hydrophilicity, particle size and surface properties in
addition to the "additives" incorporated during particle formulation. The chemistry of
the polymer is a most important tool to control the properties of microparticles. This is
why efforts to develop a better drug delivery system are concentrated on the polymer
chemistry aspect.
1.1.5 Recent improvements in polymeric drug delivery systems
The properties of polymers can be altered by changing the monomeric composition,
molecular weight and via post-polymerisation alterations to the polymer backbone
(Pasut & Veronese 2007; Li & Wallace 2008; Noga et al 2008; Kobayashi 2009;
Kobayashi 2010). Although FDA approved polyesters have proven useful due to their
biodegradability and drug loading, their applications are limited because these polymers
lack free functional groups for post-synthetic modifications (Pasut & Veronese 2007).
If the physicochemical properties of the polymers could be tuned for different drugs to
encourage better drug-polymer interactions, this would result in an increase in the range
of possible applications. Control over drug delivery rates and prolonged bioavailability
in the human body can provide added advantages in terms of improved patient
compliance, reduced frequency of drug administration, improved consistency of blood
drug levels and increased safety of high-potency drugs (Lordi 1986).
Some synthetic polymers are being used in the pharmaceutical industry for packaging,
tablet coatings, tablet/syrup formulations as well as for drug delivery (Grover et al
2000). Synthetic polymers are ideal and well established tools for drug delivery because
of their versatile composition and compatibility with drugs. The main requirement for
polymeric materials for drug delivery applications is that they improve efficacy, are
biocompatible, non-toxic and non-immunogenic, result in higher drug loading, slower
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drug release and most importantly are able to degrade (biodegradable) and/or are
excreted completely by the body without being deposited at any site within the body.
Polymeric materials bearing these properties have an improved potential for controlled
and targeted delivery of drugs either in the form of microspheres/nanoparticles (Jain
2000; Jhunjhunwala et al 2009), matrices or membranes (Du et al) along with other
formulations that can be administered via different routes including parenteral,
implantation, pulmonary, oral, inserts and transdermal (Brannon-Peppas 1995; Youn et
aI2008).
Some drug formulations based on a limited number of polymeric carriers have received
FDA approval while others are still in various stages of clinical trials (Middleton &
Tipton 2000; Guerin et al 2004; Distel et al 2005). Basic research into the development
of novel polymers and techniques for the development of drug delivery systems is
ongoing and aimed at the synthesis of novel biodegradable polymers for improved drug
delivery.
1.2 BIODEGRADABLE POLYMERS
Recognition of the important role and use of biodegradable polymers in drug delivery
applications has influenced the successful design and synthesis of a range of novel
polymeric materials (Greenwald et al 2003; Farokhzad & Langer 2006; Li & Wallace
2008). Some of these are FDA-approved for drug delivery applications and have been
successfully marketed (Table 1.2).
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Table 1.2
Some pharmaceutical products based on biodegradable polymers marketed in Europe
& USA
Commercial product Polymer Drug Manufacturer
Trelstar™ Depot PLGA Triptorelin Pfizer
Decapeptyl" SR PLAorPLGA Triptorelin Ipsen- Beaufour
Decapeptyl'" PLGA Triptorelin Ferring
Suprecur" MP PLGA Buserelin Aventis
Nutropin Depot" PLGA Growth hormone Genentech
Sandostatin'" LAR PLGA-glucose Octreotide Novartis
Somatuline" LA PLGA Lancreotide Ipsen-Beaufour
Arestin" PLGA Minocycline OraPharma
FDA approval of polymer-based drug delivery systems opened the door for further
research into the design and synthesis of new polymeric materials for the development
of novel drug delivery systems (Kobayashi 2009). More recently novel biodegradable
polymers have been synthesised and evaluated as carriers for improved controlled
delivery of drugs (Dutt & Khuller 2001; Jhunjhunwala et al 2009) or as modes of
targeted delivery of genes (Bivas-Benita et al 2004) or proteins/enzymes (Dutt &
Khuller 2001; Otsuka et al 2003).
There are a number of classes of polymer, currently in use for drug delivery
applications, including polyesters, polycarbonates, polyurethane, polyethylene and
poly(methyl methacrylate). However, polyesters have received the most attention for
drug delivery applications because of their versatility in composition, architecture,
compatibility and degradability (Kobayashi 2009; Kobayashi 2010).
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1.2.1 Biodegradable polyesters
Among the different classes of polymers, polyesters are widely studied and used as
biodegradable drug carriers for controlled drug delivery applications. All polymers
approved by FDA are polyesters, such as PLA, PCl, and PLGA, and these are the most
commonly studied and used polymers for drug delivery applications. Polyesters are
versatile biomedical materials used for a range of medical applications such as surgical
sutures (Wang et al 2002), absorbable bone plates (Eppley & Reilly 1997), artificial
skin (Schmolka 1972), tissue scaffolds (Agrawal & Ray 2001) and carriers of drugs,
such as antitumor drugs, antibiotics and hormones (Dorati et al 2007) (Table 1.2).Most
of the polyester-based biomaterials currently in use are linear and non-functional, such
as peL, PLA and PLGA (Figure 1.4).
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Figure 1.4: Chemical structure of the FDA approved biodegradable polyester, PLGA
poly{lacfic acid-eo-glycolic acid).
The incorporation of monomers bearing active functional groups such as carboxylic
acids, alcohols, amides and other reactive functionalities can affect existing properties
or impart new properties to polyesters including altered biodegradability (Bruggeman et
al 2008), increased water solubility (Sumerlin et al 2001), as well as providing sites for
further reactions to give hyper-branched polymers (HBPs) (Saha & Ramakrishnan
2009). These properties are useful to widen the applications of polyester-based drug
delivery systems, by improving drug loading of hydrophobic and/or hydrophilic drugs,
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increasing the rate of degradation and altering drug-release profiles (Anderson & Shive
1997; Bivas-Benita et a12004; Doan & Olivier 2009).
In addition, by incorporating functional monomers such as polyols into aliphatic
polyesters, functional linear- or hyper-branched polymers can be prepared. These
polymers are useful for specific biological activities and can be made responsive to
environmental stimuli (Wang et al 2002) by altering the polymer's physicochemical
properties.
Functionalities in polymers can be introduced by either the addition of free functional
groups on the polymer backbone or by altering the type of linkage between monomeric
units. For example, the effect of adding functionality into a polymer backbone was
observed when polyoxoesters were compared to the corresponding polythioesters.
Polythioesters (Figure 1.5) have very different properties compared to their
corresponding oxoesters. For example, polythioesters have melting points that are 30-
70°C higher compared to their corresponding oxoesters but have similar solubility in
organic solvents (Buhrer & Elias 1970). This approach can be successfully utilised to
control the properties of the polymeric materials for improved drug delivery.
•
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Figure 1.5: Chemical structure of an example of a polythioester, Poly(3-
hydroxybutyrate-co-3-mercaptopropionate) poly(3HB-co-3MP).
*:polymer chain consisting of same repeating units
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1.2.2 Polyester synthesis
For the past two decades, synthetic chemists have been exploring efficient pathways for
producing aliphatic polyesters with functional backbone groups (Bhattacharyya et al
1998; Kumar et al 2002; Uyama & Kobayashi 2002; Noga et al 2008).
Conventional synthesis of linear polyesters with active backbone functionalities often
involves tedious and difficult multi-step reactions, which may result in the formation of
polymer networks. Additionally, the chemical synthesis of biodegradable polymers
commonly involves the use of heavy metal-based catalysts such as the oxides of zinc
and tin which have been used in the preparation of PLA (Distel et al 2005; Chandure et
al 2008). If the resulting materials are to be used for biomedical applications, complex
purification steps usually are necessary to remove any contaminant metal catalysts from
the final product (Hyon et al 1997). Strongly acidic catalysts used to catalyse
condensation reactions tend to promote discoloration and hydrolysis of the reaction
products can also occur if the catalyst is not neutralised and separated from the product
(Chaudhary et al 1997).
To overcome the challenges and problems of chemical synthesis, a new biocatalytic
approach was developed in which metal-based catalysts were replaced by enzymes.
Biocatalysis is an alternative approach to the synthesis of both functionalised and non-
functionalised linear polyesters. The main advantages of using enzymes as catalysts
over conventional approaches are their stereospecificity (enantioselectivity and
regioselectivity) and requirement of mild reaction conditions (such as low temperatures
and shorter reaction times).
Enzymatic polymerisation often provides an environmentally favourable process, where
the starting materials and products are within the natural material cycle (Uyama &
Kobayashi 2002). So far, in vitro synthesis of not only biopolymers but also non-natural
synthetic polymers through enzymatic catalysis has been achieved (Kobayashi et al
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1997 ; Uyama & Kobayashi 2002). Additionally, enzymatic polymer synthesis is used
for the synthesis of higher molecular weight materials with lower dispersity (Taylor
1997).
Researchers have exploited various classes of enzymes for biotransformation, including,
oxidoreductases, transferases, hydrolases, ligases, lyases and isomerases. Notably, out
of the above six classes of enzymes, only the first three have shown good potential for
polymerisation (Kobayashi 2010). Lipases are hydrolases, and have shown very high
potential for polyester synthesis due to its ability to polymerise a large number of
substrates (including lactones, esters, carbonates, anhydrides and alcohols) compared to
other enzymes (Kobayashi et al 2006).
Effect of various reaction parameters on polymerisation
The intrinsic specificity, stereo-selectivity (Margolin et al 1987) and regioselectivity
(Cesti et al 1985; Therisod & Klibanov 1986; Rich et al 1995; Danieli et al 1997) of
enzymes depend on different reaction parameters (Sakurai et al 1988) such as substrate,
lipase type, enzyme preparation, reaction medium, time and temperature (Hu et al
2006), hence, affecting the overall quality of the resultant polymer. Alterations in the
reaction parameters can lead to an overall reduction in the polymerisation rate, the
polymer quality (molecular weight) (Chaudhary et al 1997) and polymer degradation.
Lipase Catalysis
Lipases are good catalysts for the esterification of low molecular mass substrates under
mild reaction conditions (Therisod & Klibanov 1986) and have also been extensively
investigated for the preparation of chiral compounds (Klibanov 1990; Santaniello et al
1992). Lipase derived from Candida antarctica has high catalytic activity towards the
ring opening polymerisation of lactones (Uyama et al 1997; Kobayashi et al 1998b;
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Kobayashi et al 1998a), polycondensation of divinyl esters and glycols (Distel et al
2005), diacids and diols (Uyama et al 1999) and polycarbonate synthesis from diethyl
carbonates (Matsumura et al 1999). This lipase is available commercially under the
brand name of Novozyme-435. It is an immobilized preparation of a triacylglycerol
hydrolase derived from C. antarctica fraction B (CAL B). The gene coding for lipase
was transferred from C. antarctica to the host organism Aspergillus oryzae. The enzyme
produced by this host organism is further immobilized onto a macroporous acrylic resin.
The fermentation extract comprises approximately 10% (w/w) of the total weight of the
immobilized resin.
Lipase-catalysed polymerisation provides an environmentally friendly pathway to
polyester synthesis due to the non-toxic nature of the enzyme and the mild reaction
conditions required. Because of the enantioselectivity of lipases, these enzymes are
extensively used for the synthesis of specific optically active isomers. The active sites
of lipases contain serine residues and lipase-catalysed polyesterification reactions
proceed via an acyl-enzyme intermediate (Uyama & Kobayashi 2002) (Figure 1.6). C.
antarctica B lipase showed the highest catalytic activity, accepts a wide range of
substrates (Sivalingam & Madras 2003) and is often preferred over the other enzymes
for vinyl ester transesterification reactions as it is stable in the presence of the
acetaldehyde by-product tautomerised from vinyl-OH (Weber & Faber 1997).
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Figure 1.6: Proposed reaction mechanism for lipase catalysed polymerisation of a
diester and diol (Uyama et al 1995)
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Activated monomers for lipase catalysed esterification
For lipase-catalysed esterification, divinyl carboxylates/esters and glycols were shown
to be effective monomers (Uyama & Kobayashi 1994; Uyama et al 1999; Uyama et a1
2000) as their polycondensation took place under mild conditions to produce polyesters
with molecular weight of higher than 10,000Da. However, polymer formation was not
observed with adipic acid or diethyl adipate under similar reaction conditions (Uyama et
al 2000). The use of divinyl adipate (DVA) as the diester substrate provided an
irreversible system for performing the polytransesterification reaction because the
reaction by-product, vinyl alcohol, rapidly tautomerizes to acetaldehyde, which results
in the continuous shifting of the equilibrium in the forward direction (Chaudhary et al
1997) (Figure 1.7).
Figure 1.7: Lipase catalysed polymerisation of divinyl adipate and propanediol (Uyama
et a11999)
21
The reaction of substrates with free -OH groups such as glycerol, is dependent on the
relative reaction rate of primary and secondary groups and it is well-known that primary
hydroxyls are more reactive (Kline et al 1998). Hence, by using glycerol,
polymerisation takes place only via the terminal primary hydroxyl groups, leaving the
secondary hydroxyl group free on the polymer backbone. This can lead to the synthesis
of functionalised polymers, with altered physicochemical properties, such as
hydrophilicity and solubility as compared to the non-functionalised equivalent (Figure
1.8).
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Figure 1.8: Pendant hydroxyl groups obtained on polymer backbone by esterification of
divinyl adipate with glycerol
Functionalised polymers can be very useful in drug delivery applications either because
of their altered physicochemical properties as compared to non-functionalised
equivalents or by providing a site for post-synthetic modifications of the polymer
backbone, such as the attachment of chemical moieties or drug molecules.
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1.2.3 Functionalised polymers
For the synthesis of functionalised polymers, a number of monomers bearing free
functional groups, such as hydroxyl, amine or carboxylate can be used (Kobayashi &
Uyama 2005). By introducing new monomers into the polymer backbone, not only can
new functional groups be introduced, but also the number of functional groups can be
varied. For example glycerol can be used to introduce one pendant hydroxyl group on
the polymer backbone, but if a sugar is used as a monomer instead of glycerol, it will
introduce a higher number of secondary hydroxyl groups and may also make the
polymer more biocompatible (Kulshrestha et al 2005). Chemically sugars are polyols in
nature and have many free hydroxyl groups, which make polymers more hydrophilic
and water-soluble. In addition, upon degradation some sugar-based polymers may enter
the metabolic pathway without causing a sudden increase in blood sugar levels and also
result in less toxic degradation products (Patil et al 1991; Rich et al 1995; Park et al
2000; Kim et al 2003; Hu et al 2006). Various sugar molecules have been used for
polymer synthesis including xylitol (Bruggeman et al 2008), sorbitol (Fu et al 2003;
Distel et al 2005; Kobayashi 2009), sucrose (Park et al 2001) and a disaccharide (Miura
et al 2004) via chemical and enzymatic routes.
An alternate approach to modify the properties of the polyester backbone is the
introduction of cyclic lactones as monomers by enzyme-catalysed ring-opening
polymerisation.
Ring opening polymerisation
The synthesis of lactone-containing polymers can be achieved chemically or
enzymatically. As the chemical catalytic routes bears the drawbacks of using of toxic
catalysts in multi-step reactions, hence, enzymes are preferred for catalysing single-step
ring-opening polymerisation under mild conditions (Figure 1.9). Lactones can afford the
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polymerisation to homo- (same repeating units) (Figure 1.9) or co-polymers (different
repeating units) (Figure 1.10), hence increasing the usefulness of such monomers
several fold.
Various research groups have reported the ring opening polymerisation of lactones via
chemical catalysis with higher molecular weights and better reaction rates (Chaudhary
et al 1998; Kobayashi 1999, 2009). Nonetheless, enzyme catalysis is developing as an
alternative synthetic route due to the nature of the polymer application and the
advantages it has over the chemical catalysis, as discussed earlier. C. antarctica B
(Novozyme 435) showed the highest catalytic activity for ring opening polymerisations
(Sivalingam & Madras 2003) and is believed to proceed via a similar acyl-enzyme
reaction intermediate as for polyester synthesis (Chaudhary et al 1998; Kobayashi
1999).
Lipase
o
Figure 1.9: Lipase catalysed ring opening polymerisation of lactone to a homopolymer.
The reactivity of lactones of various ring sizes has been extensively studied for lipase
catalysed synthesis of various homo- and copolymers. It was observed that when using
conventional chemical catalysts, the large-sized lactones exhibited lower
polymerizability than smaller ring lactones due to their lower ring strain. However,
using enzymes resulted in the greater polymerisation of large ring lactones compared to
smaller lactones (Chaudhary et al 1998). Another advantage of using alkanoic lactones
as monomers is that varying the ring size can be used to control the polymer's
hydrophobicity - the larger the ring the more hydrophobic the polymer.
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Lipase catalysis is able simultaneously to perform ring-opening and condensation
polymerisation (Figure 1.10) in the same pot, leading to a copolymer. Chemical
synthesis, however, is devoid of such versatility. This property of the lipase-catalysed
synthesis can afford polymers with the same repeating units (homo-polymer) or with
varying monomeric units (copolymers). Polymer properties can therefore be tailored by
using monomers possessing different chemistries and properties.
Figure 1.10: Simultaneous ring opening and condensation polymerisation involving a
lactone to a copolymer (Kobayashi 2009)
An alternate approach to alter the backbone chemistry is to introduce different
functional groups within the polyester backbone, such as replacing the oxygen in
polyoxoesters by sulphur to produce polythioesters.
Potyth ioesters
Higher melting points, lower aqueous solubilities and higher heat stabilities along with
the ability to degrade quickly are important properties which make polythioesters good
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candidates for drug delivery applications as compared to their equivalent polyoxoesters.
For example, polyre-thiocaprolactone) had a 45°C higher melting point than the FDA-
approved corresponding oxoester PCL (Kato et al 2005).
Because a direct reaction of diacids as monomers is not possible for the synthesis of
polythioesters, acid chlorides and phenol esters are usually used (Buhrer & Elias 1970).
The drawbacks with the chemical synthesis of polythioesters are the same as for
oxoesters. During the last 2 decades different chemical approaches have been adapted
for the synthesis of polythioesters including, interfacial polycondensation (Podkoscielny
& Wdowicka 1985), free radical, anionic and cationic ring opening polymerisation
(Sanda et al 1999) and ring opening polycondensation (Kato et al 2005). These are too
complex for the commercial synthesis of these polymers and perhaps this is why these
polymers have not yet been studied for drug delivery applications.
To overcome these synthetic problems, scientists have explored the use of enzymes to
catalyse thioesterification reactions (Weber et al 1999; Weber et al 2006) via the direct
enzyme-catalysed polycondensation of mercaptoalkanoic acids, dithiols and ring-
opening polymerisation of cyclic thioesters (Kato et al 2005, 2006, 2007), which was
not possible by chemical catalysis. Kato and co-workers reported the lipase (C
antarctica) catalysed synthesis of an aliphatic polythioester with a molecular weight of
34 kDa, which had a 20°C higher melting point than the corresponding oxoester (Kato
et aI2005).
As discussed earlier, to be efficient drug carriers polymers are required to bear specific
physical and chemical properties. The most important properties are their
biocompatibilityand lack of immunogenicity. Most of the monomers available do not
yet have FDA approval to be consumed in pharmaceutical products; hence research is
mainly focused on those monomers which have already been used for either
26
pharmaceutical applications or as food components, such as poly( ethylene glycol)
(PEG).
PEG copolymers
PEG, as a monomer, not only makes polymers more hydrophilic, but also is an FDA-
approved polymer for pharmaceutical use. After its first introduction in the 1970s, the
attachment of polyethylene glycol to enzyme molecules (process called as PEGylation)
became a good strategy for modifying enzymes, without affecting activity (Abuchowski
et al 1977). Since then a number of research groups have focussed their work on the
utilisation of PEG in drug delivery systems. PEGylation was initially aimed at the
preparation of drug/protein conjugates with modified pharmacokinetic profiles (Harris
2001; Jeong et al 2008).
Because PEG is a diol, it can be polymerised with diacids or esters into polyesters.
Various research groups have reported PEG copolymerisation with lactones, acids,
esters, dioxane and carbonates (Delgado C 1992; Veronese 2001; He et al 2003; Dong
& Feng 2004; Chang-Moon Lee 2005; Parrish 2005; Veronese & Pasut 2005;
Ghahremankhani et al 2007; Pasut & Veronese 2007; Ganji & Abdekhodaie 2008;
Gong et al 2009; Hu et al 2009). The applications of PEG to alter the chemistry of the
polymers increased several fold by using functionalised PEGs. This gave researchers an
easy route to change polymer properties by exploiting the functional groups for
conjugating, attaching or cross linking with various chemical moieties (Jeong et al
2000; Greenwald et al 2003; Chang-Moon Lee 2005). As PEG has terminal hydroxyl
groups, it can react either by chemical catalysis (Cho et al 1999; Dong & Feng 2004;
Zhou et al 2004), enzyme catalysis (Delgado C 1992; Kumar et a12002; He et al 2003)
or via catalyst-free synthesis (Lin et aI2005), to form a part of a polyester chain.
Many proteins and small drug molecules can easily pass through the kidneys, leading to
shorter half lives or can trigger the immune system which results in the generation of
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neutralising antibodies. PEGylation also gives a promising solution to these problems
(Harris & Chess 2003).
1.2.4 Post-Synthetic modifications in polymers
The presence of free functional groups on the polymer backbone can be used for
grafting or conjugating various chemical moieties to modify the properties of the
polymers, hence widening their applications. Enzymes are not good catalysts for the
modification of polyesters, as they may cause enzymatic degradation of the polymers.
The various chemical approaches available also have the potential to degrade the labile
ester linkages, via hydrolysis or by the use of heavy metal catalysts (Noga et al 2008).
Hence, to overcome this problem, various coupling agents can be used, such as
dimethylaminopyridine (DMAP), dicyclohexylcarbodiimide (DCC), and
diisopropylcarbodiimide (DIC) amongst others (Moore & Stupp 1990). Kolhe and co-
workers attached various chemical groups and drug molecules, such as ibuprofen, onto
polymer pendant hydroxyl groups using DCC (Kolhe et al 2004). This is a good
example of modifying polymers to increase the drug payload. This approach not only
gives improved control over the release of the drug but also helps to increase the
solubility of the drug molecules (Kolhe et al 2004; Namazi et al 2005). Conjugation of
drugs to polymers was first introduced in the 1970s when Ringsdorf (1975) attached a
range of drug molecules onto a water-soluble polymeric carrier. Based on a similar
approach various products have now been developed, such as conjugates of
doxorubicin, camptothecin, cyclodextrin, paclitaxel and galactosamine as summarised
by Li & Wallace (2008). Pasut and Veronese (2007) have also summarised a list of
polymer-drug conjugates which are marketed for clinical trials.
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The different approaches discussed above provide routes to develop biodegradable
polymeric systems bearing broad chemistries which can be used for controlled delivery
of drugs.
1.2.5 Stability and degradation of polymeric drug carrier
Degradability of polymers is another pivotal property for the effective use of these
materials as drug carriers and polymers intended for drug delivery should degrade
completely under physiological conditions. Formulation developers can alter the
polymer chemistry to control the biodegradation rate according to the specific drug
delivery applications. For example, PLGA is rapidly biodegradable, which makes it
useful in vaccine delivery applications (Wang et al 1990).
Biodegradable polyesters usually degrade by the random hydrolysis of the backbone
chain (Kulkarni et al 2007) into diacid and diol units rapidly via "self-catalysis" (Figure
1.11). Some polyesters such as polycaprolactone (PCL) need an external catalyst or an
initiator for degradation, resulting in a relatively slower rate of degradation. Hence, PCL
is mainly used in tissue scaffolds, but also has uses as drug delivery devices which need
very long half lives, for example as sutures marketed under the brand name Monocryl'"
(Bezwada et al 1995).
Synthetic polyesters have an advantage over other polymers because of the potential in
varying their stereochemistry and copolymer ratio, which can allow the degradation rate
of the polymers to be tailored to match the application.
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Figure 1.11: Scheme ofhyd
The degradation behaviour of polymeric particles also has been studied widely in vitro
by either exposing polymeric micro-spheres to an aqueous environment (Schliecker et al
2003; Distel et al 2005; Dorati et al 2007; Fehling et al 2007), different pH buffers
(Fehling et al 2007; Partini & Pantani 2007), high temperatures (thermolysis or
pyrolysis) (Nur et al 2007), UV and daylight (photolysis) (Feller et al 2007) or
enzymatic degradation (Zhao et al 2007). Depending on various chemical properties of
the polymer backbone and the presence/absence of functionalities, polymers degrade to
different extents under these extreme conditions.
Degradation of polyesters is advantageous for certain drug delivery applications;
however this may also result in decreased shelf lives of the materials. The storage of
polymers under different environmental conditions namely temperature, light and
humidity has the potential to alter the physical and chemical properties of the polymers,
leading to a decreased shelf life. Nonetheless, the literature available on the stability and
degradation of polymers under storage/shelf conditions, addressing the natural
degradation pathway and degradation rates during storage is scarce (Gopferich 1996;
Delgado et al 1998).
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1.3 AIMOF THE PROJECT
Few polymers have FDA approval and hence commercial applications. Different drugs
bear different properties hence, the same polymeric carrier will not always be suitable
for the delivery of different types of drugs. Therefore, rather than developing a new
system for each drug, it would be easier to design a system which possesses adaptable
physicochemical properties making it feasible to "tune-up" the polymeric carrier
according to the drug chemistry.
This project aims to develop a library of novel polyesters for potential use in pulmonary
drug delivery and investigate the effect of small incremental changes on the
encapsulation and release of various drugs from microparticles. The strategy to develop
such a system is divided into the following three stages:
a) Polyester Synthesis:
The development of a lipase-catalysed synthetic method is required which can be used
for the synthesis of a library of functionalised polyesters under mild reaction conditions
and shorter reaction durations. Hence, a library of polyesters with varying physical and
chemical properties will be synthesised, characterised and then investigated for
improved encapsulation and slower release of drugs of varying chemistry.
b) Drug encapsulation and release
A detailed exploration of microparticle formulation and encapsulation is required to
understand and improve the drug load of various therapeutic agents into stable
microparticles of desired sizes. One potential advantage of novel polymers would be
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their use for pulmonary drug delivery. The release profile of the drugs from polymeric
entities will supply the rationale for altered polymer chemistry and would feedback into
the polymer synthesis to design polymers having the desired properties.
c) Stability and degradation of polyesters and microparticles
Obtained polyesters should be investigated for their ability to degrade in vitro under the
simulated physiological (pulmonary) environment. Although the polymers are required
to be biodegradable, at the same time they must be stable under normal storage
conditions. Measured stability and degradation profiles of the synthesised polymers will
feedback into polymer synthesis for the development of stable biodegradable polyesters.
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Synthesis and Characterisation of a
Library of Polyesters
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2.0 BACKGROUND
Polymer chemistry is one of the variables which can be altered to develop materials
with the desired physicochemical properties for drug delivery applications.
The presence of active functional groups like carboxylic acids, alcohols, amides and
other reactive functionalities impart properties to polyesters including altered
biodegradability (Oh et al2007) and increased water solubility (Sumerlin et aI2001),
as well as providing sites for further polymerisations or post-synthetic modifications.
Although most polymers have reactive end groups, functionalised polymers can be
obtained by synthesising polymers with functional groups distributed along the
backbone. For example, sugar molecules have a higher number of free -OH groups,
hence many researchers have used these monomers for the synthesis of functional
polymers. Some of the commonly used sugar monomers are xylitol (Bruggeman et al
2008), sorbitol (Uyama et al 2000; Fu et al 2003), sucrose (Park et al 2001) and
disaccharides and these have been reacted via both chemical and enzymatic routes
(Miura et al 2004). Regioselective enzyme catalysis is a useful way of polymerising
monomers bearing varying chemistries.
For enzyme-catalysed esterification, divinyl carboxylates and glycols were shown to
be effective monomers (Uyama & Kobayashi 1994; Uyama et al 1999; Uyama et al
2000) and the polycondensation reaction took place under mild conditions to produce
polyesters with molecular weights greater than 10,000Da, as reported by Kline et al
(1998a) for the synthesis of polyglycerol adipate (PGA). Based on the same strategy
Namekawa et al (2000) reported the synthesis of polyglycerol adipate-co-
pentadecalactone (PGA-co-PDL) by the combined condensation and ring-opening
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polymerisation of diacid, diol and lactone monomers, leading to the synthesis of
lactone-containing polymers in single-step reactions, which would otherwise require
a multi-step chemical reaction (Kumar et al 2000; Namekawa et al 2000; Ceccorulli
et aI2005).
In addition to the ring-opening polymerisation of lactones, diacids, diols, esters and
their derivatives are very good candidates for lipase-catalysed polymerisation
reactions. This makes the application of lipase-catalysed reactions even wider and
polyesters with required properties can be synthesised. For example, polyethylene
glycol (PEG) is a diol that can be polymerised with diacids or esters into polyesters
(Dong & Feng 2004; Ghahremankhani et aI2007). Its presence in the polymer chain
imparts certain characteristics to the polymer, such as improved targeted and
controlled delivery of therapeutics (Otsuka et al 2003). Lipase catalysis has also
shown potential for the synthesis of polythioesters. However, many of these
published studies only demonstrate the successful synthesis of such biomaterials on a
very small scale, providing proof of principal that these materials can be prepared
rather than making them in useful quantities.
Post-synthetic modification of polymers widens the applications of these materials,
as various properties can be altered by conjugating new chemical moieties onto the
polymer backbone. Various coupling agents, such as dimethylaminopyridine
(DMAP), dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide (Moore &
Stupp 1990) can be used for the attachment of molecules to the pendant functional
groups on the polymer backbone.
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Recently, several papers outlined new routes to develop biodegradable polymeric
systems with varying chemistries which have the potential to be used for a broad
range of controlled drug-delivery applications (Kobayashi et al 1998; Kobayashi
1999; Uyama et al 1999; Namekawa et al 2000; Kim & Dordick 2001; Kim et al
2003). However, there is a need for the scaling up of these new polymerisation
reactions to a useful scale to enable the application of these materials to drug
delivery.
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2.1 AIMS OF THE STUDY
The aim of this chapter was to extend the studies of Kallinteri et al (2005) and
Thompson et al (2006) on PGA and PGA-co-PDL and develop a polyester library
with incremental changes in the chemistry of the polymers to obtain materials of
different molecular weight, hydrophilicity and melting temperatures by using
different functionalised and non-functionalised monomers in varying ratios. The
obtained polymers would then be assessed for drug encapsulation and release.
The first objective was to study the effect of various polymerisation reaction
parameters, such as the quantity of enzyme used, solvent type and volume, substrate
selection; monomer feed ratio and reaction duration, on the enzyme-catalysed
polymerisation of divinyl adipate and glycerol and to obtain a good yield of
poly(glycerol adipate) (PGA), of the desired molecular weight (8-10 kDa) in useful
quantity (-10-1 OOg).
Subsequently the optimal reaction conditions were applied to the synthesis of a
library of biodegradable polyesters and polyester-co-lactones for potential use in
colloidal drug delivery systems. Monomer type, ratio of lactone (monomer),
incorporation of PEG units, type of ester linkage (oxoester or thioester) and
increasing the number of pendant -OH functional groups were explored to produce
polymers of varying chemistry and functionality. These were later exploited for post-
synthetic modifications by the attachment of stearic acid and ibuprofen to the
polymer backbone via Dee coupling reactions. The chemical structure and physical
properties of the synthesized polymers were studied via nuclear magnetic resonance
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(NMR), infrared spectroscopy (IR), gel permeation chromatography (GPC),
differential scanning calorimetery (DSC), and contact angle measurements.
2.2 EXPERIMENTAL
2.2.1 Materials
Novozyme 435 (a lipase derived from Candida antarctica and immobilised on an
acrylic macroporous resin) was purchased from Bio Catalytics, USA and stored over
P20S at SoC prior to use. Divinyl adipate (DVA) was purchased from Flurochem,
UK and used as received. Glycerol, pentadecalactone, caprolactone, 1,3-
propanediol, 1,4-butanediol, sorbitol, dithiothreitol, 1,3-propanedithiol,
triethyleneglycol, polyethylene glycol ISOODa (PEG1SOO), methoxy-polyethylene
glycol 2000Da (PEGme2000) and stearic acid were purchased from Sigma-Aldrich,
UK. Ibuprofen was obtained from (BDH). Poly(lactic acid-co-glycolic acid) (PLGA)
was obtained from PURAC Biomaterials, The Netherlands. Tetrahydrofuran (THF),
dichloromethane (DCM), chloroform, methanol (MeOH), dimethylformamide
(DMF) and polystyrene standards were purchased from (Fischer, UK) and deuterated
dimethyl sulphoxide (DMSO-d6) and deuterated chloroform (CDCh) were obtained
from CIL, USA. All glassware was thoroughly dried prior to use.
2.2.2 Polymer synthesis
The effects of different experimental parameters on the synthesis of the simplest
polymer in the library, poly(glycerol adipate) (PGA) were studied. A series of
enzyme-catalysed polymerisation reactions based on those developed by Kobayashi
et al (1999) were carried out adopting standard procedures from Kallinteri et al
(2005) for the lipase-catalysed polycondensation of glycerol and DVA (Table 2.1).
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Table 2.1
Monomers used to synthesise PGA
Monomer Molecular weight (glmol) Structure
Glycerol 92.09 HO~OH
OH
o
Divinyl adipate (OVA) 198.22 o~
2.2.2.1 Synthesis of PGA
OVA (9.9 g, 0.05 mol) and glycerol (4.6 g, 0.05 mol) were added to a clean, dried
three-neck 250 ml round bottom flask, followed by THF (15 ml). The flask was
immersed in a water bath maintained at 50°C, to the level of liquid in the flask and
allowed to equilibrate for a minimum of 10 minutes. A stirring rod fitted with a
Teflon paddle (l5x52 mm, Sigma) was placed in the flask, with the stirrer paddle
held just above the bottom of the flask (approximately 2-3 mm) to limit crushing of
the enzyme support. A mechanical overhead stirrer (Heidolph RZRI stirrer) was
secured over the water bath with the stirring rod held in place with a Quickfit
thermometer adaptor. The system was also fitted with an open top condenser (to
enable release of the acetaldehyde produced as a by-product of the reaction) and the
free open neck of the flask stoppered. To such a set-up, 0.5 g (2.5% w/v) of
Novozyme 435 was added via the available flask neck and the residual resin washed
from the sides of the glassware with an additional 5 ml THF (making the total
volume of THF used 20 ml). Stirring commenced at 2000 rpm (setting 6 on the
Heidolph RZRI stirrer) and the reaction was allowed to proceed for 24 hours.
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After 24 hours stirring was halted. THF was used as the processing solvent (unless
stated otherwise). THF (100 ml) was added to the flask, washing any residual
polymer off the stirring paddle. Additional THF (50 ml) was added if the suspension
was very viscous. The contents of the flask were then vacuum-filtered by standard
Buchner filtration through 2 layers ofGFIA (Whatman) filters to remove the residual
immobilised enzyme and stop any further reaction. The filtrate was poured into a
round bottom flask and the solvent removed via rotary evaporation at 80°C (Laborota
4000, Heidolph Instruments attached to Rotavac plug and pump). The flask was then
heated to 100°C for 30 minutes using a hotplate.
The resultant viscous polymer sample was transferred, without being cooled down,
into a jar and stored overnight in the vacuum oven (60°C) to remove any traces of
solvent, then sealed and stored over silica gel in the refrigerator.
2.2.2.2 Effect of reaction conditions on PGA synthesis
To study the effect of various reaction parameters on the polymer synthesis, a series
of experiments were performed altering some of the reaction conditions of the
standard procedure (2.2.2.1), as summarised in table 2.2.
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Table 2.2
Variation in reaction parameters
Reaction Parameters ChangesN ariations
Heating medium
Stirring mode
Solvent moisture
Solvent volume
Solvent evaporation
Enzyme concentration
Reaction Duration
Water bath, hotplate
Overhead stirrer, magnetic stirrer
Hydrous THF* , anhydrous THF
5, 20, 25, 50 ml
Allowed or restricted
0.34 , 1.34 , 2.5, 3.4 % (w/w)
0- 35 hours
*: Used without drying.
2.2.2.3 Synthesis of the polymer library
A library of novel polymers (list of polymer abbreviations, page xii) with varying
chemistries was synthesised (Table 2.3) using the following general method.
General procedure for the synthesis of a library of polyesters
0.05 Molar equivalents of each monomer were added to a round bottom flask,
followed by THF (25 ml). The flask was immersed in a water bath maintained at
50°C and equipped with a stirrer paddle. The system was also fitted with an open top
condenser. To such a set-up, l g (3.4% w/v) of Novozyme 435 was added. Stirring
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commenced at 2000 rpm and the reaction was allowed to proceed for 24 hours (48
hours for polythioesters).
After 24 hours stirring was halted. THF was used as the processing solvent (unless
stated otherwise). The contents of the flask were then vacuum-filtered by standard
Buchner filtration through 2 layers ofGFIA (Whatman) filters to remove the residual
immobilised enzyme and stop any further reaction. The solvent was removed via
rotary evaporation. The resultant polymer sample was transferred into a jar and
stored overnight in the vacuum oven (60°C) to remove any traces of solvent, then
sealed and stored in refrigerator over silica gel.
Purification/washing of the copolymers
To pre-melted copolymer (10 g) in a round bottom flask, MeOH (100 ml) was added
and the resulting solution was agitated thoroughly to dissolve unreacted monomers
and small molecular weight fragments of polymers. Copolymers insoluble in MeOH
were filtered via vacuum filtration using a Buchner filtration. The obtained product
was air dried and stored in an air tight container in the refrigerator over 3A molecular
sieves until required.
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Table 2.3
Categories of polymers synthesised based on monomeric compositions and chemical
classification
Class and Type of polymer Functionalised* Non-functionalised*
Polyoxoesters Straight chain PGA PPA
PBA
PTEGA
Co-lactone PGA-co-CL PPA-co-CL
PGA-co-PDL PBA-co-CL
PPA-co-POL
PBA-co-POL
PTEGA-co-POL
Polyol PSA-co-POL -
Polythioester Straight chain PDTTA PPTA
Co-lactone POTTA-co-POL PPTA-eo-POL
PEG-copolymers Straight chain PGA-PEG PPA-PEG
PBA-PEG
Co-lactone PGA-co-CL-PEG PPA-co-CL-PEG
PGA-co-POL-PEG PPA-co-POL-PEG
PEGme-copolymers Straight chain PGA-PEGme PPA-PEGme
PBA-PEGme
Co-lactone PGA-co-CL-PEGme PPA-co-CL-PEGme
PGA-co-POL-PEGme PPA-co-PDL-PEGme
*: see list of polymer name abbreviations
2.2.2.4 Polymer processing and purification
To ensure that the products were free from any residual monomers and the
purification procedure was capable of completely removing unreactedlunattached
PEG and small molecular weight fragments, two different purification processes
were compared using a physical mixture of monomer (PEG) and polymer (PGA-co-
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PDL). Two different solvents, MeOH and water, were tested for their purification
abilities via the following procedure.
a) Controlled washing with water:
PGA-co-PDL (13.5 kDa, 0.5 g) was physically mixed with 0.1 g of PEG (1500 Da)
in a 100 ml round bottom flasks. Distilled water (8.0 ml) was added and the contents
of the flask agitated thoroughly to ensure complete dissolution of soluble contents.
This solution was filtered through a 0.8 urn pore size filter (Whatman) to remove the
undissolved polymer. The polymer residue was air dried overnight at room
temperature and the filtrate containing PEG was freeze dried. Both solid residues
were analysed via GPC for qualitative analysis and purity.
b) Controlled washing with methanol:
PGA-co-PDL (13.5 kDa), (0.5g) was physically mixed with either O.lg of PEG
(1500 Da) or PEG-me (2000 Da) in a 100 ml round bottom flask. MeOH (8.0 ml)
was added to each round bottom flask and the contents of the flasks were agitated
thoroughly to ensure complete dissolution of soluble contents. This solution was
filtered through a 0.8J..l1l1pore size filter (Whatman) to remove the insoluble polymer.
The polymer residue was air dried overnight at room temperature. MeOH from the
filtrates containing PEG and PEG-me was removed under vacuum to obtain the solid
dried PEG and PEG-me. The PEG, PEGme and polymer residues were analysed via
GPC for qualitative analysis and purity.
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2.2.3 Post-Synthetic modifications of polymers
2.2.3.1 Polymer-ibuprofen conjugation
In a closed 100 ml round bottom flask, 10 ml of DCC (2.5 mmol, 0.0515 g/ml in
DMF) and 10ml of ibuprofen in DMF (1.25 mmol for 50% and 2.50 mmol for 100%
conjugation) were added at room temperature. The reaction mixture was mixed on a
magnetic stirrer for 15 minutes. 20 ml of PGA-co-PDL (2.75 mmol, 0.061 g/ml in
DMF) was slowly added to the solution while stirring. The round bottom flask was
fitted with a drying tube and the reaction mixture stirred at room temperature for 24
hours. After 24 hours, the reaction mixture was filtered through a Whatman filter
(GF/A) via vacuum filtration, to remove the by-product, dicyclohexylurea, which
was discarded. The filtrate containing the conjugated product underwent rotary
evaporation for the complete removal of solvent at 200rpm and 100°C. The obtained
waxy solid product was collected and unreacted ibuprofen was removed before
analysis using the procedure discussed in following section.
2.2.3.2 Polymer-stearic acid conjugation
For the conjugation of stearic acid to PGA-co-PDL, the same procedure was adopted
as described under 2.2.3.1.
Purification of conjugated products
The conjugated material was dissolved in 25 ml DCM to give a clear solution,
followed by addition of 20 ml MeOH (as a non-solvent). The solution was left to
evaporate over a hot plate until the total volume reduced by half and it became
turbid. The solution was allowed to cool to room temperature and filtered using
vacuum filtration. The purified product was collected on the filter paper. The
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resulting solid, white, powdery material was stored in sealed jars. The drug-polymer
conjugate was analysed using GPC, FTIR, DSC and NMR (section 2.2.4).
2.2.4 Analytical procedures
Monomers and polymers were analysed by gel permeation chromatography (Ope),
differential scanning calorimetry (DSC), contact angle measurement, nuclear
magnetic resonance (NMR) spectroscopy and Fourier transform infrared (FTIR)
spectroscopy while the moisture/water content in the monomers was determined by a
Karl Fischer titration.
2.2.4.1 Molecular weight analysis (Gel Permeation Chromatography(GPC))
Gel permeation chromatography (GPC) was used for the determination of molecular
weight and molecular weight distribution. A Viscotek GPC system, TDA Model 300
coupled to a gpcMAX integrated solvent and sample delivery module (degasser,
pump and auto-sampler) was used with OmniSEC 4.2 software. The system was
fitted with two ViscoGEL GMHHR-N columns (also stored in the detector oven at
40°C), using THF (or chloroform for polythioesters) as the eluent with a flow rate of
1 ml/min. The Rl detector alignment and instrument sensitivity parameters were
previously calibrated using a range of polystyrene standards with different molecular
weights. Polystyrene standards and polymer samples were prepared at 10 mg/rnl in
THF in dry 7 ml glass vials. The solutions were mixed for an hour on a roller-mixer
(SRTI, Stuart) to allow the polymers to fully dissolve. The samples were then
filtered (0.2 urn PTFE syringe filters, Whatman) into 2.0 ml glass vials. PTFE septa
(Sigma) were used in the vial lids to avoid solvent evaporation and clogging up of
the injecting needle. 100 JlI of polymer solution in THF was injected in all cases.
Blank THF samples were run prior to the other samples. Three injections were taken
from each vial. Once completed, the peaks were manually identified and the
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retention volumes used to determine the molecular weight usmg a polystyrene
standards calibration graph.
2.2.4.2 Thermal analysis (Differential Scanning Calorimetery (DSC))
A TA instrument DSC 2910 calorimeter previously calibrated with an indium
standard was used for thermal analysis. Samples weighing 5-10 mg were sealed in
aluminium pans, at 25°C and then heated at a rate of 10°C/minute to 90°C followed
by cooling to -25°C at the same rate. The same cycle was repeated to observe the
changes in thermal properties upon heating/cooling. The melting temperatures (Tm)
were obtained in both heating and cooling cycles, while glass transition temperatures
(Tg) were calculated as the mid-point of the heat capacity change.
2.2.4.3 Hydrophilic character measurement (Contact angle measurement)
The contact angle measurement technique was used for the measurement of the
hydrophilic character of solid polymers. Thin polymer films were placed on the
standard stage of the previously-calibrated instrument, Attension (Theta Lite, CAM-
101) by KSV instruments. The instrument was linked with a computer and controlled
by the Attension one software. A very small aliquot of water (6-10 Ill) was dropped
on the polymer film via a pre-calibrated syringe needle and photographs of the
dropping water droplet were taken until the droplet stabilised on the surface via a
built-in digital camera at 16ms frame interval for 60ms. The circular model of drop
profile fitting method was applied on these images to measure the contact angle.
2.2.4.4 Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR spectra were recorded on a Bruker Avance 300 MHz spectrometer operated via
XWIN-NMR v3.5 and expressed in parts per million (b) from internal
tetramethylsilane. The samples were prepared in 7 ml clear vials at a concentration of
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-100 mglml in high quality deuterated solvent by dissolving small quantities
(approximately 100 mg) of the material in 1 ml chloroform-d containing 0.05%
tetramethylsilane. The resulting solutions were then transferred into NMR sample
tubes (Wilwad 5 mm NMR tubes, Goss Scientific Instruments Ltd.) and capped.
Glycerol, however was dissolved in DMSO-d6 containing 0.05% tetramethylsilane.
The Bruker automated program for IH-NMR (PROTONI6) and 13C_NMRwere
used. The data was collected at 320K using standard Bruker pulse sequences and
micro-programs. The IH spectra were integrated to show the relative ratio of protons.
2.2.4.5 Fourier Transform Infra Red (FTIR) Spectroscopy
FTIR spectra were collected using a Perkin Elmer Spectrum BX spectrometer fitted
with a PIKE Technologies MIRacle sampling accessory and using Spectrum v5.0.1
for data storage and processing. The sample was placed directly on the ATR stage
and scanned over the range 4000cm-1 to 600cm-1 with l cm" resolution. Each
measurement was an average of 16 scans.
2.2.4.6 Karl Fischer Titration
Water content was determined using a Karl Fischer titrator (701 KFT Titrino, 703 Ti
Stand Metrohm). The titration vessel was filled with hydranal solvent in order to
sufficiently cover the electrode. A syringe was used to transfer 10 ~l of distilled
water, of known weight, into the vessel and the mixture was stirred and titrated to the
amperometric end-point using KF reagent (hydranal composite 5K). The water
equivalence factor (F) was obtained in mglml and the procedure was repeated with a
known weight of monomer/solvent sample. The titer volume (V) of water of the
sample was determined and the water content was calculated by multiplying the F
with the V value and expressed as percentage of weight of water (% w/w) present in
the sample.
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2.2.5 Characterisation data
2.2.5.1 Functionalised and non-functionalised linear polyesters
Poly(glycerol adipate) (PGA) -1:1
PGA was synthesised by the general procedure via the reaction of glycerol (0.05 mol,
4.60 g), divinyl adipate (0.05 mol, 9.91 g) in 1:1 ratio and Novozyme (1.0 g).
o
Pale yellow viscous liquid, monomer composition calculated (1:1), e = 50.10 ± 5.36,
Mw: 10171Da, IR u max: 3439.6, 2949.0, 2869.5, 1729.8, 1456.5, 1380.5, 1165.6,
1061.5, 906.7, 753.6, IH-NMR (OH CDCh, 300 MHz): 1.69 (s, 4H, H-e, f), 2.39 (s,
4H, H-d, g), 4.18 (m, 4H, H-a, c), 5.2 (s, H, H-h).
Poly(I,3-propanediol adipate) (PPA) -1:1
PPA was synthesised by general procedure via the reaction of 1,3-propanediol (0.05
mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g) and Novozyme (1.0 g).
1 a c*~ o 0 *o
Pale yellowish viscous liquid, monomer composition calculated (1 :1), Mw: 5387 Da,
IR u max: 2943.1,2874.4, 1718.4, 1476.3, 1467.4, 1416.8, 1372.4, 1255.0, 1162.4,
1138.7, 1054.5, 1027.5,946.9, 731.7 em", IH-NMR (OH CDCh, 300 MHz): 1.70 (t,
4H, H-e, f), 1.90 (q, 2H, H-b), 2.35 (t, 4H, H-d, g), 4.18 (t, 4H, H-a, c).
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Poly(I,4-butanediol adipate) (PBA) -1:1
PBA was synthesised by general procedure via the reaction of 1,4-butanediol (0.05
mol, 4.50 g), divinyl adipate (0.05 mol, 9.91 g) and Novozyme (1.0 g).
[ a c.\O~O
Pale yellow viscous liquid, monomer composition calculated (I: I), Mw: 7369 Da,
IR umax: 2953.55, 2872.44, 1725.48, 1460.94, 1417.72, 1397.91, 1367.67, 1254.94,
1158.41, 1063.18, 956.52, 908.35, 733.63 ern", IH-NMR (OH COCl3, 300 MHz):
1.70 (m, 8H, H-e, f, i, c), 2.37 (t, 4H, H-d, g), 3.68 (t, H-b), 4.19 (t, 2H, H-a).
Poly(triethyleneglycol adipate) (PTEGA) -1:1
PTEGA was synthesised by general procedure via the reaction of triethylene glycol
(0.05 mol, 7.50 g), divinyl adipate (0.05 mol, 9.91 g) in 1:I ratio and Novozyme (1.0
g).
\
c' d
• ~o~~o
o d' e' 0 c
o
Pale yellow highly viscous liquid, monomer composition calculated (l:1), Mw: 8785
Da, IR u max: 2867, 1727, 1453, 1382, 1349, 1242, 1172, 1123, 1064, 948, 860 em'
I, IH-NMR (OH CDCb, 300 MHz): 1.66 (q, 4H, H-b,b'), 1.85 (t, 0.7H, terminal
group), 2.35 (t, 4H, H-a, a'), 3.65 (s)-3.69 (t) (9H, H-d, e, d', e'), 4.23 (t, 4H, H-c, c')
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Poly(lactic acid-co-glycolic acid) (PLGA) -1:1
Sample received from PURAC biomaterials.
White crystalline solid, monomer composition calculated (1:1), Mw: 9500 Da, e =
75.81 ± 1.34, Tm = 34.28°C, IR u max: 3517.27, 2946.66, 1744.43, 1450.74,
1421.98, 1381.58, 1269.63, 1166.05, 1128.70, 1083.77, 845.04, 746.04 em", IH_
NMR (8H CDCh, 300 MHz): 1.65 (d, 3H, H-a), 4.7 (s, 2H, H-c), 5.25 (q, IH, H-b).
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2.2.5.2 Functionalised and non-fundionalised linear polyesters via ring-
opening copolymerisation of lactones
a) Co-caprolactone
Poly(glycerol adipate-ce-e-caprolactone) (PGA-co-CL) -1:1:1
PGA-co-CL was synthesised by general procedure via the reaction of glycerol (0.05
mol, 4.60 g), divinyl adipate (0.05 mol, 9.91 g), €-caprolactone (0.05 mol, 5.71 g)
and Novozyme (1.0 g).
o
o
Highly viscous liquid, monomer composition calculated (1:1 :0.7), Mw: 1855 Da, IR
u max: 3446.5,2937.9,2865.9, 1726.0, 1456.5, 1387.4, 1162.8, 1050.8, 734.7 ern",
IH-NMR (8H CDCh, 300 MHz): 1.40 (m)-1.7 (q) (8H, H-e, e', g, h), 2.38 (m, 4H, H-
d, d', i), 3.70 (m, 3H, H- f), 4.04 (m, 4H, H-a, b, c), 5.2 (s, H, H-j).
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Poly(I,3-propanediol adlpate-eo-e-caprolactone) (PPA-co-CL) -1:1:1
PPA-co-CL was synthesised by general procedure via the reaction of 1,3-propanediol
(0.05 mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g), s-caprolactone (0.05 mol, 5.71)
and Novozyme (1.0 g).
o
o
Viscous liquid, monomer composition calculated (l:1:0.45), Mw: 4901 Da, IR u max:
2938.0, 2865.9, 1725.6, 1456.5, 1418.9, 1390.1, 1360.5, 1159.5, 1042.8, 734.9 em",
IH-NMR (8H CDCh, 300 MHz): 1.40 (m, 1.5H, H-g), 1.70 (m, 6H, H-e, e', h), 1.85
(m) - 1.9 (q) (3H, H-b, f), 2.35 (m, 4H, H-d, d'), 4.05 (t)-4.18 (t) (4H, H-a, c).
Poly(I,4-butanediol adipate-ce-e-caprolactone) (PBA-co-CL) - 1:1:1
PBA-co-CL was synthesised by general procedure via the reaction of 1,4-butanediol
(0.05 mol, 4.50 g), divinyl adipate (0.05 mol, 9.91 g), e-caprolactone (0.05 mol,
5.71g) and Novozyme (1.0 g).
a c
O~o
o
o
Viscous liquid, monomer composition calculated (1: 1:0.40), Mw: 18388Da, IR u
max: 2953.3,2870.9, 1725.1, 1458.5, 1417.9, 1395.1, 1367.5, 1150.1, 1061.5, 734.9
em", IH-NMR (8H CDCh, 300 MHz): 1.40 (m, 1.5H, H-g), 1.70 (m, 9H, H-e, e', h,
k, e, f), 2.35 (m, 4H, H-d, d', i), 3.75 (t, H-b), 4.1 (m, 4H, H-a).
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b) Co-Pentadecalactone:
Poly(glycerol adipate-co-m-pentadecalactone) (PGA-co-PDL)
PGA-co-PDL was synthesised by general procedure via the reaction of glycerol (0.05
mol, 4.60 g), divinyl adipate (0.05 mol, 9.91 g) and Novozyme (1.0 g). The amount
of e-pentadecalactone used was (0.025 mol, 16.01 g) for 1:1:0.5 ratio, (0.05 mol,
12.02 g) for 1:1:1 ratio and (0.075 mol, 18.03 g) for 1:1:1.5 ratio.
o
a) 1:1:0.5
Soft solid, monomer composition calculated (1: 1:1), e = 70.02 ± 1.2, Mw: 15600 Da,
r,= 38°C, r, = 24°C, IR u max: 3448.8, 2915.3, 2848.0, 1729.0, 1463.3, 1365.9,
1162.3, 1058.8, 720 em", IH-NMR (OH CDCh, 300 MHz): 1.30 (s, 19H, H-g), 1.65
(m, 10H, H-e, e', h), 2.35 (m, 8H, H-d, d', i), 4.05 (q)-4.18 (m) (7H, H-a, b, c, t), 5.2
(s, H, H-j).
b) 1:1:1
White solid powder, monomer composition calculated (1: 1:1), e = 65.65 ± 2.36, Mw:
17560 Da, r, = 42°C, IR u max: 3451.2,2915.3,2847.8, 1729.5, 1463.2, 1463.2,
1365.9, 1160.8, 1040.0, 719.9 ern", IH-NMR (OH CDCh, 300 MHz): 1.34 (s, 22H,
Il-g), 1.65 (m, 8H, H-e, e', h), 2.32 (m, 6H, H-d, d', i), 4.05 (q)-4.18 (m) (6H, H-a, b,
e, t), 5.2 (s, H, H-j).
c) 1:1:1.5
White solid powder, monomer composition calculated (1:1:1.2), Mw: 29149 Da, Tg
= 36°C, Tm = 52°C T, = 50°C, IR \) max: 3454.7,2914.7,2847.5,1729.7,1462.9,
1366.0, 1162.5,957.6, 719.6 ern", IH-NMR (OH CDCI3, 300 MHz): 1.30 (s, 25H, H-
g), 1.68 (m, 9H, H-e, e', h), 2.32 (m, 6H, H-d, d', i), 4.05 (q)-4.l8 (m) (6H, H-a, b, c,
f), 5.2 (s, H, H-j).
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Poly(I,3-propanediol adipate-co-m-pentadecaladone) (PPA-co-PDL) -1:1:1
PPA-co-PDL was synthesised by general procedure via the reaction of 1,3-
propanediol (0.05 mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g), 00-
pentadecalactone (0.05 mol, 12.02 g) and Novozyme (1.0 g).
o
o 0
White solid powder, monomer composition calculated (1:1:0.6), e = 77.71 ± 1.52,
Mw: 8566 Da, Tg = 45°C, Tm = 56°C T, = 36°C, IR u max: 2916.3, 2848.1,1728.2,
1463.0, 1414.4, 1365.3, 1255.4, 1158.5, 1052.4, 953.5, 730.5 ern", IH-NMR (8H
CDCh, 300 MHz): 1.30 (s, 15H, H-g), 1.65 (m, 6H, H-e, e', h), 1.9 (q, 1.2H, H-b),
2.30 (m, 4.3H, H-d, d', i), 4.05 (t)-4.18 (t) (4H, H-a, c).
Poly(I,4-butanediol adlpate-co-m-pentadecalactone) (PHA-eo-PDL) -1:1:1
PBA-co-PDL was synthesised by general procedure via the reaction of 1,4-
butanediol (0.05 mol, 4.50 g), divinyl adipate (0.05 mol, 9.91 g), oi-pentadecalactone
(0.05 mol, 12.02 g) and Novozyme (1.0 g).
a c
o~o
o
White solid, monomer composition calculated (1: 1:0.5), Mw: 15960Da, IR u max:
2916.25,2848.71,1728.30,1464.03,1415.42,1398.01, 1366.64, 1256.61, 1160.98,
1064.44,956.21, 722.01 ern", IH-NMR (8H CDCh, 300 MHz): 1.30 (s, 14H, H-g),
1.65 (rn, 9H, H-e, e', h, k, c), 2.30 (m, 4H, H-d, d', i), 3.7 (t, H-b), 4.05-4.17 (m, 4H,
H-a, c).
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Poly(triethylene glycol adipate-co-m-pentadecalacfone) (PTEGA-co-PDL)
PTEGA-co-PDL was synthesised by general procedure via the reaction oftriethylene
glycol (0.05 mol, 7.50g), divinyl adipate (0.05 mol, 9.91 g) and Novozyme (1.0 g).
The amount of ro-pentadecalactone used was (0.025 mol, 16.01 g) for 1:1:0.5 ratio,
(0.05 mol, 12.02 g) for 1:1:1 ratio and (0.075 mol, 18.03 g) for 1:1:1.5 ratio.
t c' d• ~o~~oo d. e' 0 c
a) 1:1:0.5
Soft wax like solid, monomer composition calculated (1:1:0.6), Mw: 7740 Da, IR u
max: 3445, 2919, 2850, 1729, 1456, 1417, 1349, 1242, 1172 1125, 1028, 953, 861,
720 ern", IH-NMR (OH CDCh, 300 MHz): 1.26 (s, 10H, H-g), 1.65 (m, 6H, H-e, e',
h), 2.37 (m, 5H, H-d, d', i), 3.65 (t)-3.7 (t) (8H, H-b, b', c, c'), 4.05 (t, H, H-t), 4.25
(t, 4H, H-a, a').
b) 1:1:1
White amorphous powder, monomer composition calculated (1:1:1), Mw: 23801 Da,
Tm= 49.816°C, r,= 39.86°C, IR u max: 2915, 2848,1729,1462,1415,1349,1287,
1254,1168 1128,956,919,865, 720 em", IH-NMR (OH CDCh, 300 MHz): 1.26 (s,
22H, H-g), 1.62 (m, 8H, H-e, e', h), 2.36 (m, 6H, H-d, d', i), 3.62 (t)-3.68 (t) (8H, H-
b, b', c, c'), 4.05 (t, 2H, H-t), 4.24 (t, 4H, H-a, a').
c) 1:1:1.5
White amorphous powder, monomer composition calculated (1: 1:1.5), Mw:
17413Da, Tg= 49.32°C, Tm = 61.18°C, r,= 49.84°C, IR u max: 2915, 2848,1729,
1462,1415,1349,1287,1254,1168,1128,956,919,865, 720 ern", IH-NMR (8H
CDCh, 300 MHz): 1.26 (s, 34H, H-g), 1.65 (m, I1H, H-e, e', h), 2.34 (m, 7H, H-d,
d', i), 3.63 (t}-3.7 (t) (8H, H-b, b', c, c'), 4.05 (t, H, H-f), 4.22 (t, 4H, H-a, a').
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Poly(sorbitol adipate-co-m-pentadecalactone) (PSA-co-PDL) -1:1:1
PSA-co-PDL was synthesised by general procedure via the reaction of sorbitol (0.05
mol, 9.10 g), divinyl adipate (0.05 mol, 9.91 g), co-pentadecalactone (0.05 mol, 12.02
g) and Novozyme (1.0 g). The solvent, acetone (50 ml) was used in this reaction
instead of THF at 90°C.
m rn'
o
oOH OH
o
OH
mn
OH
m'"
White solid, monomer composition calculated (1:1 :0.5), Mw: 3258 Da (Chloroform
GPC), IR \) max: 3417.73, 2916.45, 2848.60, 1729.84, 1462.04, 1367.28, 1335.00,
1219.66, 1172.33, 1093.29,956.29 em", IH-NMR (OH CDCh, 300 MHz): 1.30-1.38
(d, 24H, H-j, a, f), 1.65 (m, 7H, H-g, g', I), 2.l8 (s, H, H-m, m', m", m'''), 2.30 (m,
4.0H, H-h, h', k), 4.05 (t)-4.l8 (t) (3H, H-b, c, d, e).
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2.2.5.3 Functionalised and non-functionalised linear PEG-copolymers
Poly(glycerol adipate--co--PEG) (PEG-PGA-PEG) -1:1:0.01
PEG-PGA-PEG was synthesised by general procedure via the reaction of glycerol
(0.05 mol, 4.60 g), divinyl adipate (0.05 mol, 9.91 g) in 1:1 ratio, polyethylene glycol
(0.0006 mol, 1 g) and Novozyme (1.0 g).
o
0, tz. A /o~'f\ "0/ !;:;h' r
I
Pale yellow viscous liquid, monomer composition calculated (1:1:0.04), Mw: 3836
Da, IR u max: 3439.4, 2946.5, 2870.7, 1728.0, 1456.5, 1418.9, 1380.5, 1165.9,
1132.9, 1052.0,940.6, 753.5, IH-NMR (8H CDCh, 300 MHz): 1.68 (m, 4H, H-e, e'),
2.38 (m, 4H, H-d, d'), 3.65 (s, 6.4H, H-f, g, h), 4.08 (m) - 4.18 (m) (4H, H-a, b, c),
5.1 (s, H, H-i).
Poly(I,3-propanediol adipate - co - PEG) (PEG-PPA-PEG) -1:1:0.01
PEG-PPA-PEG was synthesised by general procedure via the reaction of 1,3-
propanediol (0.05 mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g), polyethylene
glycol (0.0006 mol, 1 g) and Novozyme (1.0 g).
o
0, tz. A /o~'f\ "0/ ~ r
°Viscous liquid, monomer composition calculated (1:1:0.01), Mw: 3747 Da, IR u
max: 2943.1, 2873.0, 1718.4, 1476.2, 1476.2, 1416.9, 1372.6, 1254.9, 1163.4,
1055.0,1027.4,947.1,731.6 em", IH-NMR (cSH CDCh, 300 MHz): 1.65 (q, 4H, H-e,
e'), 1.96 (q, 2H, H-b), 2.35 (q, 4H, H-d, d'), 3.64 (s, 1.5H,H-f,g,h), 4. 18(t,4H,H-a,c).
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Poly(glycerol adipate-co-m-pentadecalactone}-co-PEG (PEG-PGA-co-PDL-
PEG) -1:1:1:0.01
PEG-PGA-co-PDL-PEG was synthesised by general procedure via the reaction of
glycerol (0.05 mol, 4.60 g), divinyl adipate (0.05 mol, 9.91 g), co-pentadecalactone
(0.05 mol, 12.02 g), polyethylene glycol (0.0006 mol, 1 g) and Novozyme (1.0 g).
White solid powder, monomer composition calculated (1:1:0.8:0.02), Mw: 8566 Da,
Tg = 40°C, Tm = 52°C T, = 41.5°C, Tm (2nd heat cycle) = 53°C, IR u max: 3447.0,
2915.7, 2848.4, 1730.7, 1463.8, 1417.0, 1242.9, 1164.8, 720.1 em", !H-NMR (OH
CDCI3, 300 MHz): 1.28 (s, 21.5H, H-g), 1.65 (m, 8H, H-e, e', h), 2.38 (m, 6H, H-d,
d', i), 3.64 (s, 2.6H, H-j, k, 1),4.05 (m)-4.18 (m) (5H, H-a, b, c, f), 5.1 (s, H, H-m).
Poly(1,3-propanediol adipate-co-Ol-pentadecalactone}-co-PEG (PEG-PPA-co-
PDL-PEG) -1:1:1:0.01
PEG-PPA-co-PDL-PEG was synthesised by general procedure via the reaction of
1,3-propanediol (0.05 mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g), (0-
pentadecalactone (0.05 mol, 12.02 g), polyethylene glycol (0.0006 mol, 1 g) and
Novozyme (1.0 g).
o
White solid powder, monomer composition calculated (l:1:1.4:0.018), Mw: 6649
Da, Tg = 41°C, Tm = 53°C T, = 43.8°C, Tm (2nd heat cycle) = 55.5°C, IR u max:
2916.0,2848.5, 1729.5,1463.6,1415.3, 1256.1,1160.9,1052.0,953.5,721.0 ern",
IH-NMR (OH CDCh, 300 MHz): 1.26 (s, 28H, H-g), 1.64 (m, IOAH,H-e, e', h), 1.96
(q, 2H, H-b), 2.35 (m, 7.6H, H-d, d', i), 3.64 (s. 2.5H, H-j, k, I), 4.05 (t) - 4.16 (t)
(7H, H-a, c, f).
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Poly(glycerol adipate-co-E-caproladone)-co-PEG (PEG-PGA-co-CL-PEG) _
1:1:1:0.01
PEG-PGA-co-CL-PEG was synthesised by general procedure via the reaction of
glycerol (0.05 mol, 4.60 g), divinyl adipate (0.05 mol, 9.91 g), s-caprolactone (0.05
mol, 5.71 g), polyethylene glycol (0.0006 mol, 1 g) and Novozyme (1.0 g).
Highly viscous solid, monomer composition calculated (1:1:1:0.02), Mw: 3075 Da,
IR u max: 3447.0, 2938.1, 2865.8, 1727.8, 1456.5, 1418.9, 1387.3, 1162.5, 1052.5,
911.0, 734.8 em", 'H-NMR (OH CDCh, 300 MHz): 1.40 (m, 2H, H-g), 1.64 (m, 8H,
H-e, e', h), 2.38 (m, 6H, H-d, d', i), 3.64 (s, 3H, H-j, k, 1),4.06 (m)-4.18 (m) (7H, H-
a, b, c, f), 5.1 (s, H, H-m).
Poly(l,3-propanediol adipate-eo-e-caprolactone)-co-PEG (PEG-PPA-co-CL-
PEG)-l:l:l:O.Ol
PEG-PPA-co-CL-PEG was synthesised by general procedure via the reaction of 1,3-
propanediol (0.05 mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g), e-caprolactone
(0.05 mol, 5.71 g), polyethylene glycol (0.0006 mol, 1 g) and Novozyme (1.0 g).
o
o
Very soft solid, monomer composition calculated (1:1:1.2:0.017), Mw: 5057 Da, IR
u max: 29415.6, 2865.7,1726.0,1456.5,1358.5,1160.1,1060.8,963.6, 738.1 em",
IH-NMR (OH CDCb, 300 MHz): 1.4 (m, 2.2H, H-g), 1.64 (m, 9H, H-e, e', h), 1.98
(q, 2H, H-b), 2.36 (m, 7H, H-d, d', i), 3.64 (s, 2.3H, H-j, k, I), 4.05 (t)-4.18 (t) (6H,
H-a, b, c, f).
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2.2.5.4 Funenonalised and non-functionalised linear PEG me-copolymers
Poly(glycerol adipate-co-PEGme) (PGA-PEGme) -1:1:0.01
PEGme-PGA was synthesised by general procedure via the reaction of glycerol (0.05
mol, 4.60 g), divinyl adipate (0.05 mol, 9.91 g) in 1:1 ratio, methoxy polyethylene
glycol (0.0005 mol, 1 g) and Novozyme (1.0 g).
o
Pale yellow viscous liquid, monomer composition calculated (1: 1:0.02), Mw: 9982
Da, IR u max: 3413.5, 2948.0, 2870.7, 2358.6, 1730.2, 1456.5, 1418.9, 1381.2,
1165.9, 1134.0, 1061.9,906.7, IH-NMR (DH CDCh, 300 MHz): 1.65 (t, 4H, H-e, e'),
2.38 (t, 4H, H-d, d'), 3.64 (s, 4.6H, H-f, g), 4.18 (m, 4H, H-a, b, c), 5.1 (s, H, H-i).
Poly(I,3-propanediol adipate-co-PEGme) (PPA-PEGme) -1:1:0.01
PEGme-PPA was synthesised by general procedure via the reaction of 1,3-
propanediol (0.05 mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g), methoxy
polyethylene glycol (0.0005 mol, 1 g) and Novozyme (1.0 g).
o
0," v..._ .A'Y\ '-o~ r;;h)
o
Very soft solid, monomer composition calculated (1:1:0.01), Mw: 5264 Da, IR u
max: 2902.6, 2943.2, 2357.0, 1718.6, 1476.3, 1416.8, 1372.6, 1255.3, 1164.1,
1055.0,1027.6,946.7,731.8 em", IH-NMR (DH CDCh, 300 MHz): 1.65 (q, 4H, H-e,
e'), 1.98 (q, 2H, H-b), 2.36 (q, 4H, H-d, d'), 3.64 (s, 2H, H-f,g), 4.15 (t, 4H, H-a, c).
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Poly(glycerol adipate-co-m-pentadecaladone)-PEGme (PGA-co-PDL-PEGme)
PEGme-PGA-co-PDL was synthesised by general procedure via the reaction of
glycerol (0.05 mol, 4.60 g), divinyl adipate (0.05 mol, 9.91 g), re-pentadecalactone
(0.05 mol, 12.02 g) in 1:1:1 ratio and Novozyme (1.0 g). The amount of methoxy
polyethylene glycol used was (0.00025 mol, 0.5 g) for 1:1:1:0.005, (0.0005 mol, 1 g)
for 1:1:1:0.01 and (0.0010 mol, 2 g) for 1:1:1:0.02.
o
1:1:1:0.005
White solid powder, monomer composition calculated (1:1:1.5:0.01), Mw: 3775 Da,
Tg = 36°C, Tm = 53°C Te = 43.4°C, Tm (2nd heat cycle) = 51°C, IR u max: 3449.8,
2916.9, 2849.1, 1729.8, 1463.8, 1414.8, 1367.0, 1243.0, 1162.6, 720.2 ern", IH_
NMR (DH CDCh, 300 MHz): 1.28 (s, 28H, H-g), 1.65 (m, 10H, H-e, e', h), 2.35 (m,
10H, H-d, d', i), 3.64 (s, 1.5H, H-j, k), 4.04 (m)-4.l8 (m) (7H, H-a, b, c, f), 5.2 (s, H,
H-m).
1:1:1:0.010
White solid powder, monomer composition calculated (1:1 :1.4:0.01), Mw: 4729 Da,
Tg = 36°C, Tm = 55°C T, = 42°C, Tm (2nd heat eycle) = 52°C, IR u max: 3449.4,
2917.0, 2849.3, 1729.8, 1463.8, 1414.9, 1367.0, 1288.1, 1162.1, 720.2 em", IH_
NMR (DH CDCh, 300 MHz): 1.28 (s, 27H, H-g), 1.65 (m, 10H, H-e, e', h), 2.35 (m,
8H, H-d, d', i), 3.64 (s, 2H, H-j, k), 4.04 (m)-4.18 (m) (7H, H-a, b, c, f), 5.2 (s, H, H-
m).
62
1:1:1:0.020
White solid powder, monomer composition calculated (1:1:1.3:0.02), Mw: 6478 Da,
= 34°C, Tm = 55°C T, = 43.7°C, Tm (2nd heat cycle) = 52°C, IR u max: 3448.3,
2917.1, 2849.3, 1729.9, 1463.9, 1414.9, 1366.9, 1243.1, 1162.4, 720.3 em", IH_
NMR (OH CDCh, 300 MHz): 1.28 (s, 26H, H-g), 1.65 (m, 10H, H-e, e', h), 2.35 (m,
7H, H-d, d', i), 3.64 (s, 3.5H, H-j, k), 4.04 (m)-4.18 (m) (7H, H-a, b, c, f), 5.2 (s, H,
H-m).
Poly(I,3-propanediol adipate-co-m-pentadecalactone)-PEGme (PPA-co-PDL-
PEGme) -1:1:1:0.01
PEGme-PPA-co-PDL was synthesised by general procedure via the reaction of 1,3-
propanediol (0.05 mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g), oi-
pentadecalactone (0.05 mol, 12.02 g), methoxy polyethylene glycol (0.0005 mol, 1 g)
and Novozyme (1.0 g).
Lac
'\"o~o o
o
White soft solid, monomer composition calculated (1: 1:.0.5:0.006), Mw: 9595 Da, Tg
= 40°C, Tm = 55°C T, = 41.8°C, Tm (2nd heat cycle) = 53°C, IR u max: 2916.2,
2848.6, 1729.6, 1463.7, 1415.4, 1365.6, 1255.9, 1160.1, 1052.1,953.5 ern", IH_
NMR (OH CDCh, 300 MHz): 1.28 (s, 14H, H-g), 1.65 (m, 5.5H, H-e, e', h), 1.96 (q,
H, H-b), 2.34 (m, 4H, H-d, d', i), 3.64 (s, 1.2H, H-j, k), 4.04 (t)-4.16 (t) (4H, H-a, c,
f).
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Poly(glycerol adipate-co-E-caproladone}-PEGme (PGA-co-CL-PEGme) -
1:1:1:0.01
PEGme-PGA-co-CL was synthesised by general procedure via the reaction of
glycerol (0.05 mol, 4.60 g), divinyl adipate (0.05 mol, 9.91 g), e-caprolactone (0.05
mol, 5.71g), methoxy polyethylene glycol (0.0005 mol, 1 g) and Novozyme (1.0 g).
Wax like solid, monomer composition calculated (1:1 :1.2:0.016), Mw: 6017 Da, IR
umax: 3447.1,292.5,2866.0,2357.1, 1729.2, 1456.5, 1418.9, 1161.0, 1062.4,963.3
ern", IH-NMR (OH CDCh, 300 MHz): 1.40 (m, 2H, H-g), 1.64 (m, 9H, H-e, e', h),
2.38 (m, 7H, H-d, d', i), 3.64 (s, 3H, H-j, k), 4.05 (t)-4.18 (m) (7H, H-a, b, c, f), 5.1
(s, H, H-m).
Poly(I,3-propanediol adipate-co-E-caproladone}-PEGme (PPA-co-CL-PEGme)
-1:1:1:0.01
PEGme-PPA-co-CL was synthesised by general procedure via the reaction of 1,3-
propanediol (0.05 mol, 3.80 g), divinyl adipate (0.05 mol, 9.91 g), s-caprolactone
(0.05 mol, 5.71 g), methoxy polyethylene glycol (0.0005 mol, 1 g) and Novozyme
(1.0 g).
o
~
a c
• b
o~o
o 0
Very soft solid, monomer composition calculated (1:1:1.3:0.012), Mw: 5221 Da,IR
u max: 2941.5, 2865.6, 2358.6, 1726.2, 1456.5, 1419.0, 1358.7, 1159.5, 1060.6,
963.8, 909.0, 736.9 em", IH-NMR (8H CDCb, 300 MHz): 1.4 (m, 2.4H, H-g), 1.65
(rn, 9.5H, H-e, e', h), 1.96 (q, 2H, H-b), 2.35 (m, 7H, H-d, d', i), 3.64 (s, 2.2H, H-j,
k), 4.04 (t)-4.18 (t) (6.6H, H-a, c, 0.
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2.2.5.5 Functionalised and non-fundionalised polythioester
Poly(I,3-propanedithiol adipate) (PPTA) -1:1
PPTA was synthesised by general procedure via the reaction of 1,3-propanedithiol
(0.05 mol, 5.4 g), divinyl adipate (0.05 mol, 9.91 g) and Novozyme (1.0 g). This
reaction was solvent free, and drying tube with molecular sieves was used.
o
o
o
Both structures, presented above were confirmed. Transparent VISCOUS liquid,
monomer composition calculated (1:1), Mw: 2000 Da, IR u max: 2927.1, 1729.9,
1710.3,1644.9,1442.0,1412.0,1373.1,1139.9,1055.0, 1004.5,948.0,843.2,757.9
em", IH-NMR (8HCDCb, 300 MHz): 1.70 (m, 4H, H-e, e'), 1.90 (m, 2H, H-b), 2.35
(m, 2H, H-d'), 2.60 (m, 2H, H-d), 2.75 (m) - 2.95 (m) (4H, H-a, c).
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Poly(I,3-propaneditbiol adipate-co-m-pentadecalactone) (PPTA-co-PDL) - 5:1:1
PPTA-co-PDL was synthesised by general procedure via the reaction of 1,3-
propanedithiol (0.25 mol, 27 g), divinyl adipate (0.05 mol, 9.91 g), to-
pentadecalactone (0.05 mol, 12.02 g) and Novozyme (1.0 g). This reaction was
performed in bulk (solvent free) at 120°C for 96 hours on a hotplate, and drying tube
with molecular sieves was used.
*
o
s~o
f o
*
o~s
f
o
s
o
Both structures, presented above were confirmed. Pale yellowish solid, monomer
composition calculated (2:1:1), Mw: 2262 Da, IR u max: 2916.71, 2848.20, 1729.71,
1688.36, 1384.06, 1290.15, 1243.50, 1164.22, 1065.16, 719.19 ern", IH-NMR (8H
CDCh, 300 MHz): 1.30-1.38 (m, 10H, H-j), 1.65 (m, 4H, H-g, g', 1),1.95 (m, 2H, H-
e), 2.30 (m, 2.0H, H-I, d), 2.60 (m, 2H, H-h,h', k), 4.1 (t)-4.21 (t) (3H, H- d, 0.
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Poly(dithiothreitol adipate) (PDTTA) -1:1
PDTT A was synthesised by general procedure via the reaction of dithiothreitol (0.05
mol, 7.71 g), divinyl adipate (0.05 mol, 9.91 g) and Novozyme (1.0 g).
c
OH
.{s
OH
c'
c
OH
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OH
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s o~.
o
o
o
o
Both structures, presented above were confirmed. Transparent viscous liquid, Mw:
300 Da, IR u max: 3417.60, 2927.1, 1735.15, 1644.38, 1413.56, 1385.96, 1293.0,
1135.90, 1047.04,947.40 ern". NMR not obtained because of the poor solubility of
polymer.
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Poly( dithiothreitol adipate-co-co-pentadecalactone) (PDTT A-co- PDL) - 0.5: 1: 1
PDTTA-co-PDL was synthesised by the general procedure via the reaction of
dithiothreitol (0.025 mol, 3.85 g), divinyl adipate (0.05 mol, 9.91 g), (0-
pentadecalactone (0.05 mol, 12.02 g) and Novozyme (1.0 g). This reaction was
performed in bulk (solvent free) at 1l0DC for 48 hours on a hotplate, and a drying
tube with molecular sieves was used.
c
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Both structures, presented above were confirmed. Pale yellowish soft rubber-like
solid, monomer composition calculated (1: 1:0.5), Mw: 10144 Da, IR u max:
3442.49,2922.57,2354.38,2127.08,1727.00,1644.45, 1455.30, 1415.10, 1384.46,
1135.5, 1061.67, 752.19 em", IH-NMR (OH CDCh, 300 MHz): 1.30-1.38 (m, 8H, H-
g), 1.65 (m, 12H, H-d, d', i), 2.35 (m, lOH, H-a, a', f), 2.70 (m, 2H, H-c, c'), 2.80 (m,
9H, H-e, e', h), 3.65 (m, 2H, H-b, b').
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2.2.5.6 DCC-~atalysedcoupllng of stearic acid to PGA-co-PDL
Poly(gly~eroladipate-~o-co-pentadecala~tone)-~onjugatedstearic acid (PGA-co-
PDL-CI8)
PGA-co-PDL-CI8 was synthesised by general procedure (2.2.3.1) via the reaction of
PGA-co-PDL (2.75 rnrnol, 1.22g) and stearic acid (1.35 rnrnol, 0.35g for 50% and
2.75 rnrnol, 0.71g for 100%), using DCC as catalyst.
a) 500/0
Soft white solid, % conjugated 50% (calculated), Mw: 16555 Da, Ig = 47°C, Im =
64°C, r;(second heat cycle) = 48°C, T, = 18°C, IR u max: 3470.9, 2918.5, 2846.5,
2115.8,1730.9,1655.16,1517.8,1408.1,1384.9, 1257.3, 1168.5, 1088.2,890.2,
657.4 em", 'H-NMR (8H CDCh, 300 MHz): 0.88 (t, 3H, H-j), 1.30 (s, 74H, H-g, k),
1.65 (m, 16H, H-e, e', I, h), 2.35 (m, 10H, H-d, d', i, m), 4.05 (q)-4.18 (m) (5H, H-a,
b, c, t).
b) 100%
White solid powder, % conjugated 33.33% (calculated), Mw: 18476 Da, Ig = 42°C,
Im = 56°C, Im (second cycle) = 58°C, T, = 23°C, IR u max: 2916.16, 2846.35,
1730.85, 1655.48, 1517.19, 1452.94, 1384.98, 1220.33, 1168.24, 1082.80, 726.80
ern", 'H-NMR (8H CDCl}, 300 MHz): 0.88 (t, 3H, H-j), 1.30 (s, 119H, H-g, k), 1.68
(m, 30H, H-e, e', 1, h), 2.32 (m, 23H, H-d, d', i, m), 4.05 (q)-4.l8 (m) (9H, H-a, b, c,
t).
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2.2.5.7 Dee catalysed coupling of ibuprofen to PGA-co-PDL
Poly(glycerol adipate-co-CD-pentadecaladone)-conjugated ibuprofen (PGA-co-
PDL-Ibu)
PGA-eo-PDL-Ibu was synthesised by general procedure via the reaction of PGA-co-
PDL (1.22g) and ibuprofen (0.282 g for 50% and 0.565 g for 100%) using DCC as
catalyst.
a) 50%
Soft white solid, % conjugated 50% (calculated), Mw: 18219 Da, Tm = 42°C, Tm
(second heat cycle) = 40°C, T, = 34°C, IR u max: 3488.8, 3289.0, 2921.4, 2849.4,
2116.1, 1665.3, 1535.6, 1384.0, 1227.7, 1088.1, 1062.8,891.1,657.9 em", IH-NMR
(<>H CDCb, 300 MHz): 0.89 (t, 6H, H-p, p'), 1.30 (s, 47H, H-g), 1.49 (d, 4H, H-k),
1.65 (m, 35H, H-e, e', h), 2.35 (m, 12H, H-d, d', I, n), 3.69 (m, IH. H-j), 4.05 (q)-
4.18 (m) (9H, H-a, b, c, 1), 7.2 (d, 4H, H-l, 1', m, m').
b) 100%
White solid powder, % conjugated 16.66% (calculated), Mw: 17413 Da, Tg = 36°C,
Tm = 43°C, Tm (second cycle) = 38°C, T, = 31°C, IR u max: 3473.2,2915.6,2848.0,
1729.9, 1649.9, 1452.6, 1365.7, 1163.9, 1077.5,921.8, 720.8 em", IH-NMR (<>H
CDCh, 300 MHz): 0.89 (t, 6H, H-p, p'), 1.30 (s, 138H, H-g), 1.49 (d, 4H, H-k), 1.65
(m, 57H, H-e, e', h), 2.35 (m, 42H, H-d, d', i, n), 3.69 (m, IH. Il-j), 4.05 (q)-4.18 (m)
(37H, H-a, b, c, 1), 7.2 (d, IH, H-I, 1', m, m').
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2.3 RESULTS AND DISCUSSIONS
2.3.1 Polymer synthesis
2.3.1.1 Poly(glycerol adipate) (PGA)
Poly (glycerol adipate) (PGA) has previously been synthesised by the condensation
of divinyl adipate (DVA) and glycerol, using the lipase from C. antarctica
(Kobayashi et al 2006). This type of polymer has also recently shown great potential
for new drug delivery applications (Kallinteri et al 2005; Purl et al 2008). In the
literature, reports of PGA and related polymers' syntheses tend to be on a very small
scale (less than 1 gram) for the synthesis of combinatorial libraries of polymers,
mainly to show that enzymes can be used for the synthesis of a variety of different
polymers (Namekawa et al 2000; Kim & Dordick 2001). Here, the synthesis of PGA
was studied on a larger scale (100g) to obtain a useful yield for application to drug
delivery studies. By altering the monomers used, derivatives of this polymer can be
designed and synthesised for use in effective encapsulation and attachment of drug
molecules.
PGA was synthesised successfully at 65-70% yield. Although this product was not
purified to remove oligomers, the spectral and chromatographic data indicates that
the product was free of any un-reacted monomers.
Figure 2.1: Chemical structure of PGA
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PGA obtained was a viscous liquid at room temperature and was used without any
further processing. The chemical structure of poly(glycerol adipate) is given in figure
2.1 which is supported by the characterisation data of PGA as summarised in section
2.2.5.1.
a) Molecular weight analysis:
Polymer molecular weight was determined by gel permeation chromatography
(GPC). For determination of the molecular weight via GPC, two common methods
can be used, namely, Conventional calibration and Universal calibration methods.
Chaudhary et al (1997) used the Universal Calibration method, which applies a
relationship between the hydrodynamic volume and the retention time for GPC
molecular weight determination and proved that by using polystyrene or PEG-based
standards the materials' molecular weights were overestimated. Therefore, they
applied two methods for calculating the absolute molecular weight including
MALDI-MS and GPCV (Chaudhary et al 1997).
The GPC instrument used in this investigation was equipped with a refractive index
detector along with low angle light scattering laser and intrinsic viscosity detectors
which in theory would enable absolute polymer molecular weights to be obtained.
However, due to the nature of the polymer (PGA), no reliable and reproducible
response was recorded, because PGA has a relatively low molecular weight and low
refractive index increment (dn/dc) values, hence, the GPC accurate mass detectors
(or triple detectors) did not produce reliable or reproducible results. This problem
was addressed by using the refractive index response versus time plot to enable a
calculation of the molecular weight based on the more standard method of molecular
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weight versus polystyrene standards (conventional calibration method). This also
allowed a direct comparison of the polymer molecular weights obtained here with
those cited in literature.
With the conventional calibration method, retention volumes of known polymer
standards, for example polystyrene or PEG, are used for plotting a calibration curve.
This curve is then used for the determination of the molecular weight of the polymer,
by using the straight line equation, obtained from the standard curve. However, this
method only gives an accurate mass if the material being analysed is the same as that
used to generate the calibration graph. Other research groups commonly use
polystyrene standards for calibration purposes for the analysis of PGA and related
polymers (Kline et al 1998b; Thompson et al 2006).
The molecular weights in the present work were determined versus polystyrene
standards. Thus from a series of 6 molecular weight polystyrenes (Mw = 650 to
50000Da) a calibration curve was obtained and the Mw for these samples were
determined, The molecular weight ofPGA was 10500Da (versus polystyrene). Based
on the suggested structure it was proposed that the polymer chain contains 55 units
(as one unit has a molecular weight of 190Da).
A representative GPC chromatogram of PGA is shown in figure 2.2a, which
illustrates that the polymer is free of any residual monomers. The peak corresponding
to the polymer is quite broad, hence, implying that the polymer is not mono-disperse
in nature (PDI > I). Polydispersity index (PDI) is ratio of weight average molecular
weight (M») to number average molecular weight (Ms). POI is considered an
important indicator of reaction completion, if the POI is 1, all the chains in the
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polymer have the same number of repeat units and equal molecular weights
indicating the product is mono-dispersed. It was observed that for enzyme reactions
PDI values normally increase with the degree of polymerisation as reported earlier
by McCabe & Taylor (2004).
Hence, as expected, the synthesised material contains fragments of various chain
lengths, with different molecular weights and number of repeat units. The quoted
molecular weight (10500Da) was determined using the retention volume at peak
maximum. Hence, this does not give the absolute molecular weight of the polymer
sample. Since no absolute M; (weight average molecular weight) and M, (number
average molecular weights) were obtained, no poly dispersity index (PDI) values
were calculated.
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Figure 2.2 (a): Representative GPC chromatogram of PGA
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Figure 2.2 (C): Representative 1H-NMR spectrum of PGA
b) Structural confirmation:
Structural elucidation was carried out by FTIR and IH NMR techniques. FTIR was
also utilised for end group analysis of the polymer, which enabled confirmation of
the reaction completion or product formation. The FTIR spectrum (Figure 2.2b) of
the backbone polyester (PGA) clearly indicates the hydroxyl group at 3450 em-I and
the large carbonyl peak at 1727 em-I. Further, the disappearance of bands related to
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terminal vinyl groups of DVA at 1650 em" confirms the complete consumption of
monomers during the polymerisation.
The polymer was characterised via the proton assignments and integration of the IH_
NMR spectrum (Figure 2.2c). It was observed that there was no evidence of any
vinyl groups, which can be confirmed by the disappearance of signals at 04.5, 4.8
and 7.3 corresponding to terminal vinyl protons, from the starting material (DVA).
The IH-NMR integration method (Kolhe et al 2004) was used to calculate the actual
monomer ratio in the polymer. For DVA, the methylene (-CH2) group, corresponding
to 4 protons (d, gat 2.39 ppm) was considered as standard, and the variable multiplet
at 4.18 ppm, corresponding to 4 -CH2 protons (a, c) of glycerol were used for the
calculation.
ForPGA:
a) Number of -CH2 protons (2.39 ppm) = 4protons = 1molecule of DVA
b) Number of -CH2 protons (4.18 ppm) = 4protons = 1molecule of Glycerol
= 1 molecule of DVA + 1 molecule of glycerol
c) Ratio between DVA and Glycerol = 1:1 (DVA: glycerol)
For PGA synthesis, monomers were added in an equimolar ratio. Because DVA can
only attach to glycerol a 1:1 ratio of monomers was expected. The above calculation
supports the assumption that the monomer feed ratio and actual monomer ratio in the
polymer were the same.
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Although this reaction was previously utilised by Kallinteri et al. (2005) for the
preparation of PGA for drug delivery studies, a detailed study of the effect of
reaction parameters on the polymerisation reaction was not carried out. Hence, once
the reaction was successfully performed on the larger scale (-1 ~Og) with good
product yield, the effects of different reaction parameters were studied on the
polymerisation of PGA. However, this was done on a slightly smaller scale of 10-
15g, because it was not cost effective when large amounts of the polymer were not
required.
2.3.1.2 Effect of reaction conditions on polymer synthesis
Reaction conditions were varied to study the effect on the molecular weight of PGA
obtained.
Two different heating media, a metallic heating mantel fixed on a hot plate
and a water bath, were compared to study the effect of the heating source on the
polymerisation reaction. No difference in polymer molecular weight was observed
between these, as similar molecular weight polymers were obtained (Table 2.5). The
use of a hot plate as the heating medium for the polymerisation reaction was found to
be a viable alternative option to the water bath for PGA synthesis. Both heating
media provided the same temperature but the added advantage of using a hot plate
was the water-free environment, as no water vapours were present around the
reaction setup, hence minimising hydrolysis of polymer due to the introduction of
moisture. However, one considerable drawback of using the hotplate is the
incomplete immersion of the reaction contents in the heating mantle, which resulted
in an uneven heating of the viscous reaction mixture. Thus the water bath was
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selected as the heating medium for all future reactions for consistency of heating
during polymer synthesis.
Table 2.5
Effect of heating medium on PGA molecular weight
Heating medium Molecular weight (Da)
Water bath
Hot plate
9500 Da
8700 Da
Two different stirring modes, using a magnetic stirrer and an overhead
stirrer, were investigated using a hotplate as the heating medium. It was observed
that magnetic stirring failed to ensure proper mixing of the reactants resulting in the
production of lower molecular weight polymers (Table 2.6). This can also be
observed from the GPC traces shown in figure 2.3, which indicate the presence of a
residual amount of monomer and small oligomers. This is probably due to the
relatively small size of the magnetic bar (as compared to a Teflon paddle) and its
inability to rotate and mix the increasingly viscous reaction mixture. Additionally,
the magnetic stirrer may crush the enzyme support, resulting in loss of enzyme
activity leading to less polymerisation and hence an overall reduction in molecular
weight. All these factors result in an incomplete reaction, hence, unreacted
monomers and very small molecular weight fragments can be seen at the tail of GPC
chromatogram of the magnetically stirred polymer sample (Figure 2.3). At high
enzyme loading, the enzyme beads become viscous and settle down or 'sink' in the
reaction medium, resulting in the generation of two phases of medium with different
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enzyme concentrations. Therefore, strong mixing is required to ensure an equal
distribution of enzyme throughout the medium. This is why the polymer synthesised
via magnetic stirring had a considerably lower molecular weight with a broader peak
as compared to the overhead stirrer produced material. The overhead stirrer is a
powerful means of stirring, and so improves the enzyme diffusion while in an
increasingly viscous medium.
Table 2.6
The effect of different modes of stirring on molecular weights of PGA
Stirring mode Molecular weight (Da)
Magnetic stirrer 3500 Da
Over head stirrer 8700 Da
Magnetic stirrer
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Figure 2.3: GPC chromatogram of PGA synthesised using an overhead stirrer
(green line) and magnetic stirrer (black line) for mixing of the reaction.
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Moisture content is one of the most important factors playing a vital role in
polyester synthesis by maintaining the hydrolysis/condensation equilibrium. Hence,
the moisture content of all the reactants was determined prior to use. The amount of
moisture measured using Karl Fischer analysis was often different from the water
content stated on the manufacturer's specifications. This may affect the enzyme
activity, reaction equilibrium and hence the polymer molecular weight. A summary
of these results are provided in table 2.7, which indicates that the amount of moisture
in the reaction was higher than expected.
Table 2.7
Percent moisture content of reactants specified in the manufacturer's certificate of
analysis and determined with a Karl Fischer titrator
Monomers % Moisture
Measured Manufacturer's specifications
DVA 0.5 N/A
Glycerol 0.9 0.1
Novozyme 435 0.2 N/A
Tetrahydrofuran Not obtained 0.05
Tetrahydrofuran anhydrous 0.5 0.002
Traces of water associated with the enzyme are essential for optimum enzyme
activity but also have the potential to hydrolyse the diester monomer and polyester
end groups. The polymerisation reactions depend on simultaneous polymerisation,
degradation and enzyme deactivation. Throughout these reactions only the moisture
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content of Novozyme 435 was kept constant by placing it over activated silica and 3
A molecular sieves. All other reactants were used without any further steps to reduce
moisture content. However, in the polymerisation reaction the solvent constitutes the
largest proportion. Therefore it has the potential to alter the reaction behaviour or
product quality by introducing moisture into the reaction medium. To assess these
two different types of THF, hydrous and anhydrous were studied. The molecular
weights of polymers obtained are given in table 2.8, indicating that when anhydrous
THF was used, a polymer with considerably lower molecular weight was produced.
Table 2.8
Effect of solvent moisture on molecular weight of PGA
Solvent type Molecular weight (Da)
Hydrous THF
Anhydrous THF
10171
5733
As discussed earlier, some moisture is required for optimal enzyme activity
(Chaudhary et al 1998), the results obtained further support the hypothesis that very
low moisture contents led to decreased enzyme activity, hence, incomplete reaction.
PGA synthesised in the anhydrous THF contained a higher number of small
molecular weight fragments and un-reacted monomers (Figure 2.4), further proving
that decreased enzyme activity resulted in incomplete reaction even after 24 hours.
Additionally, this observation further confirms that decreasing moisture results in
decreased enzyme (Novozyme 435) activity which is in accordance with the
investigations done by Chaudhary et al (1998).
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Figure 2.4: GPC chromatogram of PGA synthesised in hydrous (green line) and
anhydrous THF (black line).
It is also worth mentioning here that immobilised enzymes (such as Novozyme-435)
have water molecules trapped near the active sites, but in the case of pure enzymes
(CAL-B), the situation will be other way around, as the enzyme support would not be
there to keep hold of moisture thus result in better enzyme activity (Billie et al 2000).
This further highlights the advantage of using immobilized enzyme for these
reactions. ovozyme 435 requires a certain amount of moisture from its acrylic resin
support for catalytic acti ity (Chaudhary et al, 1998). Addition of anhydrous solvent
leaches moisture away from the acrylic resin resulting in a decreased ability of the
enzyme to catalyse polymer synthesis. Moreover, it was observed that the acrylic
resin starts deteriorating and passes through the filter, resulting in low molecular
weight equi alent peaks in the GPC chromatograms. This reaction requires a balance
between the ater content required for enzyme activity and that which would cause
hydrolysis of the products. Anhydrous solvents, whilst minimising hydrolysis also
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result in decreased enzyme activity, hence leading to the synthesis of low molecular
weight polymers.
Degradation of the enzyme support also affects the quality of the PGA polymer, as
under anhydrous conditions the polymer product changed from a characteristic
transparent, yellowish colour and viscous appearance to an opaque, brownish and
very low iscosity liquid. Moreover the longer the enzymatic residue (along with fine
acrylic resin) remains in the polymer, the more polymer degradation occurs. Figures
2.5 show the effect of decreasing moisture on the Novozyme 435 particles.
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Figure 2.5: Effect of volume of anhydrous THF on enzyme support integrity after
24hours: (a) 20 ml, (b) 10 ml and (c) 5 ml.
The quantity of enzyme used in anhydrous media was further increased 10 times (to
5g) which resulted in an increase in molecular weight from 6500 Da to 9500 Da.
This further supports the theory that a decrease in enzyme activity occurred in the
presence of anhydrous solvent which resulted in a polymer of lower molecular
weight being obtained. Increasing the amount of active enzyme resulted in a higher
molecular weight polymer being formed. Hence, it may be concluded that in such
reactions, where moisture content leads to decreased enzyme activity, addition of
more enzyme will favour the reaction.
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Solvent volume plays a crucial role in polymer synthesis in terms of
provision of appropriate space for monomers to polymerise. Less solvent will reduce
the freedom of monomers to form long straight chains of polymer, resulting in
increased cross linking. Excessive solvent will result in increased distances between
monomers and cause synthesis of many small chains of polymers, with low
molecular weight.
A series of reactions were designed to investigate the effect of solvent volume on
PGA synthesis. Molecular weights obtained throughout this series of experiments
(Table 2.9) illustrated that there was no significant difference observed in the
molecular weights of the polymers obtained. A lower volume of solvent appeared to
result in a lower molecular weight than that obtained using a larger volume of
solvent. Literature studies indicate that high molecular weight polymers can be
obtained by solvent-free synthesis (Apurva et al 1997), but the results obtained with
the published methods were not reproducible and either no polymer or very low
molecular weight polymers were synthesised. All such reported reactions were
carried out on very small scales, and the reason for not reproducing the results at
large scale may lie behind the fact that not enough moisture for enzyme activity was
available in such reactions or mixing was more difficult. Based on the results
obtained, for any further reaction the solvent volume was set at 20-25 ml.
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Table 2.9
Molecular weights of PGA obtained using different volumes of solvent (l'HF)
Solvent (THF) volume (ml) Molecular weight (Da)
5
20
25
50
9782
10009
13363
12413
Further to the studies related to solvent volume, it was observed, during some
reactions carried out by undergraduate project students, that when solvent evaporated
from the reaction mixture via improperly closed joints of the reaction flask, this
effected the polymer molecular weight. Hence, a series of reactions under controlled
solvent evaporation were carried out to investigate this observation.
A senes of experiments was designed to study the effect of solvent
evaporation on PGA synthesis. An increase in evaporation was directly proportional
to the considerable increase in molecular weight observed (Table 2.10). These results
indicated that if solvent was allowed to evaporate to some extent from the reaction
medium, it affected the molecular weight and physical properties of the polymer,
possibly by facilitating cross linking, when solvent volume decreased.
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Table 2.10
Molecular weight of PGA obtained under sealed and open reaction systems.
Reactor Status Molecular weight (Da)
ClosedlEvaporation limited
OpenlEvaporation allowed
9000
14000
Further investigations were carried out, by allowing the solvent to evaporate over 24
hours of reaction then more THF was then added to the same reaction medium and
left for a further 24 hours, before stopping the reaction. It was observed that solvent
evaporation resulted in a slight increase in molecular weight of the polymer but if
more solvent was added to the same reaction system, the molecular weight started to
decrease slightly presumably via hydrolysis (Table 2.11).
Table 2.11
Change in molecular weight of PGA with addition and removal ofTHF
Solvent status in reactor Molecular weight (Da)
Solvent evaporated
Additional solvent added
13417
12208
These results provided valuable information on the real-time control of molecular
weight whilst proving the requirement for strict control over the reaction conditions
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to get reproducible polymerisation that results in polymers with the same molecular
weight and properties.
The next step was to study the effect of the concentration of enzyme on PGA
synthesis. It is already well established that enzyme concentration affects the
molecular weight and hence polymer properties (Chaudhary et al 1995). In a series of
experiments various amounts of enzyme were used and the results obtained indicated
that the molecular weight of the polymers increased considerably with increased
concentration of enzyme (Table 2.12). These results are in accordance with the
studies done by Uyama et al (1995), who also reported an increase in polymer
molecular weight and yield by increasing the amount of lipase. To achieve the
desired molecular weight of 10-12 kDa, the enzyme concentration was kept to 3.4%
w/w Novozyme 435 for PGA synthesis in all further reactions.
Table 2.12
Effect of en:..tyme concentration on PGA molecular weight
Enzyme concentration
(% wlw monomers)
Molecular weight (Da)
0.34%
1.3%
3.4%
5733
6609
9468
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The effect of reaction time on polymer synthesis was studied in the fmal series of
experiments by removing a small amount of reaction matrix at specific time
intervals. This was then dissolved in 2 ml of THF and filtered through 0.45J.1m
membrane filters to a GPC vial. Molecular weight analysis was performed at specific
time intervals from 1 to 40 hours. It was observed that polymer molecular weight
increased as a function of time until 24 hours, followed by a sharp decrease thereafter
(Figure 2.6). These results support the fact that increasing time has an effect on
polymer properties (molecular weight) as reported earlier by Kumar & Gross (2000).
The corresponding GPC traces are shown in figure 2.7. Hence, 24 hours reaction
durations were selected for all of the subsequent reactions. It is worth noting that, in
enzyme catalysed polymerisation, the reaction duration allows conversion of
monomers to polymer but at the same time enzyme activity can reduce over time,
hence leading to a slower increase in molecular weight, the hydrolysis reaction can
then lead to an overall decrease in polymer molecular weight (MacDonald et al
1995).
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Figure 2.6: Change in molecular weight of PGA with respect to reaction duration
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Polyesterification reactions occur in three stages, the first stage is characterised by
very rapid transesterification, in the second stage the polymerisation and chain
growth proceeds to a high molecular weight product, while in the third stage, the
polymerisation rate decreases to limit the molecular weight of the polymer and chain
growth. After the third stage the polymer starts degrading via hydrolysis (Billie et al
2000), which can also be seen in figure 2.7. Side reactions including hydrolysis and
deactivation of biocatalysts also cause low molecular weight products. The
increasing chain length causes a decrease in enzyme specificity and diffusional
resistance to enzyme, which is also a hindrance to obtaining greater molecular weight
of the product (Billie et al 2000).
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Figure 2.7: Overlaid GPC chromatograms of PGA obtained after various reaction
durations. Black: 5 hours, Green: 24 hours, Red: 32 hours
In addition to hydrolysis, the hydroxyl groups of the added diol were involved in
transesterification reactions which caused scissions of the high molecular weight
polyester, hence the extent of transesterification was proportional to the reduction in
average molecular weight of the polyester, as also confirmed by the findings of
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McCabe & Taylor (2004). Kumar and Gross (2000) proposed that with an increase in
molecular weight, the available number of hydroxyl groups decreases, resulting in
transesterification rates slowing down also.
It is established that the first 30 minutes of transesterification is very important, but
because of the kinetics and energetic status of these reactions, the system cannot
remain isothermal, until temperature controlling measures are in place (Apurva et al
1998). Apurva et al observed a 20-25°C increase in temperature during this phase
due to insufficient heat transfer, when DVA and 1,4-butanediol reacted in a water
bath with the help of a magnetic stirrer (Apurva et al 1997). To solve the problem
Billie and co-workers designed a isothermal reactor, but temperature changes were
observed in the initial part of the reaction, which was dependent on enzyme
concentration (Billie et al 2000). Hence, for the uniformity of reaction conditions, a
24 hour reaction duration was opted for all following reactions.
Once all the reaction parameters were studied for PGA synthesis, the following
reaction conditions were set as optimal parameters; A water bath was used to
maintain the temperature at 50°C; 25ml solvent (normally THF) was added to the
reaction mixture in a properly sealed reaction vessel with the enzyme concentration
of3.4%(w/v) and the reaction was left stirring via an overhead stirrer (Teflon paddle)
for 24 hours.
A series of experiments were then conducted using identical reaction conditions, for
the evaluation of reproducibility of the synthesis of PGA of a desired molecular
weight of approximately 10 kDa. Three PGA syntheses were carried out on different
days, under the same reaction conditions and the results obtained are summarised in
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table 2.13. These results indicate that polymers synthesised using optimised reaction
conditions were reproducible.
Table 2.13
Reproducibility of PGA synthesis under identical reaction conditions
Experiment (month) Molecular weight (Da)
2
3
Average
8952
10009
10210
9723
Once optimal reaction conditions were obtained, polymerisation reactions usmg
various other monomers were performed under the same reaction conditions to
produce polyester-co-lactones and PEG-copolymers. As some of the products were
solid at room temperature, purification procedures were applied for the removal of
unreacted monomers (if any) and small chain fragments or oligomers. Because
monomers with different solubilities were used, the need for a standard procedure
was highlighted, which enabled the removal of a broad range of impurities.
monomers, fragments and oligomers. The following section describes the
development of the purification procedure.
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2.3.2 Polymer processing and purification
To obtain a useful product it was necessary to remove unreacted monomers and
small molecular weight fragments from the crude material. Both water and methanol
are good solvents for the monomers used as well as the small molecular weight
polymer fragments formed, and did not dissolve co-polymers such as PGA-co-PDL.
They can therefore be used to purify these polymer samples once polymerisation is
terminated.
The ability of MeOH and water to effectively remove any residual unreacted
monomers and oligomers was evaluated. A physical mixture of monomer (PEG) and
polymer (PGA-co-PDL) was prepared to mimic the original unpurified sample. The
overlaid GPC chromatogram (Figure 2.8) of the physical mixture of polymer, PEG
and unpurified polymer sample shows that although peaks corresponding to both
analytes eluted at different retention volumes, both peaks overlapped each other
hence, it is a possibility that small concentrations of residual unreacted PEG were not
detected by GPC (Figure 2.8). Therefore, washing of such polymers is very
important to ensure a pure and monomer-free product.
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Figure 2.8: GPC chromatogram of a physical mixture of PEG and PGA-co-PDL
(black line) overlapped with chromatograms of pure PEG (green line) and
unpurified PGA-co-PDL-PEG sample (red line)
A physical mixture of PGA-co-PDL with PEG or PEGme was added to water and
mixed thoroughly. Analysis of the filtrate and residue clearly indicated that all of the
PEG passed into the filtrate leaving pure, clean polymer on the filter paper as a
residue. Chromatographic analysis (Figure 2.9) confirmed that there were no traces
of unreacted PEG and PEGme in the polymer samples.
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Figure 2.9: GPC chromatogram of PEGme in filtrate (red line), PGA-co-PDL
(green line) and PGA-co-PDL-PEG (black line) washed in water
Since previous studies confmned that water is a major source of degradation of these
polymers via hydrolysis, efforts were made to replace water with another suitable
solvent to avoid polymer degradation. Dong and Feng (Dong & Feng 2004) and
Tefani et al (2006) reported the use of MeOH for the removal of unreacted PEG.
Hence, MeOH was used as the purification solvent. It was observed that all PEG is
removed from the polymer-PEG mixture, suggesting that MeOH can be used instead
of water for the removal of PEG. Methanol is also a better choice than water because
of the improved solubility of the monomers and small oligomeric fragments in
methanol, while the efficacy of water is limited to the removal of only unreacted
PEG from the polymer. The fronting of the PEG peak in methanolic filtrates is
because of the removal of small molecular weight fragments of the polymers, which
results in a lowering of the PDI values (expressed by peak narrowing) of polymer
peaks as shown in figure 2.10.
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Figure 2.10: GPC chromatogram of PEGme in wash (red line), PGA-co-PDL-
PEGme (black line) and PGA-co-PDL-PEGme after washing in MeOH (green line)
Hence it was additionally confmned that water can only remove PEG but not
polymer (pGA-co-PDL), because of its insolubility in water. The effectiveness of
MeOH for not only the removal of PEG but also oligomeric fragments is evident in
the analysis of filtrate samples (Figure 2.11), where it is clearly evident that although
water is a good solvent to remove PEG, it failed to remove small molecular weight
fragments from the polymer matrix.
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Figure 2.11: GPC chromatogram of pure PEGme (black), PEO(me) in water wash
(green) and PEOme in MeOH wash (red)
Purification or re-crystallisation of polymers is required to ensure that polymer
samples are free from unreacted monomers or low molecular weight fragments. All
solid polymers that underwent re-crystallisation or re-precipitation from MeOH had
decreased polydispersity and increased peak symmetry because of the removal of
low molecular weight moieties and removal of unreacted monomers. Liquid
polymers could not undergo the recrystallising/purification process because of their
viscous nature and solubility in MeOH and other organic solvents. Hence, PGA was
used without any further purification.
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2.3.3 Development of a polymer library
Of all the polymers synthesised, PGA has the simplest structure, therefore it was
selected as a model polymer to study the effect of varying different reaction
parameters on polyester synthesis. This helped determine optimal conditions and
allow control over some properties of the polymer obtained. However, the nature of
this polymer was not very useful for drug delivery unless further modified (Kallinteri
et al 2005). Hence, a library of more complex functionalised polyesters was
synthesised, as discussed in following sections.
2.3.3.1 Functionalised and non-functionalised linear polyester synthesis
The divinyl ester monomer (DVA) was enzymatically polymerised with terminal
diols, including glycerol, 1,3-propanediol and 1,4-butanediol. The same reaction
conditions were used for the synthesis of all polymers with and without pendant
hydroxyl groups on the polymer backbone. Lipase from C. antarctica (lipase CA)
was used in a non-aqueous medium (THF). In most cases, the monomers were
quantitatively consumed but the product was not obtained in high yield (60-65%).
This may be due to the formation of a significant proportion of methanol-soluble
oligomers which were removed during the purification/processing stage. The
completion of the polymerisation was confirmed with the consumption of all
monomers, as no bands corresponding to terminal vinyl group appeared in the
corresponding FTIR and NMR spectra (section 2.3.1.1). However, hydrolysis of the
vinyl esters may have taken place during the polymerisation. Lipases regioselectively
catalyse the esterification of primary alcohols (Kobayashi 2009), hence, from FTIR,
a decrease in the band corresponding to the -OH group in case of glycerol and the
complete disappearance of the -OH bands from the diol monomers confirmed the
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consumption of the monomers. The practically observed ratio of monomer units was
also the same as the experimental ratio in which the monomers were used. The
molecular weight of PGA was 10 kDa with 50 repeating units. While the molecular
weights of non-functionalised, hydrophobic polymers based on 1,3-propanediol
(PPA) and 1,4-butanediol (PBA) were in the range of 5.3-7.3 kDa (Table 2.14).
Based on the same reaction a novel non-functionalised hydrophilic polymer,
PTEGA, was synthesised from the esterification of triethylene glycol and DVA.
FTIR analysis of PTEGA also showed complete disappearance of the bands
corresponding to -OH and vinyl groups and the molecular weight was confirmed as
8.7 kDa. This illustrates the successful use of the enzyme catalysed reaction for the
synthesis of a range of versatile polymers. Although the synthesis of PBA via
enzyme catalysis was previously reported by Apurva et al (1998), and the synthesis
of PGA, PPA and related polymers have been reported by Kobayashi et al (2006),
generally on the micro-scale. Using the optimal conditions studied, all these
polymers were synthesized at useful scale (up to 100g) via one-step reactions.
Application of the same reaction method for the synthesis of the novel polymer,
PTEGA, indicates the versatility of this reaction. The summarised results of the
polymer synthesis are tabulated in table 2.14. All of these polymers (at room
temperature) were very soft solids or highly viscous liquids. The reason for this
physical appearance lies in the fact that the polymeric units have shorter carbon chain
lengths (9-10 carbon chains). Further purification of these polymers was not possible,
because of the solubility of the high molecular weight and low molecular weight
fragments of the polymer in same solvents.
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PLGA, of a comparable molecular weight and of high purity (monodisperse) was
purchased as a solid polymer at room temperature. Even though it had shorter chain
length, it was probably solid because it had been purified. PLGA is an FDA-
approved polymer and has been extensively studied (Jain 2000).
The PLGA chain consisted of 65 repeat units, while the hydrophilic polymer, PGA
had 50 repeating units. On the other hand both PPA and PBA consisted of 40
repeating units and PTEGA was made up of 35 repeating units. Polymer properties,
such as hydrophilicity and degradation can be altered by controlling the repeating
units (Oster et al 2004) and number of pendant functional groups per chain
(Bhattacharyya et al 1998). These contribute to the polymer properties and behaviour
during drug delivery applications, and hence can be further exploited for the
synthesis of polymers with desired properties.
The properties of all the synthesised polymers were compared against PLGA. The
hydrophilicity of PGA was compared to PLGA. The contact angle (8) on the surface
of these polymers showed that, as expected, PGA has a smaller contact angle
(SO.l0±5.36) than PLGA (7S.81±1.34) due to the presence of free -OH groups
making PGA more hydrophilic than PLGA. Hence, glycerol was selected in further
polymerisations to both impart hydrophilic character to the material and afford
pendant hydroxyl groups.
Neither PGA, PPA, PBA nor PTEGA showed any measurable thermal properties and
Tg, Tm and T, values were not obtained over the range of -2SoC to 150°C. These
polymers are very viscous at room temperature and did not solidify even at -2SoC nor
did they boil/evaporate at 100°C. However, the equivalent PLGA polymer, a solid at
room temperature, has a Tm of 34.28°C. A polymer with a low glass transition
temperature (Tg) and melting point (Tm) can be used effectively in drug delivery
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applications as it can melt and release the drugs at body temperature. However, at the
same time storing it at room temperature can decrease its shelf life by increasing
degradation, resulting in a loss of important properties.
Polymer properties can be altered by incorporating different monomers which can
help to make the polymers useful in drug delivery applications. Hence, PGA, PPA
and PBA were copolymerised with lactones and PEG in an attempt to obtain
materials with relatively higher molecular weights and solid states with higher Tg and
Tm values. These polymers are discussed in the following sections.
2.3.3.2 Funetienalised and non-functionalised linear polyesters via ring-
opening copolymerisation of lactones
Thompson et al (2006), reported the large scale synthesis of PGA-co-PDL and its
subsequent investigation for ibuprofen delivery, while Gaskell et al (2006) reported
the application of the same polymer for pulmonary delivery of chymotrypsin. In this
work variations ofPGA-co-PDL were synthesised altering the properties to make the
polymer more hydrophilic or more functionalised to study the effect of this on the
quality and type of drug encapsulation.
Polymers equivalent to PGA-co-PDL, and PBA-co-PDL were synthesized with
varying carbon chain lengths by introducing caprolactone (seven carbon members)
instead of pentadecalactone (a 15 carbon chain) or by introducing triethylene glycol
instead of glycerol to obtain PGA-co-PCL and PTEGA-co-PDL. The ratios of the
repeating units were varied to alter the hydrophobicity of the polymer (PGA-co-PDL
1:1:1 and PGA-co-PDL 1:1:1.2). The numbers of pendant functional groups were
altered by using non-functionalised polymers such as PPA-co-PDL, PBA-co-PDL or
by using sorbitol, a sugar, as a monomer (PSA-co-PDL).
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All the resulting polymers were obtained in good yields of about 60% (Table 2.15).
Because of their solid states co-PDL polymers showed narrow molecular weight
dispersities in GPC and were free of smaller molecular weight fragments.
The IH-NMR integration method (Kolhe et al 2004) was used to calculate the actual
monomer ratio in the polymer. For DVA, the methylene (-CH2) group, corresponding
to 4 protons (d, d' at 2.32ppm) was considered as standard, and the variable multiplet
at 4. 18ppm, corresponding to 4 -CH2 protons (a, c) were used for glycerol, while the
sum of all protons at 1.34, 1.65, 2.32 and 4.05ppm were used to calculate the ratio of
PDL in polymer. These polymers are complex in nature and have a broad distribution
of molecular weight and chain lengths, therefore protons signals overlap each other.
This decreases the accuracy of the one dimensional IH-NMR calculation to
determine the exact monomeric ratio but does provide an estimate of the polymer
composition, which can be used to explain and predict polymer properties.
For PGA-co-PDL:
a) Number of -cH2 protons (2.32ppm) = 4protons = 1molecule of DVA
b) Number of -CH2 protons (4.18ppm) = 4protons = 1molecule of glycerol
= 1molecule of DVA + 1molecule of glycerol
c) Number of -CH2 protons (1.34, 1.65, 2.32 and 4.05ppm) = 28protons
= 1molecule of PDL
d) Ratio between DVA and glycerol = 1:1:1 (glycerol:DV A:PDL)
For PGA-co-PDL synthesis, glycerol and DVA were added in equimolar ratio, while
the amount of PDL was varied. Because DVA can react with glycerol or PDL, there
are multiple possibilities of attachment of monomers expected, leading to a random
polymer.
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The NMR calculation supports the assumption that because monomer feed ratio and
actual monomer ratio is not same, the polymer would be "random" in nature. Under
consistent reaction conditions and assuming that monomers do not have similar
reactivity, the polymers were presumed to be most likely random in nature as
previously established by Namekawa et al (2000), which was then further confirmed
from the J3C_NMR spectrum of polymer, where by the peak corresponding to
carbonyl groups (0 I73-174ppm) was split in six peaks, corresponding to six possible
ways the three monomers can join.
Two lactones were selected for copolymerisation, a seven-membered ring, e-
caprolactone (CL) and a fifteen membered ring, m-pentadecalactone (PDL). The
results presented in the table 2.15 showed that co-PDL polymers yielded products
with a higher lactone ratio than co-CL polymers. For instance, a 1:1:0.7 ratio of
monomers in PGA-co-CL was achieved when monomers were mixed in ratio of
I :1:1. On the other hand the corresponding 1:1:1 ratio of monomers in PGA -co-PDL
was achieved from the mixing of 1:1:1 ratio of monomers. The details of the results
are summarised in table 2.15.
Additionally, because of the small ring size, co-CL polymers did not result in high
molecular weight polymers, hence causing all co-CL polymers to form viscous
products at room temperature. On the other hand PGA-co-PDL based materials
yielded solid products with high molecular weights. It is already established that the
control imparted to lipase-catalysed ring-opening polymerisation reactions is not
good and the molecular weight range and PDI of the products are very high
(Kobayashi et al 2001).
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When the amount of added lactone was varied (0.5, 1 and 1.5moles) relative to the
other monomers, it was observed that the ratio of monomers in the product was near
to 1:1:1, regardless of the amount of added lactone. These results suggest that
monomers are linked in equimolar ratios giving an A-B-C-C-C-A-B-A-B-A-B-C
type polymer. However, this change in the monomer ratio also resulted in a
difference in the physical properties of polymers obtained. For instance, all polymers
were solid at room temperature but increases in the lactone ratio from 1:1:1(17.5
kDa) to 1:1:1.2 (29 kDa) caused an increase in Tm from 42.31 °C to 52.34°C. The
same trend was observed for the contact angle of these polymers, as e for 1:1:0.5 was
70.02±1.20 while for 1:1:1 the observed e was 65.65±2.36. Hence, suggesting that
molecular weight is the not only difference but these polymers also have different
chemistries, which cannot be explained by the IH_or 13C_NMRanalysis.
The obtained results confirm that functionalised polymers (with pendant hydroxyl
groups) were successfully synthesised possessing the desired properties of higher
molecular weight, higher Tm- lower Tg values and in the solid state at room
temperature. The corresponding non-functionalised (no pendant -OH) polymers,
PPA-co-PDL and PBA-co-PDL, were also synthesised. These polymers also have the
desired material properties; higher molecular weight, higher hydrophobicity, and
higher Tm and lower Tg values, that are required for drug delivery applications as
discussed in chapter 1.
One more important thing worth noting here is that PGA-co-PDL 1:1:1 and PPA-co-
PDL 1:1:1, which differ only in the presence of -OH groups also exhibited different
physical properties. A higher hydrophobicity (contact angle) and a 14°C higher Tm of
the PPA-co-PDL was observed while the lactone ratio and molecular weight is lower
than that of PGA-co-PDL. This signifies the effect of pendant hydroxyl groups on
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the polymer properties. Based on a similar reaction, PTEGA-co-PDL was
synthesised as a non-functionalised hydrophilic polymer. It was observed that
PTEGA-co-PDL (1:1:1) and the corresponding PGA-co-PDL (1:1:1) have similar Tm
values which may be considered an effect of the higher molecular weight.
Sorbitol was used as a monomer to obtain hydrophilic polymers with more pendant
hydroxyl groups. The synthesis of such polymer products was more complex as these
more hydrophilic polymers were not soluble in non-polar organic solvents.
Additionally, the presence of higher numbers of -OH groups (four hydroxyl groups
per unit) on the polymer backbone caused hydrogen-bonding between polymer
chains which made them insoluble in polar organic solvents.
The polymer in which the lactone ratio was less than expected (1:1:0.5), can be
explained by the facts that lipase have more tendency to polymerise at primary
hydroxyl groups (regioselectivity) resulting in a higher ratio of sugar in the polymer.
Additionally, a higher number of -OH groups made the medium more hydrophilic
leading to a smaller molecular weight (3.2 kDa) polymer. A similar effect of more
hydrophilic monomers on polymer molecular weight was also observed when PEG
was used as a monomer (discussed in following section).
The results obtained in this section further illustrated that hydrophilic copolymers
with and without functional groups were successfully synthesised via the same
reaction scheme, involving both ring-opening and polycondensation polymerisation.
Following this, attempts were made to synthesise block copolymers of these co-
lactones with PEG. These types of polymers have hydrophilic and hydrophobic
segments (are amphipathic) and may afford better drug loading.
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2.3.3.3 Functionalised and non-functionalised linear PEG-copolymers
The importance of using PEG block copolymers in drug delivery is already
recognised by materials scientists (Harris 2001; Dong & Feng 2004). Many
researchers have focussed their work on the synthesis of PEG copolymers with either
PLGA (Ghahremankhani et al 2007) or polycaprolactone (PCL) as they are FDA-
approved biomaterials (Yuan et al 2000). In terms of improving the properties of
polymers investigated here, PEG was used as a monomer for the synthesis of block
copolymers.
Although, lipase-catalysed PEG copolymer synthesis by ring-opening polymerisation
of lactones has previously been reported (He et al 2003), the synthesis of PEG
copolymers via simultaneous ring opening and polycondensation has not been
reported before. As PEGs have terminal hydroxyl groups, lipase catalysis was
explored for the copolymerisation with monomers such as glycerol, DVA and PDL
for the synthesis of different novel polymers as listed in table 2.16 and 2.17. The
physical states of the resulting polymers were generally similar; short chain
copolymers were viscous liquids or soft solids at room temperature with molecular
weights in the range of 3-5 kDa.
The IH-NMR integration method (Kolhe et al 2004) was used to calculate the actual
monomer ratio in the polymer. In addition to the designated peaks of DVA, glycerol
and PDL, the peaks at 3.6ppm, corresponding to CH2 protons of PEG, were used to
calculate the ratio of PEG in polymer.
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For PGA-co-PDL-PEG:
a) Number of -CH2 protons (2.39ppm) = 4protons = 1 molecule of DVA
b) Number of -CH2 protons (4.18ppm) = 4protons = 1 molecule of glycerol
= 1 molecule of DVA + 1 molecule of glycerol
c) Number of -CH2 protons (l.3ppm) = 24protons = 0.84 molecule of PDL
d) Number of -CH2 protons (3.64ppm) = 2.6protons = 0.02 molecule of PEG
e) Ratio between DVA and glycerol = 1:1:0.8:0.02 (glycerol:DVA:PDL:PEG)
For PGA-co-PDL synthesis, glycerol, DVA and PDL were added in an equimolar
ratio while the amount of PEG was varied. Because DVA can attach to glycerol,
PDL or PEG, hence there are multiple possibilities for the attachment of monomers
to form a random polymer. Based on NMR calculations it is most likely that PEG
and PEGme copolymers were "random" in nature.
Work carried out at Boehringer Ingelheim (Germany) suggests that PEG-based
copolymers for drug delivery applications must have 5-15% PEG in the polymer
chain while for medical devices PEG should be less or equal to 5%. The synthesised
polymers have PEG contents in accordance with these guidelines. The results shown
in the following table (2.16) also confirms the findings of He et al (2003) that
increasing the molar feed ratio of lactonelPEG increased the molecular weights of
the product. This is why all the PEG and PEGme copolymers gave higher PEG
contents in polymers. PGA-co-PDL-PEGme copolymers are solid at room
temperature, although they have lower molecular weights than corresponding
colactones. However, they have higher Tm values, but lower Tg values, which makes
these polymers useful candidates for drug delivery applications.
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All PGA copolymers of PEG and PEGme exhibited higher PEG contents (Tables
2.16 and 2.17) compared to PPA based PEG copolymers which showed lower PEG
and PEGme contents. These observations were attributed to the fact that increasing
hydrophobic contents in the reaction mixture lead to the occurrence of a biphasic
reaction medium (where one phase consists of polar PEG and triol contents and the
other phase consists of non polar diol and lactone contents), as indicated in the
previous studies (Poojari & Clarson 2010). This is why the reaction of PEG and
PEGme with glycerol yielded polymers with a higher %PEG as compared to the diol
(1,3-propanediol)-based polymers.
However, no significant differences in Tmand Tg values were noted between PGA
and PPA based PEGIPEGme copolymers. But further results obtained by using other
monomers such as PDL, helped to conclude that the thermal properties could be
altered, not only by the polymer molecular weight but also by changing the
chemistry of the polymers. For example, PGA-co-PDL-PEGme (4.7 kDa) has the
same Tm(55°C) as compared to PPA-co-PDL-PEGme (9.5 kDa). The difference of
4.8 kDa in the molecular weight of two polymers is compensated by the difference of
8.6% PEGme content, resulting in the polymers with same melting point. PGA-co-
PDL-PEG polymers have similar Tmvalues but very high Tg values (40°C) which is
higher than required for drug delivery applications to the human body. From the
combined NMR calculation and the molecular weights of the PEG copolymers, it
was observed that one polymer chain typically consists of one PEG molecule along
with 5-12 repeating units of the PGA or PGA-co-PDL. The obtained triblock
polymer ratio was close to that of the monomer feed ratio. On the other hand, diblock
polymers exhibited greater differences from the monomer feed ratio, which altered
the polymer properties. These observations were in accordance with studies by He et
al (2003).
109
-e==e.•....
(,j==r-.
-.uo
'-"
Go
'-"
~o
.~
>
<Il::so
~:>
.-
o
<?
-o
<?
.-
oo
::to
I
-oo
-:t
No
<?
00
<?- -
-o
<?
-o
<?--
Noo--
-oo--
::to
I
o-
-
-C!
<?
-
c
W
0...
I
...J
U
Io
"(
~
0...
Go
'-'
--uo
'-'
'"::soo
'":>
No
c?
-o
c?-
.-
~
o
-o
c?
::c:o
I
Q)
Eo
u.J
Q..
I
<o
Q..
-oo
lr!
-
tr\oo
c?
::c:o
I
Q)
Eo
u.J
Q..
I
..Jo
Q..
Io
U
I<o
Q..
-oo
~-
o.-
~
<?--
::to
I
Q)
E
@
Q..
I
..Jc
Q..
Io
U
I
<o
Q..
-o
c?
lr'l
c?.--.-
o
No
c?
.-
o
c?.-
-
::c:o
I
Q)
@
Q..
I
..Jc
Q..
Io
U
I
2
r--.-
o
\0
tr\
o
-~
<?.-
::to
I
Q)eo
u.J
Q..
..Ju
Io
U
I
~
Q..
.-.-
.-
oo
~.--
-o
c?
The presence of PEG and PEGme in polymer chains not only imparts some
beneficial characters for drug delivery applications, but also helps the polymer to
degrade quicker at specific environmental conditions (temperatures above Tg), via
hydrolysis. The details of effects of PEG on drug encapsulation and release are
discussed in chapter 3.
2.3.3.4 Functionalised and non-functionalised linear polythioesters
Polythioesters are a relatively new class of polymers and have not yet been fully
explored for drug delivery applications. Polythioesters have many advantages over
the corresponding oxoesters, for instance, higher melting points, high reactivity and
quicker degradation (discussed in section 2.0). The previously reported syntheses of
polythioesters are by "biological procedures" or biosynthesis, using microorganisms
(Kawada et al 2003), by interfacial polycondensation (Podkoscielny & Rudz 1993)
and by lipase catalysis (Podkoscielny & Wdowicka 1985; Kato et al 2006). These
reactions were generally performed on a 0.2mmol scale (-0.03g), hence, in this work
polythioesters were synthesised on a useful scale (-15-20g) to investigate their
potential in drug delivery applications.
Polythioesters were synthesised using 1,3-propanedithiol and dithiothreitol as
monomers with divinyl adipate and pentadecalactone. These reactions were
performed in solvent-free environments because the higher reaction temperatures
(120°C) would result in complete evaporation of the solvent. The use of enzyme
catalysis proved a successful approach for the direct esterification of non-protected
thiol groups. Removal of the by-product, water, was carried out by fitting a drying
tube on the reaction flask.
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An additional aspect is the lower specificity of lipase towards thioesters (Ohmer et al
1996), which makes this reaction proceed at a slower rate. This is why a higher feed
of thiol, longer reaction duration (48 hours) and higher temperatures (120°C) are
required for such reactions. This is considered to be the main reason for the low
molecular weights of the obtained products (Table 2.18). Hence, these polymers
were viscous or soft solids at room temperature. It is well established that solvents
also effect the polymerisation in different ways depending upon the monomers used
and product properties (for example solubility, molecular weight and chain length of
polymer) (Namekawa et al 2000). Hence, a decreased solubility of polymer in the
reaction medium will result in chain scission and low molecular weight products
(McCabe & Taylor 2004), which can be attributed to the low molecular weight of the
polythioesters.
The PDTTA-co-PDL obtained was a solid at room temperature but in the form of a
rubber-like material, not a solid crystalline powder like the corresponding oxoesters.
Cross linking of polymer chains may have occurred - dithiothreitol has both terminal
thiol and pendant hydroxyl groups and can react at either site. As the reactivity of
thiols via lipase catalysis is lower than that of hydroxyl groups, not all monomers
may have been consumed in the reaction. The FTIR spectrum of PDTTA-co-PDL
has two separate bands corresponding to carbonyl groups, one from the thioester link
and a second from the oxoester. This suggested that the polymer has two different
types of ester linkages (shown in characterisation data, 2.2.5). The same observations
were reported by Hedfors et al (2005)where only 70% of thiol was polymerised with
caprolactone.
The NMR interpretation is more complex as two polymeric structures are possible
for the same product; with the sulphur adjacent to carbonyl group and the oxygen
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adjacent to carbonyl group, as represented in the characterisation data in section
2.2.5.5. Although polythioesters and the respective colactones were synthesised
successfully via lipase catalysed reactions, the obtained polymers were not
crystalline, hence may have limited use in drug delivery applications. Further
explorations of the properties of these polymers are discussed in detail in chapter 3.
Another reason for synthesising polythioesters was their predicted quicker
degradation rate. The detailed studies of the degradation of these polythioesters are
discussed in chapter 4.
2.3.4 Post-synthetic modification of the PGA-co-PDL
Many researchers have worked on the development of an improved controlled and
targeted drug delivery system. A new strategy to increase the blood circulation time
of drugs was developed by Liu et al (1999) who conjugated drugs to PEG molecules.
Conjugation of drugs to various chemical moieties can not only increase their blood
circulation time but also ensure the targeted delivery of the drug by minimising the
exposure to the physiological environment, hence preventing any side reactions of
the drug. In the present work, ibuprofen and stearic acid were conjugated via
terminal carboxylic acid groups to the free hydroxyl groups on polymer backbones
via DCC assisted conjugation reactions. Stearic acid, being a component of fatty
acids, is biocompatible and has low toxicity. Stearic acid consists of an eighteen
carbon-long chain, hence it was attached onto polymer backbone to make it more
hydrophobic. Either stearic acid or ibuprofen molecules were attached to 50% or
100%of the available hydroxyl groups on the polymer backbone.
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Previously researchers used an excess of carboxylic acid with the intention to react
all -OH groups present (Kolhe et al 2004). To study the effect of conjugation on
polymer properties, different amounts of ibuprofen and stearic acid were attached.
Hence, in two separate experiments 50% and 75% of available -OH groups of
polymer were conjugated. The average molar ratio of ibuprofen/stearic acid to
polymer used was calculated on the basis of average molecular weight and average
number of free hydroxyl groups on the polymer backbone.
Purification of the products was achieved by washing with a mixture of solvents,
which lead to a product of broad molecular weight dispersity. This problem could be
addressed in the future by using a dialysis membrane of specific molecular weight
cut-off.
Successful conjugation was confirmed by the disappearance, or considerable
decrease in intensity, of the -OH band (around 3400cm-1) in the FTIR data of the
product (section 2.5.5), while a considerable increase in molecular weight further
confirmed the successful ibuprofen/stearic acid-polymer conjugation. Although
polymers were purified, GPC chromatograms confirmed the presence of some
unreacted ibuprofen or stearic acid in the conjugated polymer samples. Additionally
the broad GPC peaks suggested the high polydispersity of the product molecular
weight, which suggests that either conjugation had not completely taken place or
perhaps, during the process, polymer chains had broken down (to create lower
molecular fragments) or cross-linking had occurred between the -OH group of
polymer backbone and the terminal group of the polymer chain, which could create
longer or cross-linked polymeric chains.
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The lH-NMR integration method (Kolhe et al 2004) was used to estimate the
conjugation ratio. For stearic acid, the terminal methyl group, corresponding to 3
protons 0, at 0.88ppm) was considered as standard, and the variable singlet at
1.30ppm, corresponding to 22 -CH2 protons (g) of PGA-co-PDL-C18 or PGA-co-
PDL-ibu were used for the calculation. As 3 protons correspond to 1 stearic acid
molecule, 28 protons were subtracted from the total number of protons at 1.30ppm,
leaving behind the only protons corresponding to "g" protons of polymer. As one
molecule of polymer contains 22 "g" protons, all obtained "g" protons were divided
by 22 to get the polymer molecules in conjugated product. A similar procedure was
followed with ibuprofen. In case of ibuprofen 6 protons corresponding to two methyl
groups (p, p') at 0.89ppm were considered as the standard and compared against the
-CH2 protons ("g") at 1.30ppm. A sample calculation is shown below, while all the
results are summarised in table 2.19.
For 50% stearic acid:
a) Number of -CH3 protons (0.88ppm) = 3protons = 1molecule of stearic acid
b) Number of -CH2 protons (1.30ppm) = 74protons = 28H of stearic acid + 46 H of
polymer = 1 molecule of stearic acid + 2 molecules of polymer
c) Ratio between stearic acid and polymer = 1:2 (stearic acid: polymer) or 50%
stearic acid.
Previously, Thompson et al (2008), reported the ibuprofen conjugation of ibuprofen
acid chloride to PGA-co-PDL in feed ratios of 100% and 50%, but only 12.6% and
6.8% drug-conjugation was achieved whereas, through DCC coupling reaction, in the
present work, 33% and 50% drug conjugation is reported. However, a non-linear
relationship between drug conjugation and molecular weight was observed in both
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cases. The Dee coupling proved to be a more efficient technique for drug
conjugation because during ibuprofen acid chloride synthesis, the polymer is directly
exposed to acid, which has a high potential to degrade the polymer's ester groups.
The Tm values were considerably lower for Dee coupled ibuprofen-polymer
conjugates as compared to acid chloride synthesis, which indicates that the presence
of ibuprofen induced strain at ester linkages and weakened the interchain forces
(hydrogen bonding) of the polymer backbone.
On the other hand, an increase in the Tm values of DCC-coupled stearic acid-polymer
conjugates indicates a stabilisation of giant polymer structures, and Tm increases with
increasing stearic acid content.
In conclusion, the successful conjugation of ibuprofen and stearic acid to PGA-co-
PDL took place and conjugated products were obtained with various percentages of
the conjugated species. The obtained products may have undergone cross-linking
which resulted in higher molecular weights and polydispersity of the products.
Inclusion of chemical moieties (stearic acid and ibuprofen) not only increased the
molecular weight of the products but also altered the physical properties of the
polymer (for example Tm). These products were further explored for their use in drug
delivery applications (as discussed in chapter 3, Drug Encapsulation and Release).
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2.4 CONCLUSION
An enzyme-catalysed esterification method was developed. This method was
successfully used for the synthesis of a library of polyesters by incorporating a
variety of monomers to afford incremental changes in chemistry, molecular weight,
hydrophilicity and functionalisation of the polymer backbone. It was observed that
small alterations not only in experimental factors and reaction variables but also in
monomer chemistry play a crucial role to obtain materials having the desired
properties. The reactions were successful and products were obtained on a larger
scale with higher yields than previously reported. Hence, the materials produced can
be effectively use for investigations of the relation between polymer and drug
chemistry for the applications to encapsulate range of drugs.
These polymers may have better potential as drug carriers either by encapsulating a
range of drugs possessing different physicochemical properties or by releasing the
conjugated drug from the polymer backbone. This hypothesis is discussed in the next
chapter (Drug Encapsulation and Release).
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Drug Encapsulation and Release
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3.0 BACKGROUND
A polymeric microparticulate system with maximal drug loading and high
encapsulation would result in a reduced quantity of the carrier (polymer) being required
for the administration of a sufficient amount of drug to the target site. This, in turn,
would prevent overdosing and would lead to reduced drug toxicity while controlled
drug release from microparticles is required to maintain the minimum drug level in
blood. Drug release depends on multiple factors, including polymer molecular weight,
hydrophilicity, particle sizes and surface properties in addition to "additives" in particle
formulation.
A number of techniques for drug encapsulation have been discussed in chapter 1. One
of the most common techniques is the emulsion solvent evaporation method. A number
of experimental parameters in this technique can affect the encapsulation efficiencies, as
listed in table 3.1;
Table 3.1
Factors affecting microparticulate formulation using the emulsion solvent evaporation
technique
1. Solubility of polymer in dispersed phase (organic solvent)
2. Solubility of drug in continuous phase (aqueous phase)
3. Miscibility of continuous and dispersed phases
4. Ratio of dispersed phase to continuous phase
5. Viscosity of emulsion (polymer concentration and molecular weight)
6. Interaction between drug and polymer
7. Solvent removal rate (mixing speed a boiling point of organic solvent)
8. Surfactant/emulsifier (type and concentration)
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These experimental parameters will affect the rate of solidification of microparticles and
result in the alteration of encapsulation efficiencies. Apart from controlling the
mechanical parameters (mixing speed, boiling point and concentration), polymer/drug
chemistry and surfactant choice play important roles in determining the drug loading
and encapsulation efficiencies. Hence, researchers in this field have altered the polymer
chemistry to address the control and improvement in drug encapsulation efficiencies
(Watts et al 1990; Whateley 1992; Jain 2000; Kumar et al 2006; Zhengxing et al 2009).
The chemical properties of polymers can be altered by various parameters, such as
molecular weight and hydrophilicity. The hydrophilicity of polymers can be influenced
by the type and ratio of monomers in a polymer chain which can be used not only to
control the encapsulation efficiencies but also alter the release rate of a drug from the
microparticulate formulation (Wei et al 2004). The molecular weight of polymers can
be controlled during synthesis or via post-synthetic modifications, as discussed earlier
in chapter 1.
Researchers have explored various approaches to control drug encapsulation and
release, such as altering the monomeric composition or the use of various polymers or
additional materials as additives or excipients during the microparticle formation
process (Watts et al 1990; Whateley 1992). For example, PEG has been used not only as
a surfactant but also for its properties as a channelling agent to enhance the release of
drugs from microparticles (Arida et al 1999). Another example of such an additive is
Labrafil® (a non-ionic amphiphilic PEG derivative), which has been studied for
controlling the release of ibuprofen from PLGA microparticles (Fernandez-Carballido et
al 2004). Controlling the release of the active pharmaceutical ingredient (API) is the
main application of polymer-based drug delivery systems. Hence, along with improving
the encapsulation efficiencies, efforts were made by researchers to control the release of
API (Whateley 1992). However, FDA approved polymers can be used for only one type
123
of drug (freely or poorly water soluble) at one time. For example, PLGA is good for the
encapsulation of poorly water soluble drug but also provides burst releases of the drug.
However, water soluble drugs showed lower encapsulation efficiencies (Ito et al 2008).
Hence, there is a need to study the effect of both formulation and chemical parameters
in the development of any new polymeric drug delivery system which can ideally be
used for a range of drugs possessing different physicochemical properties. In this work,
the polymers synthesised previously (chapter 2) were used to encapsulate drugs from
two different classes (antibiotics and NSAIDs), bearing different aqueous solubilities
and chemistries. Experiments were designed to study the effects of a number of
formulation parameters and the varying polymer chemistry on the encapsulation of
these different drug compounds.
3.1 AIM OF THE STUDY
The aim was to investigate the effects of altering the hydrophilicity of drugs and
polymer chemistry on encapsulation efficiencies and to assess the release profiles of the
drugs.
This was achieved by studying the effects of particle formulation parameters on particle
size, surface properties and drug encapsulation using a model polymer, PGA-co-PDL,
and a model hydrophobic, poorly water soluble drug, ibuprofen. In light of the obtained
results, the encapsulation of four drugs, bearing different properties (molecular weight,
hydrophilicity and water solubility), were then evaluated with a full range of polymers
of varying physicochemical properties (chapter 2). The drugs selected for this study (in
order of increasing water solubility) were indomethacin, ibuprofen, levofloxacin and
rifampicin.
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3.2 EXPERIMENTAL
3.2.1 Materials
Copolymer samples PGA (10.1 kDa), PBA (7.4 kDa), PGA-co-CL (1:1:0.7, 17.8 kDa),
PBA-co-CL (1:1:0.4, 18.4 kDa), PGA-co-PDL (1:1:1 (17.5 kDa and 8 kDa), PGA-co-
PDL (1:1:1.2 (29.1 kDa», PPA-co-PDL (1:1:0.6, 8.5 kDa), PBA-co-PDL (1:1:0.5,15.9
kDa), PTEGA-co-PDL (1:1:1 (23.8 kDa) and 1:1:1.5 (17.4 kDa», PGA-co-PDL-PEG
(1:1:0.8:0.02,8.5 kDa), PGA-co-PDL-PEGme (1:1:1.5:0.01, (3.7 kDa), PGA-co-PDL-
PEGme (1:1:1.4:0.01, (4.7 kDa», PGA-co-PDL-PEGme (1:1:1.3:0.02 (6.5 kDa»,
PLOA (50:50, 9.5 kDa), PPTA-co-PDL (2:1:1, 2.3 kDa), PDTTA-co-PDL (1:1:0.5,10.1
kDa), PSA-co-PDL (1:1:0.5, 3.3 kDa), PGA-co-PDL-CIS (33% (16.5 kDa) and 50%
(1S.5 kDa» and PGA-co-PDL-Ibu (50% (1S.2 kDa) and 17% (17.4 kDa» were
previously synthesised (chapter 2). Poly(vinyl alcohol) (PVA, 9-10 kDa Mw, 80%
hydrolysed), ibuprofen (Ibu), levofloxacin (Levo), indomethacin (Indo), rifampicin
(Rif), trifluoroacetic acid, triethylamine and phosphoric acid were purchased from
Sigma, UK. Acetonitrile (HPLC grade), ethyl acetate, butyl acetate, MEK, anisole,
acetic acid, acetone, DMSO, DCM and THF were purchased from Fischer, UK.
3.2.2 Analysis and characterisation
3.2.2.1 Analytical method development and validation
Three analytical techniques were employed for the quantitative analysis of drugs in the
microparticulate formulations and for the drug-release studies. Published analytical
methods were followed for the use of ultraviolet (UV) spectrophotometric and high
performance liquid chromatographic (HPLC) methods. For quantitative gel permeation
chromatography (OPC) a new analytical method was developed and validated. The
quantitative results of drug analyses of all three analytical techniques were compared
using ibuprofen as the model drug.
125
3.2.2.1.1 GPC
The use of GPC in quantitative drug analysis is relatively new, as it is more commonly
used for molecular weight analysis. Few research groups have previously reported the
use of GPC for quantitative analysis (Marquez-Ruiz et al 1996). Chromatographic
conditions used were the same as for the polymer analysis (chapter 2, section 2.2.4).
Sample preparation for method development and validation is summarised below.
Analytical method development and validation:
A series of ibuprofen concentrations ranging from 0.1 mg/ml to 5.0 mg/ml in THF were
prepared via serial dilutions. These standard solutions were analysed and a standard
curve for ibuprofen was plotted to allow calculation of the ibuprofen content in samples.
Peak areas for each solution were obtained using refractive index (RI) detector
responses and plotted against the ibuprofen concentration (Figure 3.1). The obtained
regression equation was used to calculate the amount of ibuprofen in the samples.
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Figure 3.1: Standard curve of ibuprofen concentrations against the area under curve
(AUC) from the refractive index (RJ) detector using GPC (n=3)
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To validate this developed method, an internal standard (polystyrene 29.3 kDa), was
added to all the ibuprofen standard solutions at concentrations of 2.5 mg/ml. It was
observed that addition of the polystyrene did not cause an effect on the quantitative
recovery of ibuprofen and no change in the linearity of the ibuprofen standard curve was
noted (Figure 3.2).
Ibuprofen
Polystyrene 29.300 De
10D 1.=:n 1.. D 16D l6D 20D 22D a s o 2:60
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Figure 3.2: GPC chromatogram of internal standard (Polystyrene 29.3kDa) with
varying concentrations of ibuprofen
3.2.2.1.2 Ui/-visible spectrophotometry
For the quantification of ibuprofen encapsulated in the microparticulate formulations by
UV spectrophotometry, the absorbance of the samples was monitored at the optimum
wavelength for ibuprofen, 273nm, using a UV -Vis spectrophotometer (Lambda 40,
Perkin Elmer, run via UV WinLab software). Quartz UV cuvettes (Spectrosil'", Sigma-
Aldrich) were used. The concentration of the drug was calculated using a calibration
curve, as obtained by the following procedure.
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Analytical method:
The UV spectrophotometric assay method for the quantification of ibuprofen was
adopted from Thompson et a1. (2007). A standard curve was obtained by analysing the
standard ibuprofen solutions of concentrations ranging from 0.1 mg/ml to 5.0 mg/ml in
THF (prepared via serial dilutions). The absorbances of the ibuprofen solutions were
plotted against the ibuprofen concentration (Figure 3.3) and the obtained regression
equation was used to calculate the amount of ibuprofen in the samples.
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Figure 3.3: Standard curve of ibuprofen concentrations against absorbance values at
273nm using UV spectrophotometery (n=3)
3.2.2.1.3 HPLC
Analytical method
For quantitative analysis of drugs in the microparticulate formulations, a UV -HPLC
assay technique was also used. An HP 1090 HPLC system, equipped with PDA
detector, an auto sampler and a Rheodyne'" sample injector (with a variable volume (1-
lOOJ.lI)sample loop) was used. A reversed-phase 150mm x 4.6mm Waters, RP-CI8 (5
urn) column was used at ambient temperature. All samples were dissolved in the
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appropriate solvent (as described in the methodology below), and filtered through
0.45J.1mfilters (Whatman) into 2.5ml sample vials. Vials were capped with PTFE seals
and placed in the autosampler. The mobile phases flow rate was I.Oml/min, while the
sample volume was set at IOJ.1l.Different mobile phases were used depending on the
drug to be analysed, as described below.
i) Ibuprofen and indomethacin
For quantification of ibuprofen and indomethacin, the analytical method was adopted
from Farrington and Regan (2007). The mobile phase for ibuprofen and indomethacin
consisted of acetonitrile:water:trifluoroacetic acid (80:20:0.1), which was mixed and
sonicated before filtering through 0.45J.1mnylon filters (Sigma). The wavelength
selected for the assay was 220nm.
ii) Levojloxacin
For quantification of levofloxacin, the analytical method was adopted from Gao et al
(2007). The mobile phase for levofloxacin consisted of acetonitrile:water:phosphoric
acid:triethylamine (14:86:0.6:0.3), which was mixed and sonicated before filtering
through 0.45J.1mnylon membrane filters (Sigma). The wavelength selected for the assay
was 293nm.
iii) Rifampicin
For quantification of rifampicin, the analytical method was adopted from Kumar et al
(2004). The mobile phase for rifampicin consisted of acetonitrile:0.05M KH2P04
(45:55), which was mixed and sonicated before filtering through 0.45J...lmnylon filters
(Sigma). The wavelength selected for the assay was 254nm.
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Standard curve
A standard curve was prepared for each drug by using standard drug solutions with
concentrations ranging from 0.1 mg/ml to 5.0 mg/ml. The detector response was
recorded for peak areas of standard solutions and plotted against the drug
concentrations. A typical standard curve for ibuprofen is shown in figure 3.4. The
obtained regression equation for each drug was used to calculate the amount of drug in
the samples.
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Figure 3.4: Standard curve of ibuprofen concentrations against area under curve using
UV detector (set at 220nm) in HPLC
3.2.2.2 Microparticle characterisation using SEM
Particles were analysed for particle size, shape and surface morphology by scanning
electron microscopy (SEM) using the following procedure.
Particles were analysed by using a JSM Jeol 840 Scanning Electron Microscope.
Aluminium stubs (13mm diameter) were layered with a carbon tab (Agar scientific) and
a sample of particles (5-10mg) was deposited on the surface and air dried. An atomic
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layer of gold was deposited onto the particle-containing stubs using the Polaron E 5000
Gold Sputter Coater. Images were taken using a Ronatech Image Capture System,
operated via PRISM software. The obtained images were used for approximate particle
size determination by drawing calibrated lines across 10 random particles in each SEM
image. The obtained data was used to calculate mean and standard deviations in particle
sizes.
3.2.3 Microparticle formulation and drug encapsulation
Ibuprofen was used as a model drug to study the effect of various encapsulation
parameters on drug encapsulation in colloidal particles via a modified single emulsion-
solvent evaporation technique (Watts et al 1990), a water-in-oil-in-water solvent
evaporation technique and a spray drying technique. Different experimental parameters
were assessed to optimise the ibuprofen encapsulation efficiency and particle properties
(size, shape, surface morphology).
3.2.3.1 General method
Oil-in-water (o/w) solvent evaporation/or poorly water soluble
drugs
The following standard method used for particle preparation was adopted from Gaskell
et al. (2008) for the encapsulation of the poorly water soluble drugs, ibuprofen and
3.2.3.1.1
indomethacin. Parameters in the adapted method were varied (Table 3.2). A Silverson
mixer (L4 RT mixer), set to varying speeds, was used to mix 160ml of aqueous phase
containing 0.2% poly(vinyl alcohol) (PVA) in a 250ml beaker. The temperature was
maintained between 22-28°C. Polymer (60 mg/ml) and drug (6 mg/ml) were dissolved
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in 5 ml of dichloromethane (DCM) and added drop-wise to the stirring aqueous phase.
The resultant oil-in-water (o/w) emulsion was further stirred for 3 hours using the
Silverson mixer at the chosen speed. Particles were collected by vacuum filtration
(Millipore) through 0.45J.1mpore size filter papers (Whatman) and washed with 2-3ml
of water, while on the filter paper. The obtained particles were analysed and
characterised for drug encapsulation and particle morphology.
Water-in-oil-in-water (w/o/w) solvent evaporation/or
water soluble drugs
Drug-loaded microparticles were prepared by a (W1/O/W2) emulsion solvent
evaporation method adapted from Blanco Preito et al (1994) for the encapsulation of
3.1.3.1.1
water soluble drugs, levofloxacin and rifampicin. A 60mg sample of drug dissolved in
1.0 ml of distilled water (W.) and 500mg of polymer dissolved in 5ml of DCM (0)
were mixed and stirred using a YellowLine (DI 25 basic) probe homogeniser, set at
8000 RPM for 15 seconds to form a WI/O emulsion (inner emulsion) at ambient
temperature. The resultant inner emulsion was added to 160 ml of a 0.2% aqueous
poly(vinyl alcohol) (PVA) solution (W2), and further stirred using a Silverson mixer
(3000 RPM) for 3 hours to allow complete solvent evaporation. Particles were collected
by vacuum filtration (Millipore) through 0.45J.1mpore size filter papers (Whatman).
Particles were washed with 2-3ml of water, while on the filter paper. The obtained
particles were analysed and characterised for drug encapsulation and particle
morphology.
3.1.3.1.3 Spray drying
The spray drying procedure for microparticle preparation was adapted from Rattes and
Oliveira (2007). Polymer, 2.5%(w/v) was dispersed in the organic phase (DCM)
without addition of any surfactants or stabiliser. The resulting dispersion was then fed to
the spray dryer (Buchi-290) under the following conditions: aspiration rate 100%, inlet
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gas temperature 68-70°C, outlet temperature 51-53°C, pump at 30% and drying air flow
rate of 50mm. The spray dried micro particles were collected and stored until further
analysis. The obtained particles were analysed and characterised for particle
morphology, without any further processing or washing.
3.2.3.2 Variation of encapsulation parameters
To study the effect of various formulation parameters on ibuprofen encapsulation
efficiency, particle size and surface properties, a series of experiments were performed
altering the formulation parameters from the standard procedure (section 3.2.3.1.1) as
shown in table 3.2. The obtained microparticles were analysed by GPC (for drug
content) and SEM (for particle morphology), using the standard procedures described in
section 3.2.2.
Table 3.2
Variation in microparticulate formulation parameters
Formulation parameters Variations
Mixing speed (RPM)
Polymer concentration (mg/ml)
Drug concentration (mg/ml)
Solvent
Polymer molecular weight (Da)
Polymer chemistry
Encapsulation procedure
1000,2000,3000
20,60,100,200
6, 12
Class II : DCM, THF
Class III : ethyl acetate, butyl acetate,
methyl ethyl ketone, anisole, acetic
acid, acetone, DMSO
2400,14400,17205,30306
PGA, PBA, PGA-co-PDL, PBA-co-PDL
PGA-co-CL, PBA-co-CL
o/w, spray drying
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3.2.4 Drug encapsulation
Four different drugs (listed in table 3.3) were encapsulated into polymers having
different properties. The drugs and polymers listed in table 3.3 differ in their water
solubility, hydrophilicity and molecular weights. All drug loaded particles were
formulated using the general method as described above in section 3.2.3.1, unless
otherwise stated. Once formulated, all preparations underwent analysis via HPLC (for
drug content) and SEM (for particle morphology) using standard procedures as
described in section 3.2.2.
Table 3.3
Properties of polymers and drugs used for drug loaded micropartic/e formulation
Drug name Class Solubility Molwt Polymer ( monomer ratios) Class
In water (mglml) (Da)
PGA-co-POL (1:1 :1) Polyester
PGA-co-POL (1:1:1.2)
Indomethacin NSAID 0.035 357.8 PPA-eo-POL (1:1 :0.6)
PBA-eo-POL (1:1 :0.5)
Ibuprofen NSAID 0.06 206.3 PTEGA -co-POL (1:1:1) Polyester
PTEGA-eo-POL (1: 1:1.5)
Levofloxacin Quinolone 25.00 361.4 PPTA-co-POL (1 :0.5:0.5) Polythioes-
Antibacterial POTTA-eo-POL (1: 1:0.5) ter
PSA-co-POL (1:1:0.5) Polyol
Rifampicin Macromol- 1.30 822.9
ecule anti- PGA-eo-POL-PEG (1:1 :0.8:0.02) PEG
biotic PGA-co-POL-PEGme (1:1 :1.5:0.01) copolymers
PGA-co-PDL-PEGme (1:1 :1.4:0.01)
PGA-co-POL-PEGme (1: 1:1.3:0.02)
PGA-eo-POL-CI8 (33%) Conjugated
PGA-coPOL-C 18 (50%) stearic
acid
PGA-co-POL-Ibu (17%) Conjugated
PGA-eo-POL-Ibu (50%) ibuprofen
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3.2.5 Drug release from microparticulate formulations
The release of the drugs from the particles was studied by analysing three batches of
particles of each formulation. A IOmg sample of drug-loaded particles was placed in
1.5ml clean and dry Eppendorf tubes followed by the addition of 1ml of PBS (PH 7.4)
at 37°C. The resultant suspensions were mixed, on an orbital shaker at lOOrpm (Stuart
scientific) and at 37°C in an incubator (Stuart scientific). Samples were periodically
collected at 0 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h and 48 h and filtered through
0.45j.lm membrane filters (Whatman). The supernatants were then collected and stored
in 2ml sealed vials at 4°C until further analysis by HPLC as described in section 3.2.2.1.
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3.3 RESULTS ANDDISCUSSION
3.3.1 Comparison of analytical techniques for drug quantification
The ability of polymers with different chemical properties to encapsulate drugs with
different water solubilities was explored. The encapsulated drugs were quantified by a
variety of analytical techniques, as reported by various research groups, including UV
spectrophotometry (Thompson et al 2007), HPLC (Farrington and Regan 2007) and a
relatively new technique, quantitative OPC. OPC is generally used for qualitative
purposes and sometimes for the quantitative estimation of low molecular weight
polymers (Marquez-Ruiz et al 1996). Here, a new method was developed and validated
for the quantitative estimation of ibuprofen via OPC. UV spectrophotometry is the most
commonly employed technique for such applications due to the fact that most linear
polymers lack chromophore groups and hence would not absorb UV or visible radiation.
Thus UV spectrophotometry is considered the simplest, most cost effective and time
efficient technique. However, during the current studies it was observed that although
the polymers utilised in these studies interfere with the absorbance over the entire UV
wavelength range (figure 3.5). The drug loaded PGA-co-PDL particles, when compared
against ibuprofen, showed an increased absorbance at all wavelengths and hence
baseline drift. The same observations were noted when blank POA-co-PDL particles
were compared against pure solvent (THF).
Keeping in view these observations, a set of experiments were designed to compare the
three analytical techniques: UV, HPLC and GPe for the quantification of ibuprofen in
two drug loaded POA-co-PDL particle formulations. The same set of samples were
analysed by each of the three techniques to keep sample variation to minimum.
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Figure 3.5: UV spectra ofTHF solutions of a) ibuprofen (blue line) and b) PGA-co-
PDL (green line) representing the interference from polymer throughout the UV range.
The results obtained (Table 3.4) further support the fact that the amount of ibuprofen
determined by UV spectrophotometry is considerably higher than that obtained by
HPLC and GPC.
Table 3.4
Comparison of quantitative ibuprofen analysis by using various analytical techniques in
two different drug-loaded particle formulations
% Encapsulated Ibuprofen
Polymer UV HPLC GPC
PGA-co-PDL (1 :1:1) 82.46 ±5.31 53.60 ±2.74 49.50 ±0.21
PGA-co-PDL (1: 1:1.5) 106.45 ±3.89 56.77 ±2.23 58.10 ±4.21
The main reason for this observation is the separation of components of analyte in both
chromatographic techniques. In both HPLC and GPC, two separate peaks were
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observed; one corresponding to ibuprofen (the main analyte) and a second peak
corresponding to the polymer in the sample. The HPLC was equipped with a UV
detector (set at 220nm) while the GPC was equipped with RI detector. In both cases the
detection of separate peaks for the polymer highlighted the importance of the use of
precise and robust analytical techniques. The results summarised in table 3.4, show that
there is a variation of around 30-40% in the results obtained by UV spectrophotometer
as compared to both chromatographic techniques. However, variations between the two
chromatographic techniques are within their error limits and are not statistically
different (P value for PGA-co-PDL 1:1:1 is 0.06 and P value for PGA-co-PDL 1:1:1.5
is 0.65). Hence, the UV spectrophotometer was not used further for quantitative analysis
in this project. HPLC was preferred over GPC because of time and cost-effectiveness.
No previous literature was found, directly comparing these techniques for drug
quantification from microparticles as it appears researchers simply use one of the
techniques. However, there are cases in the literature where it is likely that the amount
of the drug in a particle formulation is over estimated (Thompson et al 2007). To further
support the above findings the data obtained here were compared to a similar study by
Thompson et al. (2007), the details of which are discussed in section 3.3.3.3a.
3.3.2 Investigations of the effects of encapsulation parameters
Although the interfacial deposition method is reported as a method for particle
formation with PGA and related polymers (Kallinteri et al 2005), this technique suffers
the drawback of requiring stable emulsion formation and in the current studies
microparticles could not be formulated with this technology. Hence the method of oil-
in-water emulsion solvent evaporation was selected for the preparation of polymeric
particles and to study the effect of varying chemistry and other parameters on
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encapsulation efficiency and particle size. During initial studies it was observed that the
o/w technique was not suitable for the encapsulation of drugs in the viscous polymers
(such as PGA), hence PGA-co-PDL, a solid polymer at room temperature, was chosen
for the further development and exploration of these drug delivery systems. It was
observed that, under the formulation parameters described in the general method, the
emulsion-solvent evaporation technique produced distinct particles. Encapsulation of a
model hydrophobic drug, ibuprofen was investigated in the various polymers. As the
properties of the particles prepared are dependent on the chosen methodology, different
parameters, settings and procedures were altered systematically to study the effects on
the results obtained for the various materials.
Previous research on PGA-co-PDL investigated different parameters of the single-
emulsion solvent evaporation system and the effects on particle size and morphology as
well as its potential for encapsulating ibuprofen (Thompson et al 2006). The research
presented here aims to extend the previous work done by Thompson et al. (2006)
utilising a range of polymers, synthesised specifically for this study, in addition to the
assessment of the particle preparation parameters to achieve increased ibuprofen
encapsulation for therapeutic delivery.
Particles were prepared from all polymers (listed in table 3.3) using the solvent
emulsion technique described in section 3.2.3.1.1. PVA is a commonly-used emulsifier
that provides short term stabilisation of oil-in-water (o/w) emulsions. The concentration
of PVA affects the particle size: with increasing concentrations, generally smaller
particles are produced. The viscosity change of the emulsion with higher PVA
concentrations contributes to the stability of the emulsion formed. 0.2 % (w/v) PYA was
found to give a more even distribution of particle size via the single emulsion-solvent
evaporation technique (Bolourtchain et aI, 2005). Hence this concentration of PVA was
kept constant in all the drug encapsulation work in this study.
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Experimental parameters such as mixing speed, polymer concentration, solvent choice,
polymer chemistry and molecular weight were varied to study their effect on ibuprofen
encapsulation efficiency, morphology and particle size.
3.3.2.1 Effect of speed
Increasing the mixing speed of the emulsion from 1000 to 3000 RPM resulted in a
decrease in encapsulation efficiency from 66.5% to 55.0% (Table 3.5). The size of the
particles also ranged frOID16.3 urn to 1.2 !lID(Figure 3.6). These results further support
the previous studies done by Bilati et al (2005), where it was established that an
increase in speed caused smaller particles to form.
a) b)
Figure 3.6: SEM images of ibuprofen loaded PGA-co-PDL particles using a polymer
concentration 0/60 mg/ml (x1000, measuring bar = 31.6 11m)prepared at a) 1000 rpm
b) 2000 rpm c) 3000 rpm
This phenomenon can be explained by the fact that increasing the mixing speed of the
emulsion resulted in the production of smaller oil droplets loaded with ibuprofen and
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polymer which upon solvent evaporation formed smaller sized particles. As the particle
size decreased, with increasing mixing speed, the amount of ibuprofen loaded in those
particles also decreased leading to decreased encapsulation efficiency.
Table 3.5
Effect of mixing speed on ibuprofen encapsulation: Mean encapsulation efficiencies and
particle sizes tabulated (n=3).
Mixing Encapsulation Particle Size
Speed (rpm) Efficiency (%) (J.1m)
1000 66.5 ± 5.1 16.3 ± 5.2
2000 60.9± 4.5 1.5 ± 0.8
3000 55.0 ± 1.25 1.2 ± 1.0
Emulsifications at 2000 rpm yielded particles with a greater encapsulation efficiency
compared to those prepared at 3000 rpm, with no notable change in particle size.
Further decreasing of the mixing speed to 1000 rpm increased the encapsulation
efficiency by a further 5.6%. However, this reduction in speed also influenced the
particle size significantly, increasing it from 1.5 ± 0.8J..lmat 2000rpm to 16.3 ± 5.21lm at
1000rpm. This is due to the fact that at lower speed the shear experienced by the
emulsion was not strong enough to create particles of smaller sizes. However, this also
resulted in the entrapment of higher amounts of drug in the polymer matrix causing an
increase in encapsulation efficiency. These results are supported by previous studies by
Arida et at (1999), where it was established that ibuprofen encapsulation at higher
speeds resulted in decreased drug encapsulation.
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3.3.2.2 Effect of oil phase
Pharmaceutical grade III solvents are less toxic than class II solvents; hence, any
residual class II solvent will be more harmful than class III solvents (Committee for
Proprietary Medicinal Products 1998). Class III solvents, anisole, acetic acid, acetone,
methyl ethyl ketone (MEK), ethyl acetate and butyl acetate were compared with the
routinely used class II solvents dichloromethane (DCM) and tetrahydrofuran (THF).
The results indicate that butyl acetate produced particles with higher encapsulation
efficiency (53.1%) than any other class III solvent and also produced submicron sized
particles. MEK and ethyl acetate (class III) produced particles with good encapsulation
efficiencies, hence proving that they are better alternatives for pharmaceutical
preparations (Table 3.6). However, particles prepared with ethyl acetate were very large
(15.7 urn) compared to the 1.0 urn particles, prepared from other solvents.
Table 3.6
Effect of solvent on ibuprofen encapsulation. Mean encapsulation efficiencies and
particle sizes are shown (n=3).
Solvent Encapsulation Efficiency (%) Particle Size (J.Lm)
Class II Solvents
DCM 55.0 ± 1.25 1.2± 1.0
THF No particles
Class III Solvents
Acetone No particles
Acetic acid No particles
Anisole No particles
Butyl acetate 53.1 ± 3.45 0.9± 0.8
DMSO No particles
Ethyl acetate 43.1 ± 4.10 15.7±5.5
Methyl ethyl ketone 43.3 ± 3.60 1.0± 0.6
The conventionally used dichloromethane (DCM), a class II solvent, was substituted
with different class III solvents including butyl acetate and methyl ethyl ketone (MEK).
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This may result in a significant reduction in the toxic potential of the delivery system.
MEK produced particles of equivalent size to DCM but with lower encapsulation
efficiencies; however butyl acetate showed increased encapsulation efficiencies (of
approximately 10% as compared to MEK) within particles of a similar size. On the
other hand, THF, anisole, acetic acid, acetone, and DMSO did not form microparticles.
The reason could be explained on the basis of their higher boiling points, high density
and miscibility with water, which required a longer time for complete evaporation, and
resulted in an unstable emulsion formation. Hence, these solvents were incompatible
with the method used in this study.
3.3.2.3 Effect of polymer molecular weight
Particles were not obtained and hence no ibuprofen encapsulated with the lower
molecular weight PGA-co-PDL (2.5 kDa) due to its liquid state. Increasing the
molecular weight of this polymer resulted in the formation of ibuprofen encapsulated
particles with increasing encapsulation efficiencies from 55.0% (for 14.4 kDa) to 60.3%
(for 30.3 kDa), (Table 3.7).
Table 3.7
Effect of polymer molecular weight on ibuprofen encapsulation: Mean encapsulation
efficiencies and particle sizes are shown (n=3).
Molecular
Weight (Da)
Encapsulation efficiency (%) Particle Size (J.1m)
2400
14435
17205
30306
No particles
55.0 ± 1.25
55.5 ± 2.1
60.3 ± 2.55
1.2 ± 1.0
1.8±1.4
1.4±1.1
However, no major change in particle size was observed and all particles obtained were
in the range of 1.5 urn ± 0.3 urn (Figure 3.7). It is well established that increasing the
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polymer molecular weight and polydispersity causes an increase in the viscosity of the
emulsion formed which results in the higher encapsulation of drugs (Ramkissoon-
Ganorkar et al 1999; Bilati et al 2005).
a) b)
Figure 3.7: SEM images of ibuprofen-loaded PGA-co-PDL particles with different
molecular weight (xIOOO,measuring bar = 31.6f.I111)a) 14 kDa b) 30 kDa
3.3.2.4 Effect of polymer and drug concentration
Increasing the polymer (14kDa) concentration from 20 mg/ml to 200 mg/ml caused an
increase in iscosity of the emulsion system. This resulted in the oil-in-water emulsion
droplets containing higher amounts of polymer hence an observed increase in particle
size from 1.2 urn to 18.2 urn (Figure 3.8). Both higher polymer molecular weight and
higher polymer concentration in the oil phase can increase the encapsulation efficiency,
due to the increased iscosity of the emulsion, which in turn reduces the drug diffusion
to the aqueous medium (Bilati et al200S; Zhengxing et al 2009).
a) b)
Figure 3.8: SEM image of Ibuprofen loaded PGA-co-PDL particles with different
polymer concentration (x1000, measuring bar = 31.6 f.I111)a) 200 mg/ml b) 60 mg/ml
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An increased polymer content in the emulsion resulted in a significant decrease of drug
(ibuprofen) content in the resulting particles which led to a decrease in encapsulation
efficiency from 55.0% to 24.8% (P value <0.005) (table 3.8). No particles were formed
at polymer concentrations below 60 mg/ml due to no stable emulsion forming.
Table 3.8
Effect of polymer concentration on ibuprofen encapsulation: Mean encapsulation
efficiencies and particle sizes are shown (n=3).
Polymer
Concentration (mg/ml)
Encapsulation
Efficiency (%)
Particle Size
(JIm)
20
60
100
200
No particles
55.0 ± 1.25
41.4 ± 2.1
24.8± 2.6
1.2 ± 1.0
1.1±0.9
18.2 ± 4.2
Increasing the drug (ibuprofen) concentration from 6 mg/ml to 12 mg/ml resulted in a
considerable increase in drug encapsulation in the microparticles (Table 3.9). This was
due to the presence of a higher amount of drug in the emulsion and led to an increase in
particle size from 1.2Jlm to 5.5Jlm. The presence of a higher amount of drug in an o/w
emulsion can increase the encapsulation efficiency, because a more hydrophobic drug
would associate in the polymer and consequently reduce the drug diffusion to the
aqueous medium (Bilati et al 2005; Zhengxing et al 2009).
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Table 3.9
Effect of drug concentration on ibuprofen encapsulation (while keeping the polymer
concentration constant at 100 mg/ml): Mean encapsulation efficiencies and particle
sizes tabulated (n=3).
Drug
Concentration (mg/ml)
Encapsulation
Efficiency (%)
Particle Size
(J.Lm)
6.0 41.4 ± 2.1 1.1 ± 0.9
12.0 53.6 ± 2.7 5.5 ±2.5
3.3.2.5 Effect of polymer chemistry
The polymers PGA, PBA, PGA-co-CL, PBA-co-CL and PCL were unable to form
particles using this solvent-evaporation technique because of their lower molecular
weights and their liquid state at room temperature, which resulted in the formation of
unstable emulsions. Upon solvent evaporation, preparations containing PGA, PBA,
PGA-co-CL, PBA-co-CL and P-CL, appeared as uniform milky suspensions and no
particles could be collected via filtration or by centrifugation. The lack of discrete solid
particles from these materials under the given preparative methodology is due to their
physical properties and/or low molecular weight. With the solid materials, micron size
particles were obtained with variable geometry and surface properties, depending on the
polymer used and the exact experimental parameters. Only solid polymers, PGA-co-
PDL, PPA-co-PDL and PBA-co-PDL, formed stable emulsions that upon filtration
yielded white powdery products with clear filtrates. The ibuprofen-loaded particles
formed were visualised by SEM (Figure 3.9). It was observed that functionalised
polymer, PGA-co-PDL, has a rough surface, in comparison to non-functionalised
hydrophobic polymer, PBA-co-PDL. The same observation was noticed in case of
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PLGA (discussed later figure 3.11) which might be due to the effect of polymer solvent
interactions.
a) b)
Figure 3.9: SEM images of Ibuprofen loaded particles with different polymers (xl 000,
measuring bar = 31.6 f.!m)0) PGA-co-PDL b) PBA-co-PDL
The ibuprofen-encapsulated microparticles had similar encapsulation efficiency values,
regardless of the polymer used (Table 3.10). The sizes of the particles were also very
similar. Although it is well established that polymer chemistry plays a very important
role in determining drug encapsulation and particle morphology, it was observed that,
given the differences in the polymer chemistries of these three materials, there was no
significant effect on the encapsulation efficiency (P value 2: 0.5). This observation
indicates that the presence of -OH groups on the polymer backbone did not produce any
difference in the encapsulation efficiency of ibuprofen.
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Table 3.10
Effect of polymer chemistry on ibuprofen encapsulation: Mean encapsulation
efficiencies and particle sizes are shown (n=3).
Polymer Encapsulation efficiency (%) Particle Size (J.1m)
PGA No particles
PBA No particles
PGA-co-PDL 55.0 ± 1.25 1.2 ± 1.0
PPA-co-PDL 54.0 ± 1.50 1.4 ± 1.2
PBA-co-PDL 54.9 ± 1.50 1.1 ± 1.2
PGA-co-CL No particles
PBA-co-CL No particles
PCL No particles
From the SEM images (Figure 3.9), it was evident that non-agglomerated particle
formation was only achieved with ro-pentadecalactone-based copolymers (such as PGA-
co-PDL and PBA-co-PDL) which are solid at room temperature. These polymers were
off-white waxy solids at room temperature with molecular weights of 14.4 kDa and 15.9
kDa respectively. Under the applied methodology the influence of polymer chemistry
on the formation of particles was evident. Only the materials that were solid at room
temperature with higher molecular weights and minimal amounts of low molecular
weight impurities produced discrete non-agglomerated particles. Whereas, liquid
polymers could not formulate into microparticles, not only because of their liquid nature
but also because of the fact that the added emulsifier was in very low quantity (0.2%)
which did not aid the formation of particles from the liquid polymer. However, by
evaluating other surfactants and by increasing their content, discrete particle formation
was possible, such as that reported by Katare et al (2005), where PLA, a water soluble
viscous polymer, and an oil soluble surfactant were used to produce discrete particles.
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3.3.2.6 Spray drying
To evaluate the effect of a different encapsulation technique, spray drying was used for
the blank microparticle preparation and ibuprofen encapsulation using PGA-co-PDL
and PGA-co-PDL conjugated with stearic acid (PGA-co-PDL-CI8). It was observed in
the preliminary studies that blank PGA-co-PDL particles were in the range of 1urn
diameter and were agglomerated. This is in concordance with previous research by
Corrigan et al (2002) where additives such as lactose were used to improve particle
preparations. In the current study, however, 0.2% PVA was used in o/w and w/o/w
emulsion as surfactant but no external additives were used in spray drying and the
ability of the polymeric materials alone was investigated for particle preparation (Figure
3.10).
a)
c)
b)
Figure 3.10: SEM images of microparticles of a) PGA-co-PDL (x23376, magnification
bar = 4f.1!rl) b) PGA-co-PDL-CJ8(JOO%) (x4546, magnification bar = 20l1m) and c)
ibuprofen loaded PGA -co-PDL (x5156, magnification bar = 20 um) obtained by spray
drying.
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The stearic acid-conjugated polymer gave particles of a larger diameter (20J.l.m)with a
"spiky" surface (Figure 3.1Ob). It is believed that this is solely due to the
physicochemical properties of stearic acid. Figure 3.10 shows the crystallisation of
ibuprofen on the surface of particles obtained by spray drying. This is due to the fact
that during the spray drying process all drug remained associated with the particles
(either encapsulated or adsorbed on the surface), whereas in the solvent emulsion
system the excess drug was removed with the continuous phase. The particles obtained
by the spray drying technique would be expected to cause a larger initial burst release of
drug compared to the particles obtained by o/w and w/o/w technique. Hence, it would
be required for particles formulated with spray drying techniques to be washed with an
appropriate solvent for the removal of surface drugs. These studies showed potential but
also highlighted the need for further investigations, involving spray drying for the
effective encapsulation of drugs within the library of polymers studied. This was,
however, outside the scope of this project.
3.3.3 Particle preparation and drug encapsulation
After studying the effects of VarIOUS formulation parameters on a model drug,
ibuprofen, encapsulation in a "model" polymer, PGA-co-PDL, the following conditions
were selected for further evaluation of drug encapsulation studies in different polymers.
Polymer and drug concentrations were selected as 100 mg/ml and 12 mg/ml
respectively with 0.2% surfactant (PVA). The emulsion was mixed at a speed of 3000
rpm using OCM as the organic solvent (oil). The resultant particles were analysed for
drug content and release profile using HPLC. GPC was not used for drug quantification
in drug-release samples, because of the column sensitivity towards aqueous solutions.
150
The optimal obtained parameters were then used for the encapsulation of various drugs
in the library of polymers synthesised previously (listed in table 3.3) to evaluate the
effects of altering polymer chemistry on drug encapsulation and release.
3.3.3.1 Polymer selection of drug encapsulation studies
The entire library of polymers was screened for potential for drug encapsulation. As
outlined in section 3.3.2.5 the liquid polymers were unable to form microparticles via
the solvent emulsion evaporation techniques (oil-in-water and water-in-oil-in-water).
Hence only polymers that were solid at room temperature were carried forward for drug
encapsulation studies. The list of the solid polymers assessed is summarised in table 3.3.
Even though the oil-in-water emulsion solvent evaporation technique was the main
technique used in this work, its efficiency was limited to only hydrophobic (poorly
water-soluble) drugs. This is why for the encapsulation of hydrophilic (water-soluble)
drugs other techniques such as water-in-oil-in-water (w/o/w) and spray-drying were
used. Another limitation for the use of the o/w technique was the limited solubility of
some polymers to only in high boiling point solvents. For example, PSA-co-PDL is only
soluble in chloroform which has a boiling point of 61°C. This makes evaporation of
chloroform slower and incomplete from the emulsion at room temperature, and a longer
duration for solvent evaporation will result in the encapsulated drug being released back
into the continuous phase. An alternative approach of heating the solvent to facilitate the
evaporation could not be applied because of the low melting points of the polymers.
These factors made emulsion solvent evaporation technique a less efficient procedure
for the formation of discrete microparticles. As an alternative, a spray drying technique
was investigated. Table 3.11 summarises the results of micropartic1e preparation using
various polymers.
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Table 3.11
Data for microparticulate formulations prepared using various polymers and
techniques
Polymer Physical state Technique used
at room temperature
Particle size Surface
(urn)
PGA Viscous o/w N/A N/A
PGA Viscous Spray drying N/A N/A
PPA Viscous o/w N/A N/A
PBA Soft solid o/w N/A N/A
PTEGA Viscous o/w N/A N/A
PLGA Solid o/w 3-5 Smooth
PGA-co-CL (I: 1:0.7) Viscous o/w N/A N/A
PPA-co-CL (1:1:0.45) Viscous o/w N/A N/A
PBA-co-CL (I: 1:0.40) Viscous o/w N/A N/A
PGA-co-PDL (1: 1:0.5) Soft solid o/w N/A N/A
PGA-co-PDL (1: 1:1) Solid o/w 4-6 Rough
PGA-co-PDL (1: 1:1) Solid w/o/w 5-10 Rough
PGA-co-PDL (I: 1:1) Solid Spray drying >2 Smooth
PGA-co-PDL (1: 1:1.2) Solid o/w 8-12 Rough
PPA-co-PDL (I: I :0.6) Solid o/w 1-4 Smooth
PBA-co-PDL (1: 1:0.5) Solid o/w 1-4 Smooth
PTEGA-co-PDL( I: I :O.5)Solid o/w 3-5 Smooth
PTEGA-co-PDL (1: I: 1)Solid o/w 3-5 Smooth
PTEGA-co-PDL( 1:1:1.5)Solid o/w 5-10 Smooth
PSA-co-PDL (I: I :0.5) Solid o/w N/A N/A
* NIA = No particles formed
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Table 3.11 (continued)
Polymer Physical state Technique used
at room temperature
Particle size Surface
(urn)
PGA-PEG Viscous o/w N/A N/A
PGA-PEGme Viscous o/w N/A N/A
PPA-PEG Viscous o/w N/A N/A
PGA-co-CL-PEG Viscous o/w N/A N/A
PGA-co-PDL-PEG Solid o/w 3-5 Smooth
PGA-co-PDL-PEGme
1:1:1.5:0.01 Solid o/w 5-8 Porous
1:1:1.4:0.01 Solid o/w 5-8 Porous
1:1:1.3:0.02 Solid o/w 5-8 Porous
PPTA Viscous o/w N/A N/A
PDITA Viscous o/w N/A N/A
PPTA-co-PDL Soft solid o/w N/A N/A
PDIT A-eo-POL Soft solid o/w N/A N/A
PGA-co-PDL-CI8 (50%) Solid o/w 3-5 Spiky
PGA-co-PDL-CJ8 (33%) Solid o/w 3-5 Spiky
PGA-co-PDL-Ibu (50%) Solid o/w 3-5 Smooth
PGA-co-PDL-Ibu (17%) Solid o/w 3-5 Smooth
* NIA = No particles formed
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Table 3.11 summarises the results of particle formulation studies with all the
synthesised polymers. It was observed that all the viscous and very soft solid polymers
failed to formulate any microparticles via the o/w solvent evaporation technique. The
chemistry of the polymers did not affect the particle sizes considerably, as all particles
were in the range of 5-IOJ.lmin diameter. However the surface properties of the
polymers varied as a result of altering the monomers present in the polymer. For
example, the presence of stearic acid in the polymer caused a spiky surface whereas
incorporation of PEG caused smooth but porous surfaces. The details of these effects
are discussed in following section.
3.3.3.3 Effect of polymer and drug chemistry on drug encapsulation
Polymers with varying chemistries were evaluated for encapsulation of ibuprofen, a
model hydrophobic drug. The ability of these polymers was also evaluated for the
encapsulation of other drugs with different water solubilities (Table 3.3). The
hypothesis for these studies was that more hydrophobic polymers will encapsulate
higher amounts of poorly water soluble drugs and less hydrophobic polymer will
encapsulate more of the water soluble drugs.
The results of the drug encapsulation in "model" polymer, PGA-co-PDL, were
compared with the other members of the library of polyesters, as summarised in the
following sections.
a) Comparison with PLGA:
PLGA is an FDA-approved and commercialised polymer for drug delivery applications,
(as discussed in chapter I). Hence, the encapsulation of drugs in PLGA was compared
with that in the PGA-co-PDL. The results obtained in this study for the encapsulation
and release of ibuprofen from PGA-co-PDL confirms the previous findings of
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Thompson et al (2007), however the encapsulation efficiency they reported was 67%,
which is 12% higher than that reported in current studies. This difference can be
explained on the basis of the use of UV spectrophotometry as the analytical method
adopted by Thompson et al (2007), which overestimates the ibuprofen concentration, as
previously discussed in section 3.3.1.
Table 3.12 summarises the drug encapsulation efficiencies of three drugs, ibuprofen,
indomethacin and levofloxacin in PLGA and PGA-co-PDL. The data for drug
encapsulation in PGA-co-PDL confirmed that as the relative aqueous solubility of the
drugs increased a significant increase in drug encapsulation was observed (P value
0.0114), and as the water solubility of drugs increased (from ibuprofen to levofloxacin)
a more significant decrease in encapsulation efficiencies was recorded (P value 0.0001).
The highly water soluble drug rifampicin failed to encapsulate in these polymers using
the applied method because of its high water solubility.
Figure 3.11: SEM image of ibuprofen loaded PLGA microparticles (x8458, measuring
bar = lOJl111).
When the ibuprofen encapsulation results for PGA-co-PDL were compared with PLGA,
it was found that for ibuprofen encapsulation there is no significant difference (P value
0.6765) as compared to PGA-co-PDL, but a very significant increase was observed for
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indomethacin encapsulation in PLGA (P value 0.0031) which can be explained by the
higher hydrophobicity of PLGA. Although there was no difference in the particle sizes
observed (Figure 3.11), the surface ofPLGA particles were smoother compared to those
of PGA-co-PDL.
Previous studies confirm the encapsulation efficiencies of ibuprofen in high molecular
weight (34 kOa) PLGA were in the range of 46-52% using 1% PEG-300 (Labarafil")
(Fernandez-Carballido et al 2004). The results obtained in the present work are
supported by the previous research work, where a high encapsulation efficiency was
obtained for ibuprofen (about 60-75%) and for indomethacin (80-90%) in the very
hydrophobic polymer, ethyl cellulose (Bodmeier & Chen 1989). This confirms that a
more hydrophobic polymer will encapsulate a higher amount of hydrophobic drug.
In this study, the encapsulation of levofloxacin (a water soluble drug) was significantly
less in PLGA (9.5 kOa) as compared to PGA-co-PDL(17.5 kDa). Although other
studies have also reported the encapsulation of levofloxacin in PLGA, they used higher
surfactant concentrations (~1%) (Gupta et al) compared to the 0.2%(w/v) PYA used in
the present studies. Similarly, it has been reported for ciprofloxacin (water solubility 35
mglml) that with PLGA (15 kOa) and using 1%(w/v) PYA surfactant, the encapsulation
efficiencies achievable were up to 42% (Jeong et al 2008).
Table 3.12
Encapsulation efficiencies of various drugs in PGA-co-PDL and PLGA
Indomethacin
(o/w)
Drug encapsulation (%EE)
Ibuprofen Levofloxacin
(o/w) (w/o/w)
Rifampicin
(w/o/w)
Polymer
PGA-co-PDL 62.99±2.44 53.6±2.74 12.59±3.10 0.00
PLGA 79.04±3.6 54.62±2.82 8.77±4.35 0.00
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b) Effect of polymer composition:
No significant difference of ibuprofen encapsulation was observed between non-
functionalised (hydrophobic) polymers, PPA-co-PDL, PBA-co-PDL and the
functionalised (hydrophilic) polymer, PGA-co-PDL (Table 3.10). Hence, in a bid to
alter the chemical properties of polymers in terms of hydrophobicity, the type of
monomers and their amounts were varied in the polymer backbone.
A novel non-functionalised (hydrophilic) polymer, PTEGA-co-PDL was synthesized
and compared with the model polymer, PGA-co-PDL, for the encapsulation of the
hydrophobic drugs (indomethacin and ibuprofen). As illustrated in table 3.13, PGA-co-
PDL (1:1:1.2), containing an increased lactone content within the polymer, showed a
slight but not significant increase in encapsulation efficiencies. When the data for PGA-
co-PDL (1:1:1) were compared with PTEGA-co-PDL (1:1:1) (a polymer with no
pendant hydroxyl groups) it was observed that an extremely significant increase (P
value 0.0003) in ibuprofen encapsulation and a significant increase (P value 0.0107) in
indomethacin encapsulation was achieved, under similar formulation parameters.
Table 3.13
Comparison of encapsulation efficiencies of various ratios of PGA -co-P DL and
PTEGA-co-PDL with different drugs
Polymer Drug encapsulation (%EE)
Indomethacin Ibuprofen Levofloxacin Rifampicin
(o/w) (o/w) (w/o/w) (w/o/w)
PGA-co-PDL (1:1:1) 62.99±2.44 53.6±2.74 12.59±3.10 0.00
PGA-co-PDL (1:1:1.2) 66.36±6.19 56.77±2.23
PTEGA-co-PDL (1:1:1) 73.50±3.21 74.31±1.43 0.00 0.00
PTEGA-co-PDL (1:1:1.5) 74.00±3.IS 70.38±5.92
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PTEGA-co-PDL (1:1:1) is devoid of pendant hydroxyl groups but is a hydrophilic
polymer, yet encapsulation of the hydrophilic drug, levofloxacin was not observed in
this polymer. This was contrary to what was observed for PGA-co-PDL (1:1:1), where
the encapsulation efficiency of levofloxacin was 12.59±3.10%. Also, the increase in the
lactone content in triethyleneglycol-based polymers (PTEGA-co-PDL) from 1:1:1 to
1:1:1.5 did not significantly alter the encapsulation efficiencies. Similar trends were
observed when comparing the encapsulation of the two drugs in PGA-co-PDL (1:1:1.5)
and PTEGA-co-PDL (1: 1:1.5).
a)
c)
b)
d)
Figure 3.12: SEM images of drug loaded microparticles of PGA-co-PDL (1:1:1) with
a) ibuprofen (x 5571, measuring bar = 10f.1m)b) levofloxacin (x2422, measuring bar =
40j.1m)c) rifampicin (x 2411, measuring bar = 40f.1m)and ofPTEGA-co-PDL (1:1:1)
with d) indomethacin (x1181, measuring bar = 50f.1m).
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c) Comparison of PEG copolymers:
Many research groups have used PEG as a surfactant or additive while formulating
microparticles. The purpose of introducing PEG as part of polymer backbone was to
synthesise a polymer which could be formulated into microparticles without the
addition of any external additive or surfactant and also to increase the drug
encapsulation and to control the drug release. However, the PEG-copolymers
synthesised here failed to form stable emulsions on their own. Hence, 0.2% PYA had to
be added as a surfactant to formulate microparticles.
PGA-co-PDL was modified to be more hydrophilic by using PEGI500and PEGme2000as
additional monomers in the synthesis. PEG copolymer-based microparticles were bigger
than those prepared from PEG-free polymers (as summarised in table 3.11 and figure
3.13), which is supported by earlier studies (Peracchia et al 1997).
In this current work PEG was randomly distributed in the polymer chain while PEGme
was present only at the terminal position of the polymers. Hence, theoretically PEG
copolymers should be more hydrophilic than PEGme copolymers but the actual
monomer ratio in PGA-co-PDL-PEG was 1:1:0.8:0.02 (8.5kDa, 3-4 PEG units per
polymer chain) while for PGA-co-PDL-PEGme the monomer ratio was 1:1:1.4:0.01
(4.7kDa, 1-2 PEGme units per polymer chain) (Table 2.16). This indicates that PEGme-
copolymers are more hydrophobic then the equivalent PEG-copolymers, because of
lower PEGme content and higher lactone content in the polymer backbone. It was
previously established that incorporation of PEG into polymeric microparticIes usually
causes an increase in drug loading with an increased rate of drug release from these
formulations (Huang & Chung 2001). PEG also acts as a channelling agent (Arida et al
1999) hence can increase the rate of drug release.
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a) b)
Figure 3.13: SEM images of drug loaded microparficles of PGA-co-PDL-PEGme with
a) ibuprofen (x76J5) and b) indomethacin (x5063)
The effect of changing polymer chemistry was evident in the drug encapsulation results,
where a significant increase in ibuprofen encapsulation was observed for PGA-co-PDL-
PEG (P value 0.0814) but no significant increase in ibuprofen encapsulation (P value
0.9345) was recorded for PEGme copolymer (Table3.l4). The same observations were
noted for indomethacin encapsulation where the PEG copolymer showed a significant
(P value 0.0165) increase in indomethacin encapsulation whereas the PEGme based
copolymer did not encapsulate significantly more indomethacin (P value 0.5631)
compared to PGA-co-PDL. In further support of this, the levofloxacin encapsulation
results clearly indicate that the PEG copolymer, being more hydrophobic, failed to
encapsulate levofloxacin. On the other hand the PEGme copolymer with a more
hydrophilic character showed equivalent levofloxacin encapsulation to PGA-co-PDL (P
value 0.8011). Table 3.14 summarise these results.
160
Table 3.14
Comparison of drug encapsulation efficiencies of PGA-co-PDL-PEG and PGA-co-
PDL-PEGme with PGA-co-PDL
Polymer Drug encapsulation (%EE)
Indomethacin
(o/w)
Ibuprofen
(o/w)
Levofloxacin
(w/o/w)
Rifampicin
(w/o/w)
PGA-co-PDL (1:1:1)
PGA-co-PDL-PEG
62.99±2.44 53.6±2.74 12.59±3.l0
76.14±5.19 64.04±3.82 0.00
0.00
0.00
PGA-co-PDL-PEGme 64.45±3.19 53.74±0.42 13.21±2.51 0.00
The similar drug encapsulation values were observed in polymers with slightly varied
polymer compositions (Table 3.15). All ibuprofen encapsulation results were similar (P
value 0.1224 - 0.9345), hence indicating that slight variations in monomer ratios
(PEG/lactone content) does not considerably affect the encapsulation efficiencies.
Table 3.15
Comparison of ibuprofen encapsulation efficiencies of various ratios of PEGme-
copolymers with PGA-co-PDL
Polymer Monomer ratio Drug encapsulation (%EE)
Ibuprofen
PGA-co-PDL
PGA-co-PDL-PEGme
PGA-co-PDL-PEGme
PGA-co-PDL-PEGme
1:1:1
1:1:1.5:0.01
1:1:1.4:0.01
1:1:1.3:0.02
53.6±2.74
49. 14±2.85
53.74±0.42
52.87±2.36
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d) Comparison of post synthetic modification in polymer backbone:
A long-chain non-polar molecule, stearic acid, was conjugated to the pendant hydroxyl
groups of PGA-co-PDL. Based on the theoretically-available numbers of hydroxyl
groups, 50% and 100%hydroxyl groups should be conjugated. However, only 33% and
50% conjugation was achieved. As a non polar C18 chain was added to the polymer
structure, this made the polymer more hydrophobic. Tabulated results (Table 3.16)
show that increasing the stearic acid ratio (from 33% to 50%) caused a considerable
increase in ibuprofen encapsulation, hence further supporting the hypothesis that more
hydrophobic polymers will encapsulate more hydrophobic drugs. However, it was
observed that conjugating the polymer with 33% stearic acid resulted in considerably
less ibuprofen being encapsulated than with PGA-co-PDL alone. The reason for this
observation might lie in the fact that after the conjugation the polymer molecular weight
dispersity increased considerably, resulting in polymer chains of various lengths. This
alteration in polymer chemistry may have had the potential to initiate cross linking of
polymer chains, which may lead to altered drug-polymer interactions as compared to
straight chain polymers, leading to different encapsulation efficiencies.
Table 3.16
Comparison of drug encapsulation efficiencies of ibuprofen and levofloxacin in stearic
acid conjugated PGA-co-PDL with stearic acid-free PGA-co-PDL
C18 conjugated Polymer (% conjugation) Drug encapsulation (%EE)
Ibuprofen
PGA-co-PDL (1:1:1) 0
PGA-co-PDL-CI8 33
PGA-co-PDL-CI8 50
53.6±2.74
44.64±2.47
61.99±1.23
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These results indicate that by post-synthetically modifying the polymer, the drug
encapsulation efficiencies could be altered. SEM images of stearic acid conjugated
polymeric particles highlights the different surface properties, as compared to PGA-co-
PDL particles (Figure 3.14). The same observations were recorded when particles were
prepared via the spray drying technique (Figure 3.10).
On the other hand, when ibuprofen was conjugated to PGA-co-PDL, and formulated
into microparticles, the surface of the particles was smooth. The particle sizes were very
similar to the stearic acid-conjugated polymer (3-5!lm). These results further indicate
that the small alterations in polymer chemistry can not only affect the encapsulation
efficiencies but also the particle morphology.
a)
c)
b)
Figure 3.14: SEMimages of microparticles ofPGA-co-PDL-C18 (100%) a) blank
(x5813, magnification bar = lOum) and b) with encapsulated ibuprofen (x651 3,
magnification bar = 10j.1m)and c) PGA-co-PDL-Ibu (100%) (x25547, magnification
bar = 4j.1m)
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In summary, polymers with varying chemistries have been used to attempt the
encapsulation of four different drugs. Encapsulation of freely and poorly water-soluble
drugs was achieved to different levels, except for rifampicin which was not
encapsulated in any of the polymers (Table 3.17). The drug-loaded formulations
obtained were then assessed further to obtain drug release profiles.
Table 3.17
Encapsulation efficiencies of four drugs in different polymers (bearing different
chemistries)
Polymer and monomer ratios Encapsulation efficiency (%)
Indomethacin Ibuprofen Levofloxacin Rifampicin
PLGA (50:50) 79.04±3.6 54.62±2.82 8.77±4.35 0.00
PGA-co-PDL (1:1:1) 62.99±2.44 53.6±2.74 12.59±3.1O 0.00
PGA-co-PDL (1: I: 1.2) 66.36±6.19 56.77±2.23
PPA-co-PDL (1:1 :0.6) 56.04 ± 3.53 54.0 ± 1.50
PBA-co-PDL (1: 1:0.5) 54.9 ± 1.50
PTEGA-co-PDL (1:1:1) 73.50±3.21 74.31±1.43 0.00 0.00
PTEGA-co-PDL (1:1:1.5) 74.00±3.l5 70.38±5.92
PGA-co-PDL-PEG 76.l4±5.l9 64.04±3.82 0.00 0.00
PGA-co-PDL-PEGme 64.45±3.19 53.74±0.42 13.21±2.51 0.00
PGA-co-PDL-C18 (33%) 44.64±2.47
PGA-co-PDL-CI8 (50%) 61.99±1.23
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3.3.4 Drug release profiles
Drug release studies are an important part of determining the potential of a new drug
delivery system. All drug-loaded formulations (table 3.17) underwent drug release
studies and the results are discussed below.
3.3.4.1 Release of encapsulated drugs
a) Ibuprofen release
The release of encapsulated ibuprofen was studied over 24 hours. It was observed that
over this time ibuprofen release was not complete (100%) in any of the formulations
(Figure 3.15). In PGA-co-PDL (1:1:1) the maximum drug released in 24 hours was
about 80%. Making the polymer more hydrophobic reduced the drug release from these
formulations considerably (see the curves for PLGA and PPA-co-PDL, figure 3.15). It
is well established that not only the chemistry but also the particle size affects the drug
release, that is, smaller particles release more drug due to a larger surface area (Dawes
et al 2009). All three above-mentioned formulations had similar particle sizes (about
Sum) and %EE (about 53%), hence the differences in the release profiles observed were
because of the polymer chemistry. The greatest amount of the drug was released in the
first two hours for PLGA and PPA-co-PDL, but for the PGA-co-PDL, the maximum
amount of the drug was released in 6 hours followed by release of the drug at very slow
rate, supporting the zero-order release profile of ibuprofen from these polymers. Similar
to PGA-co-PDL, the drug release from ethylene glycol containing polymers, that is,
PTEGA-co-PDL, PEG and PEGme copolymers showed a zero-order release profile but
maximum drug released in 24 hours did not exceed 30% of total encapsulated drug.
According to the supposition, hydrophilic polymers should release drugs at a faster rate
because of effective interactions with water. But the observations made here were
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contrary to supposition. There are two possible reasons behind this phenomenon, as
discussed below;
1) It was previously established that microparticles obtained from PEG copolymers
may have non-homogeneity (Peracchia et al 1997). The hydrophilic entities such
as ethylene glycol monomers (TEG, PEG, PEGme) occupy the outer shell region
of the particles while the hydrophobic part (PGA-co-PDL) constitutes the inner
core of microparticles. According to this hypothesis, the hydrophobic drug
would dissolve in the hydrophobic part of the polymer; hence, it is assumed that
ibuprofen would lie in the centre of the microparticles. This will make the drug
release considerably slower compared to that from a particle made up of a
homogeneous non-polar polymer (such as PLGA or PGA-co-PDL). However,
the presence of PEG does not affect the cumulative drug release as compared to
the other polymers which is in accordance with previous studies (Peracchia et al
1997). This is why PEG copolymers are good candidates for drug delivery
systems which can markedly reduce the rate of drug release.
2) The other reason behind the slower drug release is the mechanism of drug
release. Typically the drug initially releases from microparticles via diffusion-
controlled mechanisms followed by a combination of polymer degradation and
diffusion mechanisms. Various monomers such as PEG or polyethylene oxide
(PEO) have the ability to swell in aqueous media by absorbing water, leading to
slower water penetration into microparticles, which results in slower drug
release (Jeong et al 2000). On the other hand, hydrophobic polymers can only go
through diffusion and degradation or surface erosion at relatively higher rates -
giving higher amounts of drug release.
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These results suggest that the introduction of hydrophilic monomers has a profound
effect on the percentage drug released and the way the drug releases from these
formulations (Figure 3.15). The difference in molecular weight of the polymer also
effects the drug release profile, as described earlier by Ramkissoon-Ganorkar et al
(1999) and Kim (1998).
The initial burst release of drug may be the result of washing of the drug from the
surface, as there was no specific procedure followed to "wash-out" the surface-bound
drug by the use of specific chemicals or drug removing agents, such as a sodium
carbonate solution. Leo et al (2000) have demonstrated that using a sodium carbonate
solution to wash drug-loaded microparticles removed the ibuprofen from the particles'
surface resulting in no burst release. In this work, however, particles were washed with
distilled water but due to poor ibuprofen solubility in water, the surface drug may not
have been washed away completely, as is confirmed by the results plotted in figure
3.15.
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Additionally, when polymers underwent post-synthetic modifications by conjugation to
stearic acid - a very non-polar unit, this also resulted in the release of very low amounts
of ibuprofen from these formulations as compared to the non-conjugated polymer
(Figure 3.16). The 33% conjugated polymer was expected to release a lesser amount of
drug than 50% conjugated material. This was not observed, (Figure 3.16). This
phenomenon may be explained by the actual composition of the polymers. As it has
been established that longer polymeric chains of high molecular weight interact
together, causing slower release of drugs from particles (Yang & Hon 2009), hence, the
obtained release profiles were in accordance with this explanation. Increasing the
number of stearic acid chains on polymeric molecules may have resulted in increased
intramolecular interaction. This leads to more drug-polymer interaction and a reduced
chance of surface erosion or degradation. Hence, this results in a slower release of the
drug from particles (Figure 3.16). These results indicate that post-synthetic modification
is a good alternative way of controlling the drug release from microparticles.
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Figu re 3.16: Comparison of release profiles of ibuprofen from particles prepared from
PGA-co-PDL with and without conjugated stearic acid (n=3)
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b) Indomethacin release
The release of a relatively less water soluble drug indomethacin followed the same
release pattern as that of ibuprofen (Figure 3.17). For PLGA, PGA-co-PDL (1:1:1) and
PPA-co-PDL, after an initial burst release, the drug release followed a zero order
pattern. In the first 24 hours the maximum drug release was 75% from PGA-co-PDL but
increasing the hydrophobicity of the polymer resulted in decreased drug release as can
be seen in the profiles for PLGA and PPA-co-PDL (Figure 3.17). This is in accordance
with previous studies where the rate of indomethacin release was considerably slower
than that of ibuprofen from the hydrophobic polymer ethyl cellulose (Bodmeier & Chen
1989). However, using hydrophilic polymers like Eudragit'" made the drug release rate
considerably faster. Ethylene glycol containing polymers followed the initial slower
release pattern (Figure 3.17) because of the reasons discussed in previous section.
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Figure 3.17: Release profiles of encapsulated indomethacin from various polymeric
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Other parameters which can affect drug release from these polymers are the drug
loading and drug partition coefficient (polymer/water). It is well established that higher
drug loading also results in higher drug release rate (Huang & Chung 2001), but it was
apparent from figure 3.17 that the polymer/drug chemistry and polymer-drug
interactions, played more dominating roles in determining the drug release rather than
total drug loading.
c) Levofloxacin release
The release of the more, water soluble, drug levofloxacin followed a different pattern as
compared to indomethacin and ibuprofen. Instead of a very quick release in the first 1-2
hours (as observed in case of ibuprofen and indomethacin), the drug release was slower,
reaching a maximum level after 6 hours from PGA-co-PDL and 100% release was not
achieved even after 24 hours. Based on the assumption that hydrophilic drugs might
release quicker from these polymeric formulations, these results suggest that some of
the drug is encapsulated inside the polymeric matrix and would take longer to be
released from the particles. One thing which is evident from figure 3.18 is the
considerably higher release of the drug from ethylene glycol-containing polymers than
PLGA and PGA-co-PDL.
These results are the opposite to what was observed with the hydrophobic drugs,
indomethacin and ibuprofen. Ethylene glycol units, especially PEG are already well
known for their polymeric coating and water solubility properties, which affect the drug
release. The results presented in figure 3.18 are in accordance with the previous studies
(Jeong et al 2008) where it was observed that ciprofloxacin (a water soluble drug) was
released from the hydrophobic polymer, PLGA, microparticles in 14 days but only 15-
60% of the encapsulated drug was released from microparticles in one day (Dillen et al
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2004; Jhunjhunwala et al 2009). The mechanism of drug release would be more
diffusion-controlled from hydrophilic polymers while for hydrophobic polymers surface
erosion/degradation-controlled mechanism followed by diffusion would be
predominant.
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Figure 3.18: Release profiles of encapsulated levofloxacinfrom various polymeric
formulations (n=3)
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Another observation made in the present work was the absence of a burst release -
which can be explained by the fact that during the particle formulation steps the water
soluble drugs were "washed-out" by the aqueous continuous phase, leading to a drug-
free particle surface. Hence, these results support the fact that the rate of water soluble
drug-release is considerably higher from hydrophilic polymers.
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d) Rifampicin release
Rifampicin was not successfully encapsulated in any of the microparticle formulations,
via o/w or w/o/w techniques, probably because of its large molecular size and water
solubility. However, some other groups have reported the encapsulation of rifampicin in
PLA using w/o/w emulsion technique (Manca et al 2008) by using a considerably
higher amount of PYA (4%) as the surfactant or by using the Shirasu porous glass
(SPG) membrane technique (Makino et al 2004; Doan & Olivier 2009).
A spray drying technique was also reported as successfully encapsulating rifampicin
into poly-(DL-Iactide) using halothane as the solvent (Bain et al 1999), but as discussed
earlier, ibuprofen containing microparticles obtained using the spray drying technique
were agglomerated and were not suitable for these studies. Hence the release profile of
ibuprofen loaded microparticles, obtained from spray drying was not studied. Further
exploration into the parameters for spray drying may well have proven this technique to
be useful for improved rifampicin loading into these materials.
3.3.4.2 Release of conjugated drugs
In an attempt to slow down the release of drugs from the microparticulate formulations,
the model drug, ibuprofen was conjugated directly to the polymer backbone prior to
particle formulation. Previous studies have suggested that conjugation of drugs to the
polymeric backbone considerably decreases drug-induced toxicity and ensures the
targeted delivery of drugs (Hu et al 2009). In this case the drug can only be released by
the hydrolysis of weak ester bonds between ibuprofen and the polymer. As the polymer
itself is a polyester and degrades via hydrolysis of the labile ester link, the proposed
route of drug release was via polymeric degradation. These polymers are biodegradable
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under simulated physiological conditions, but may take 6-8 weeks; so drug release
would only be completed when all polymer-drug ester bonds are broken.
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Figure 3.19: Comparison of ibuprofen release from conjugated and encapsulated
polymeric formulations in first 24 hours
Figure 3.19, shows the marked difference between drug release from encapsulated and
conjugated formulations over an initial period of 24 hours. It is noted that about 80% of
the drug was released from the encapsulated formulations within 24 hours while in the
same duration less than 10% of the drug was released from conjugated species. Even
after 35 days the drug release from conjugated species did not exceed 30% (Figure
3.20), which confirms the fact that drug release can be markedly slow when conjugating
to the polymer backbone. The difference between the release profiles of 17% and 50%
conjugated ibuprofen is because of the fact that the 50% conjugated product contains
50% ibuprofen conjugated to the polymer backbone and hence there are 50% free -OH
groups on the polymeric backbone while 17% conjugated product only had 17%
conjugated ibuprofen, hence 83% of the -OH groups were free, which makes the
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polymer relatively more hydrophilic and more prone to degradation via hydrolysis,
resulting in higher drug release (polymer degradation is discussed in detail in chapter 4).
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In summary, the chemistry of polymers has proved to be an important factor to control
the drug release from microparticulate formulations. The properties of the synthesised
functionalised polymers can be varied by post-synthetic modifications to alter the drug
release.
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3.4 CONCLUSION
These investigations indicate that several of the polymeric materials assessed
demonstrated useful encapsulation efficiencies, comparable to the FDA-approved
PLGA, but also showed a better control over the release of the drugs. Hence,
synthesised polyesters such as PGA-co-PDL and PTEGA-co-PDL have potential as
improved colloidal drug carriers for drugs. Additionally, the control over the various
particle characteristics could enable tailored preparation and delivery of a variety of
different therapeutic compounds. The similarity between particles formed from PGA-
co-PDL and PBA-co-PDL contradicted our initial assumption that the absence of free
hydroxyl groups in PBA-co-PDL would favour the encapsulation of lipophilic drugs
like ibuprofen. The study indicates that rather than slightly altering the polymer
chemistry, particle properties and drug encapsulation can be altered by modification of
experimental parameters. Use of class III solvents is possible instead of class II solvents
while not compromising particles sizes and encapsulation efficiencies. Mixing speed,
polymers' molecular weights and concentrations can be varied to tailor the particles of
desired size, properties and drug loads. Additionally these polymers have successfully
encapsulated different drugs having various water-solubilities. However, the very water-
soluble drug rifampicin failed to encapsulate in these polymers via the current o/w or
w/o/w emulsion techniques. The drug release profiles indicated the slow release from
these polymers, and it can be concluded that by varying the monomeric compositions of
the polymers, the drug release profiles and the extent of the drug released can be
markedly controlled. The strategy to slow down the release of the drugs by conjugating
the drug onto polymeric backbone was satisfactory and showed that the release of the
drug can be slowed down. There is need for further exploration of the water soluble
drug rifampicin conjugation to polymer, as the drug failed to encapsulate in any of the
synthesised polymers. These studies are helpful for the prediction of the type of
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polymer required and influence of drug properties in the aim to deliver the required
amount of drug at desired release rate.
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Stability and Degradation Studies
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4.0 BACKGROUND
The stability of pharmaceutical formulations primarily depends on the physico-chemical
properties of the raw materials, including the excipients, container system,
environmental and storage factors and their effect on the product. The stability of
biodegradable polymers is a prime issue to be considered after synthesising new
materials for potential use in drug delivery applications. The degradation rate of
polymers is affected by different parameters such as polymer nature, polymer
composition, molecular weight, hydrophilicity and physical state (viscous liquid,
crystalline or amorphous) (Dorati et al 2007). Ideally a polymer should exhibit good
storage stability, yet for successful utilisation in drug delivery applications, these
polymers also need to demonstrate complete degradation in vivo. Extensive studies have
been carried out to investigate the degradation of polymers upon exposure to simulated
physiological environments (buffers and simulated fluids) (Wang et al 1990; Anderson
& Shive 1997; Eppley & Reilly 1997; Schliecker et a12003; Meng et a12006; Lei et al
2007; Zhao et al 2007; Chandure et al 2008). For polyesters the preferred route of
degradation, under such conditions, is mainly the hydrolysis of labile ester linkages,
however this depends on monomeric composition, blending of polymeric materials and
even the configuration of the monomeric units within a polymer chain (Zamora et al
2006). Keeping in view the effect of polymer chemistry on degradation, many research
groups have altered the biodegradability of polymers via insertion of chemical moieties
near the ester linkage to vary the hydrolytic susceptibility of the material (Albertsson &
Eklund 1995). Zamora (2006) investigated the dependence of degradation on the
monomeric configuration in polyester chains. The effect of chemistry on polymer
degradation was further explored by a few research groups who discovered that the
degradation profiles of polymers could be modified by synthesising copolymers, instead
of homopolymers (Dorati et al 2007; Lei et al 2007; Zhao et al 2007; Chandure et al
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2008; Moeller 2008). Homopolymers degrade at a constant rate, but with copolymers
some fragments will degrade more slowly than the others, leading to an increase in the
overall shelf lives of these materials (Huang et al 2004). Hence, the stability of
polymers can be successfully modified by varying the monomer ratios in a copolymer
(Lenglet et al 2009). These properties widen the range of applications for these
materials in everyday life by enabling tailoring for specific functions, along with
improved use in drug delivery. Modified polymeric materials have been used to develop
numerous biodegradable and biocompatible biomaterials (He et al 2003; Dorati et al
2007; Zhao et al 2007; Gong et aI2009). Gaskell et al (2006) and Thompson et al (2007)
have evaluated the use of one such polymer, PGA-co-PDL for pulmonary drug delivery
applications.
Although various procedures are in place for studying polymer degradation; enzymatic,
thermal, soil degradation etc., for biomaterials intended for use as drug carriers, studies
of their degradation under physiological conditions is of greater importance. Previous
studies demonstrated that the degradability of polymeric materials influences the release
of drugs from polymeric microparticulate systems (Wang et al 1990). Different
polymers degrade to different extents, hence affecting the release of the associated
drugs. Degradation of polymers proceeds via two possible pathways, that is, either by
surface erosion or by random chain scission. Depending upon polymer chemistry, either
of these two pathways can cause polymer degradation. For instance, during hydrolytic
degradation, random chain scission is the preferred route of degradation. Highly
hydrophilic polymers will absorb more water and hydrolyse more quickly than more
lipophilic polymers, where water penetration into the matrix is minimal, causing the
least random chain scission (Gopferich 1996).
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The effects of extreme storage conditions have been studied on different polymers for
drug delivery and it was observed that, when employed at their extremes, such
conditions promote their degradation. Hence, the regulatory requirements for the
approval of biomaterials for colloidal drug delivery applications are: complete stability
profiles; extensive characterisation; estimation of shelf life; determination of
degradation products and the identification of any toxic by-products (Committee for
Proprietary Medicinal Products 1998;Matthews 1999; Burgess et aI2004).
A desirable polymer-based drug delivery system will have good storage stability but
will degrade easily under physiological conditions, leading to effective release of the
therapeutics. Hence, a good understanding of the stability and degradation of any new
material is required prior to the effective applications of such polymers in drug delivery
technologies.
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4.1 AIM OF THE STUDY
The aim of this part of the project was to study the effects of various storage factors,
including light, temperature and humidity on the stability of the polymeric materials, as
outlined by ICH guidelines. In the present work differences in the physical and
chemical properties of four novel polymers on stability were investigated under various
storage conditions. PGA and PGA-co-PDL possesses hydrophilic characteristics
because of the pendant functional hydroxyl groups on the polymer backbone. Both
polymers were compared to their more hydrophobic equivalents, PBA and PBA-co-
PDL, respectively.
These polymers are required to be stable with shelf lives of approximately one year but
with good biodegradability under physiological conditions. Hence, in vitro degradation
studies of these polymers were also carried out under simulated physiological
conditions. Since one potential application of these materials is microparticulate
pulmonary drug delivery, simulated lung fluid (SLF) and PBS buffer were used at body
temperature for the in vitro degradation studies. These studies were designed to provide
an understanding of the effect of polymer chemistry on the in vitro degradation of these
materials. The data obtained will be useful for the estimation of the storage shelf life
and half life of these materials in the human body.
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4.2 EXPERIMENTAL
4.2.1 Materials
Poly(glycerol adipate) (PGA) (PIa: 6609 Da and Plb: 8904 Da), poly(glycerol adipate-
co-pentadecalactone) (PGA-co-PDL) (P2: 14431 Da), poly(l,4-butanediol adipate)
(PBA) (P3: 7369 Da), poly(1,4-butanediol adipate-co-pentadecalactone) (PBA-co-PDL)
(P4: 15960 Da), poly( dithiotheritol adipate-co-pentadecalactone) (PDT AA-co-PDL,
6500Da) were previously synthesised and characterised (section 2.2) and PGA-co-PDL
microparticles (formulated in chapter 3). Deuterated chloroform (CDC b) was purchased
from CIL, USA. Potassium acetate, magnesium chloride hexahydrate, sodium chloride,
potassium chloride, sodium phosphate dibasic anhydrous, sodium sulphate anhydrous,
calcium chloride dihydrate, sodium acetate trihydrate, sodium bicarbonate, sodium
citrate dihydrate and tetrahydrofuran were purchased from Fischer Scientific. 3A
molecular sieves and indicator blue silica gel were obtained from Sigma-Aldrich and
phosphate buffered saline (PBS) pH 7.4 tablets were purchased from Oxoid.
4.2.2 Methods
4.2.2.1 Storage stability under simulated environmental conditions
Approximately 2-3g of each polymer were placed in 5 ml screw-top vials that were
capped and sealed with parafilm. These vials were then stored in 500 ml closed
containers at either 4°C±2°C (in refrigerator), 25°C±2°C (in dark cabinets at room
temperature) or 40°C±2°C (in oven). At each temperature the humidity in the containers
was controlled at either 0%±5%, 25o/o±5% or 75%±5% relative humidity (RH) using
saturated salt solutions (Brien 1948; Greenspan 1977). Temperature and humidity values
were monitored using a Therma-Hydrometer (E.T.I, model 8703). A representative
picture of a typical setup is shown in figure 4.1. A brief summary of the conditions
applied to generate a controlled temperature and humidity environment is shown in
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table 4.1. During the preliminary studies the effect of light and the effect of direct
exposure to atmospheric humidity were studied by using clear/transparent and amber
coloured vials and using open or closed vials within the containers.
Figure 4.1: A typical setup used to study polymer stability under simulated
environmental conditions.
All polymer samples were analysed immediately after synthesis, prior to storage under
simulated environmental conditions. Once equilibrated at the indicated conditions, small
quantities (10-15 mg) were removed for analysis at 20 day intervals for 3 months then at
2 monthly intervals until 6 months. All samples were analysed for physical and
chemical changes. Structural changes in the stability of samples of the polymers were
studied using FTIR, while changes in molecular weight were recorded via GPC.
Detailed analytical methods for these techniques are described under section 2.3.
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Table 4.1
Storage conditions used to maintain temperature and percent relative humidity
%RH Temperature Procedure
Oo/o±5% 4°C±2°C Pre-activated indicator silica gel mixed with 3AO
molecular sieves.
Oo/o±5%
Oo/o±5%
25o/o±5%
25o/o±5%
25o/o±5%
75o/o±5%
75o/o±5%
75o/o±5%
Pre-activated indicator silica gel mixed with 3Ao
molecular sieves.
Pre-activated indicator silica gel mixed with 3N
molecular sieves.
Sealed container containing saturated
solution of potassium acetate (CH3COOK) which
produces humidity of 23.28%±OJ4% at 4°C.
Sealed container containing saturated
solution of potassium acetate (CH3COOK) which
produces humidity of 22.51 %±O.32% at 25°C.
Sealed container containing saturated
solution of potassium acetate (CH3COOK) which
produces humidity of 21.50%±OJO% at 25°C.
Sealed container containing saturated
solution of sodium chloride (NaCI), which
produces humidity of75.51%±O.34% at 4°C.
Sealed container containing saturated
solution of sodium chloride (NaCI), which
produces humidity of 75.29%±O.12% at 25°C.
Sealed container containing saturated
solution of sodium chloride (NaCI), which
produces humidity of 74.68%±O.13% at 40°C.
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4.2.2.2 In vitro degradation in buffer
One tablet of PBS buffer (containing 150mM anhydrous sodium phosphate (dibasic)
and 0.9 (w/v"Io)sodium chloride) was dissolved in 100 ml distilled water at room
temperature in a 150 ml beaker using a magnetic stirrer until the contents were
completely dissolved. The recorded pH of the resulting solution was 7.2. Samples of 15-
20 mg of PGA-co-PDL (powder), PGA-co-PDL (microparticles) and PDTTA-co-PDL
(powder) were dispersed separately in 5 ml of PBS buffer in six screw-top vials. The
vials were gently continuously agitated with an orbital shaker (IKA, KS-130 basic) at
100RPM in an environmental incubator (Stuart, S160)at 37°C for six weeks. One of the
vials was removed weekly and the polymer sample recovered by filtration. The
recovered polymeric mass was dried between 2 layers of filter paper. Dried samples
were dissolved in 2 ml ofTHF and analysed by GPC (section 2.2.4).
4.2.2.3 In vitro degradation in simulated lung fluid
Simulated lung fluid (SLF) was prepared using the method published by Gamble (1967),
by dissolving specific amounts of various inorganic salts in one litre of distilled water,
as summarised in table 4.2.
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Table 4.2
Contents of the simulated lung interstitial fluid: listed in the order of addition.
Order Salt Quantity (gIL)
1 Magnesium chloride hexahydrate
2 Sodium chloride
3 Potassium chloride
4 Sodium phosphate dibasic anhydrous
5 Sodium sulphate anhydrous
6 Calcium chloride dihydrate
7 Sodium acetate trihydrate
8 Sodium bicarbonate
9 Sodium citrate dihydrate
0.2033
6.0193
0.2982
0.1420
0.0710
0.3676
0.9526
2.6043
0.0970
All salts were dissolved in the listed order to prevent precipitation, as it is known that
precipitation may occur by the addition of components 6-9. The starting volume of the
distilled water was 95% (950 ml) of the desired final volume (1 litre). The final pH of
the simulated lung interstitial fluid solution was measured at 7.4.
A sample of 15-20 mg of PGA-co-PDL (powder), PGA-co-PDL (microparticles) and
PDTT A-co-PDL (powder) were dispersed separately in 5 ml of simulated lung
interstitial fluid in six screw-top vials. Vials were agitated gently with the shaker at 100
RPM, stored in an environmental incubator at 37°C for six weeks. Sampling and
analysis was carried out as described under section 4.2.2.2.
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4.3 RESULTS AND DISCUSSION
4.3.1 Storage stability
It is well known that polyesters degrade in a wide variety of environmental conditions,
hence reducing their shelf life (Fujimaki 1998; Khan et al 1999). These polymers also
degrade readily upon treatment with extreme conditions such as very high temperatures
(thermal degradation) (YusufNur 2007), exposure to enzymes (enzymatic degradation)
(Zhao et aI2007), under UV and natural light (photodegradation) (Feller et a12007) and
upon exposure to moisture (hydrolysis) (Dorati et al 2007). These factors all contribute
to the degradation of polymers, which can be indicated by a decrease in molecular
weight, change in crystallinity, pH of the solution, formation of additional functional
groups and changes in terminal group chemistry. Various techniques can be used to
determine changes in polymers upon degradation, such as GPC, IR, NMR, DSC and
viscometry. Factors responsible for polymer degradation fall into two major categories:
chemical factors (hydrophilicity, molecular weight, physical state and polarity of the
molecule) and storage factors (temperature, humidity and light).
4.3.1.1 Effect of polymer chemistry
The effect of polymer chemistry on the stability of polymers synthesized during this
project was investigated by varying the monomer composition, molecular weight, free-
OH groups and carbon chain lengths. Details of the polymers studied and their
properties are summarised in table 4.3.
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Table 4.3
Physical and chemical properties of polymers used in the stability studies
Polymer Molwt State free-OH Carbon
(Da) (at room temperature) chain length
8904 Viscous liquid Yes 9
14431 Waxy solid Yes 21
7369 Soft solid No 9
15960 Waxy solid No 21
PGA
PGA-co-PDL
PBA
PBA-co-PDL
4.3.1.1.1 Effect of pendant -OH groups
The polymers tested were synthesised using either glycerol (one free -OH group per
repeat unit) or 1,4-butanediol (no free -OH group), thus altering the hydrophilic nature
of the polymers. PBA and PBA-co-PDL polymers were waxy solids at room
temperature that lacked pendant free -OH groups. They are less hydrophilic than the
corresponding PGA and PGA-co-PDL and have a lower affinity towards moisture,
which should make them less affected by humidity and temperature. On the other hand,
PGA is a viscous polymer while PGA-co-PDL is a waxy solid. They both have pendant
free -OH groups on the backbone which makes these polymers more hydrophilic, hence
more prone to degradation by increased temperature and humidity. The change in
molecular weight of these polymers after storage for six months under moderate
conditions (25°C and 25%RH) is shown in figure 4.2.
188
... 30 26.52s:
btl
'iii 25:=...
.!!! 20:lu 16.20
QJ
'0 15E
s::::
QJ 10III 7.01~
QJ...
u 5 2.99QJ
c
*' 0
PGA PGA-co-PDL PBA PBA-co-PDL
Figure 4.2: Degradation of polymers after storage at 25% RHin 25°Cfor six months
PGA and PBA differ only in the presence of free hydroxyl groups throughout the
polymer backbone, and as expected the results (Figure 4.2) indicate the greater stability
of PBA compared to PGA. These results suggest the innate involvement of the pendant
hydroxyl groups in the degradation of the polymers. The difference in stability of the
two polymers however, may also partly be due to their physical state. PBA, a solid
polymer, is more stable than the viscous PGA. Similarly comparing PGA-co-PDL and
PBA-co-PDL degradation it is noted that, under the same environmental conditions, the
pendant hydroxyl group-containing polymer (PGA-co-PDL) degraded more compared
to the PBA-co-PDL. In this case both polymers were waxy solids at room temperature.
The difference in degradation between PGA and PBA (23.53%) is much greater than the
difference between the co-lactone polymers PGA-co-PDL and PBA-co-PDL (9.19%).
Only after placing the PBA-co-PDL in the most extreme conditions tested (75% RH and
400C) was a slight increase in the intensity of the hydroxyl band (at 3500cm-l) from the
FTIR spectra observed (Figure 4.3). This observation is in accordance with the above
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results, indicating that this polymer is quite stable at ambient environmental conditions
and resists degradation even under extreme conditions.
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Figure 4.3: FTIR spectra of PBA-co-PDL before (black line) and after (blue line)
storage at 40°C and 75%RHfor six months
Contrary to this, the FTIR spectrum for PGA-co-PDL shows a considerable increase in
hydroxyl band intensity signifying the greater extent of polymer degradation (Figure
4.4). These hydroxyl groups come from the end groups of the by-products
(corresponding alcohol and acid) following hydrolysis.
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Figure 4.4: FTIR spectra of PGA-co-PDL before (red line) and after (black line)
storage at 75% RH at 40OCfor six months
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This phenomenon can be explained on the basis of the number of free -OH groups per
100-carbon-chain length of the polymer. Given the random distribution of monomeric
units in the polymer, per 100-carbon-chain ofPGA there would be 11 free -OH groups
in its back bone, whereas PGA-co-PDL would have only 5 free -OH groups. The
presence ofless -OH groups on the backbone of the polymers made these polymers less
hydrophilic and more stable than the polymers with a higher number of free -OH
groups. This hypothesis can be backed up further by the results obtained from
comparing PBA and PBA-co-PDL where less degradation was observed in the absence
of -OH groups on the backbone.
This illustrates that the presence of hydrophilic functional moieties on polymer
backbones make polymers more hydrophilic and hence more prone to degradation even
at ambient storage conditions. Their degradation is accelerated under higher temperature
and humidity storage conditions compared with those polymers which lack this
functionality.
4.3.1.1.2 Effect of carbon chain length and molecular weight
PGA-co-PDL and PBA-co-PDL have an extra 15 carbon chain of POL in the repeating
unit within their structure, compared to PGA and PBA. This results in a higher
molecular weight of a repeat unit and a more non-polar polymer backbone. While
comparing degradation of PGA with PGA-co-PDL, it was observed that PGA-co-POL
was relatively more stable than PGA over all temperature and humidity ranges. The
results obtained by both groups of polymers PGAlPGA-co-PDL and PBNPBA-co-POL
suggesting that higher molecular weight polymers are more stable than lower molecular
weight polymers. This is supported by the work of Wang et al (1990). However, with
the current polymers the influence of other chemical properties, such as pendant -OH
groups and presence of non-polar chains cannot be excluded. Therefore, to investigate
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this, the effect of molecular weight on the stability of polymers with the same chemistry
was studied. Two samples of PGA (PIa, 8904 Da) and (PIb, 6609 Da) were tested. It
was observed that under the same conditions the polymer with the lower molecular
weight degraded 80% in 3 months while the higher molecular weight PGA degraded
only 60% compared to its starting molecular weight, so a small change in molecular
weight can have a big effect on stability and degradation rates. Wang et al (1990)
reported the faster degradation of lower molecular weight polymers compared to higher
molecular weight materials, along with a decrease in their viscosity. In addition to
molecular weight, increased polydispersity also results in faster degradation.
Based on these observations, higher molecular weight polymers with no hydrophilic
functional moieties on the polymer backbone have longer shelf lives and may be more
suitable for drug delivery formulations in terms of enhanced stability. These results
have direct implications in the design of controlled release formulations, as it is
previously reported that polymer chain length and polydispersity have an impact on
drug release profiles (Ramkissoon-Ganorkar et al 1999); the details of these factors have
already been discussed in chapter 3 (Drug encapsulation and release).
4.3.1.2 Effect of storage factors
Storage factors, such as light, temperature and humidity play a major role in polymer
degradation. This is why many pharmaceutical formulations are stored in specialised
packaging for an improved shelf life of the products. For example, some tablet
formulations come in special aluminium strips or with an adsorbent silica bag in the
container. Some dosage formulations such as syrups or suspensions come in amber
coloured vials to prevent the contents from the deteriorating effect of light. According to
the British Pharmacopoeia (BP 2010) standard, 90% of the radiation, at any wavelength
between 290-450nm (UV radiation), should be absorbed by the amber glass containers.
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Keeping this in mind, the effect of these environmental factors were studied on a
selection of polymers synthesised (in chapter 2), in accordance with the published ICH
guidelines (Matthews 1999) .
4.3.1.2.1 Effect of light
PGA was selected for preliminary studies on the effect of light on polymer stability.
PGA (molecular weight 8904Da) was stored in two different types of sealed containers;
clear vials and amber-coloured vials. Initial results demonstrated that the polymer
degraded more quickly upon exposure to light. Amber-coloured vials restricted the
penetration of light to polymers, and these samples remained more stable. Figure 4.5
summarises the effect of container type on the molecular weight of PGA at 40°C under
ambient humidity. After six months PGA stored in the amber vial had a higher
molecular weight than the sample stored in the clear vial. This may be indicative of
photodegradation of these polymers. Photodegradation of polymers can be reduced by
blending polymers with other materials or by using fillers to make composites (Li et al
2008), or alternatively photolysis of such polymers can easily be prevented by storing
polymers in amber- or dark-coloured containers (Feller et al 2007).
Light irradiation of polymers modifies their physical and chemical properties, for
example inducing colour change and degradation. PGA and related polyesters have
weak ester bonds which are labile to specific environmental conditions. Hence these
materials are expected to break down via the hydrolysis of these ester bonds. Increased
temperature (thermolysis) and exposure to light (photolysis) favours the hydrolysis of
ester bonds, resulting in an increased degradation rate. The degraded material was
analysed by GPC and FTIR to give an indication of the chemistry of the degraded
polymer samples.
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Figure 4.5: GPC chromatogram of PGA prior to storage (black line) and after 6
months at 40 OCunder ambient humidity in a closed amber vial (green line) and clear
vial (red line)
To understand the qualitative nature of the degradative products, GPC traces of the
original PGA and the degraded polymer samples were overlaid along with the GPC
traces of the monomeric units, glycerol and adipic acid. Figure 4.6 very clearly shows
that the degraded polymer contains fragments of molecular weight equivalent to
glycerol, adipic acid and short oligomers of these. This indicates that, upon degradation,
PGA converts to its non-toxic, biodegradable monomeric units, which can easily be
excreted through the kidneys or enter one of the biochemical metabolic pathways
(Stefani et al 2006).
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Figure 4.6: GPC chromatogram of PGA before degradation (black) and the after
degradation at 40 OCand 75%RH stored in clear open vial (red) is overlapped with
DVA (blue) and Glycerol (green)
This data indicates that there are two major steps in the degradation of the polymer
1) Random polymer chain scission; which results in low molecular weight
polymer fragments and can easily be indicated by shifts in the retention
volume of the polymer in the OPC traces (broadening of the ope peaks).
2) Conversion to monomeric units; polymer chain scission ends with the
reversion of the polymer back to its monomeric units (development of
discrete peaks at the tails of the main peak).
4.3.1.2.2 Effect of temperature
Infrared spectroscopy has previously been adopted for hydrolytic degradation studies of
aliphatic polyesters in an alkaline environment (Partini & Pantani 2007). Rosu et al
(2009) also used FTIR to study the effect of UV light on the photodegradation of
polymers by monitoring the degradation products. FTIR spectra of the polymer samples,
stored at different temperatures for 6 months, correlated with the OPC results.
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Figure 4.7 shows an increase in intensity of the hydroxyl band for PGA samples placed
at 40°C for 6 months, while samples stored at 4°C and room temperature did not show
any increase in hydroxyl groups. It clearly demonstrates that chain scission by
hydrolysis of ester bonds results in the generation of more -OR groups, thus leading to
an increased intensity of the hydroxyl band in the FTIR spectrum.
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Figure 4.7: FTIR spectra showing polymer degradation at different temperatures
Polymers stored for 6 months at all temperatures degraded and a decrease in molecular
weight was observed, as exhibited in figure 4.8. It is clear that all polymers remain most
stable at 4°C, as the change in the molecular weight of the polymers was less than 5%
but increasing the storage temperature to 25°C (room temperature) resulted in a decrease
in molecular weight of up to 15%. This decrease in molecular weight was even more
considerable when polymers were stored at 40°C and a maximum degradation of 51%
was observed with PGA. PGA-co-PDL remained more stable than PGA in terms of
percentage decrease in molecular weight due to its higher molecular weight, carbon
chain length and solid state. At 0% RH, the molecular weight of PGA-co-PDL
decreased by 25% at 40°C while at 4°C and 25°C it remained stable. A 10% variation in
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molecular weight of PBA was observed at 4°C and 25°C and surprisingly a 7% increase
in molecular weight of PBA was observed at 40°C in the first 3 months and that increase
reached 15% over 6 months. The reason for this increase might be because in its
original form PBA is a white powdery solid and storage at 40°C resulted in the polymer
melting and hence its physical form changed, from a white powder to a wax-like solid.
This might have lead to some intermolecular rearrangements leading to an increase in
molecular weight. However, no previous literature was found to support the increase in
molecular weight observed with this polymer. Further studies are required to understand
this phenomenon and to obtain a more detailed explanation of the observed increase in
molecular weight.
No major physical changes were observed in the polymers stored at 4°C and 25°C, but
at 40°C the powdery appearance of the solid polymers was transformed to a waxy layer,
as a result of slow melting, with a colour change from white to pale yellow, which is an
indication of polymer degradation (Rosu et al 2009). Hence, if these materials were
used for particle preparation and drug encapsulation, the micropartic1es would not be
stable at 40°C due to the physical changes and melting which would result in the
deterioration of particles after 60 days. Increasing the temperature (Figure 4.8) resulted
in a proportional decrease of the molecular weight, indicating that thermolysis of ester
bonds, causing random chain scissions, had occurred and hence an increased poly
dispersity index (PDI) of all the polymers tested. PDI is an indicator of polymer
degradation, however it is also a cause of accelerated polymer degradation (Partini &
Pantani 2007). The more rapid degradation of polymers at 40°C assures the polymer
degradation in human bodies at physiological temperature (37°C) and very high
humidity.
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Figure 4.8: Polymer degradation at various temperatures} when stored in various
humidity environments: a) O%RH, b)25%RH and c) 75%RH
198
As discussed in section 4.3.1.1, PBA-co-PDL, was more stable than PGA-co-PDL with
a molecular weight decrease of only 5-17% over 6 months across the entire temperature
range studied (Figure 4.10). This is because of the lack of functional groups, low
hydrophilic character and higher molecular weight. Polymers stored near or above their
Tg degrade much faster (Zamora et al 2006) via chain breaking (Feller et al 2007). This
is because at or near its Tg, polymer molecules have enough mobility to allow structural
reorganisation which cause increased polymer degradation (Royal & Torkelson 1992).
This further explains the higher degradation of PGA (the viscous polymer) as compared
to the corresponding co-lactone (PGA-co-PDL). Figure 4.9 indicates the degradation of
PGA by showing the increased presence of lower molecular weight fragments with
increasing storage temperatures. It is evident from the increasing PDI of the GPC traces
with increased storage temperature that PGA degraded to lower molecular fragments,
while an overall shift of the peak towards a lower molecular weight indicates that the
polymer's integrity decreased by chain scission under these environmental conditions
over the monitored duration of time.
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Figure 4.9: GPC chromatogram of PGA before (black line) and after storage for six
months at 25%RH and varying temperatures: 4°C (blue line), 25"C (red line) and 40 "C
(green line).
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The deteriorating effect of temperature on polymer degradation when coupled with high
humidity increased several fold. Although similar degradation trends were observed at
different temperatures when stored in higher humidity environments, the degradation of
polymers was more rapid and deteriorative. These observations are discussed in the next
section.
4.3.1.2.3 Effect of humidity
The effect of humidity on the polymers tested is summarised in Figure 4.10. The effect
of increasing humidity on degradation was obvious for all polymers. For instance at O°C
and O%RH, PGA and PBA degraded by only 3-5%, PBA-co-PDL by 7-8% and a 10-
15% variation in molecular weight was observed in PGA-co-PDL. The storage of
polymers at higher humidity increased the polymer degradation several fold, as shown
in figure 4.10.
All polymers (except PBA-co-PDL) degraded under increased humidity and their
molecular weights decreased by 50-65%. PBA-co-PDL again exhibited a more stable
nature, degrading by only 25%. These trends indicated that higher temperatures keep
polymers in a liquid state, hence intermolecular distances remain large enough to allow
penetration of moisture. This then facilitates the cleavage of the polymer chains by
hydrolysis of labile ester bonds along with thermolysis. The data obtained at 4°C
(Figure 4.10) further supports the assumption that at lower temperatures there is not
enough intermolecular space for moisture to penetrate the polymer, hence a smaller
surface area of polymer is exposed to moisture, leading to the hydrolysis of a smaller
number of ester bonds and resulting in less polymer degradation. Hydrolysis of
polymers usually proceeds with random chain scissions and depends on monomer
structure, polymer molecular weight and copolymer ratio (Wang et al 1990). It is
assumed that hydrolysis of these ester bonds proceeds linearly with time and thus
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suggests that the controlling mechanism is a chemical reaction rather than water
diffusion, as described by Partini & Pantani (2007).
a)
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b) Effect of humidity at room temperature (25C)
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Figure 4.10: Polymer degradation at different humidity, when stored at various
temperature ,. a) at 4°C, b) at 25°C and c) at 40°C
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Table 4.10 further illustrates that humidity plays a facilitating role in the deterioration of
the polymer chains into smaller molecular weight fragments via hydrolysis. All vials
were sealed and capped and stored in their final packaging, hence there was a reduced
effect of environmental humidity. These results raised a question that if a slight increase
in humidity can degrade polymers to such a level, what would be the extent and
timescale for the degradation, if the polymers were directly exposed to the
environmental conditions. A small experiment was conducted to study the effect of
direct exposure to humidity.
Effect of direct exposure to humidity (at 40°C)
The presence of labile ester bonds makes polyesters very susceptible to humidity-
induced degradation (hydrolysis) along with thermolysis of the polymer backbone at
higher temperatures. Exposure of PGA to moisture and high temperature facilitated
degradation of the polymer into smaller molecular weight fragments and to its
monomeric units as shown in figures 4.11 .
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Figure 4.11: GPC chromatogram showing the effect of humidity on stability of the PGA
when stored in open (red line) and in closed vials (green line) for six months at 40 CC'
and 75% RH.
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The effect of humidity was observed in samples stored with an opened top at 400e and
75% RH where complete degradation of the polymer occurred after 6 months (Figure
4.11). A major change in the polymers' physical properties was also observed as a
decrease from initial high viscosity state to a very low-viscosity liquid (Table 4.4). This
further confirms that these polymers are labile to moisture and would be easily
biodegradable. While under similar environmental conditions only a 55% decrease in
polymer molecular weight was observed in closed vials (Figure 4.10), emphasising the
reduced effect these conditions have in sealed vials. These results clearly indicate the
deteriorative effects of humidity on polymers, even stored in closed vials. Table 4.4
summarises the changes in the physical properties of PGA. The molecular weight of
PGA decreased from 6609 to 933 Da within two months, followed by complete
degradation within 4 months, when exposed directly to 75% RH and 40oe.
Table 4.4
Effect of humidity on physical properties of PGA (at 40°C and 75%RH)
Duration Physical Properties
2 months
Closed Vial
Low viscosity
4 months Very low viscous liquid, free flowing
6 months Very low viscous liquid, free flowing
2 months
Open Vial
Very low viscosity
4 months Two phases: pale yellow liquid, white solid layer
6 months Two phases: pale yellow liquid, white solid layer
The order of stability at near ambient conditions (25°e and 75% RH) ranging from most
stable to least stable is PBA-co-PDL > PBA > PGA-co-PDL > PGA (Figure 4.12).
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Figure 4.12: Percentage decrease in molecular weight of the polymer at 2ye and 75%
RH after six months
This further confirms that apart from the influence of crystallinity, more hydrophilic
polymers degrade more rapidly (Dorati et al 2007), while a decrease in hydrophilicity
results in reduced interactions with aqueous media, resulting in slower degradation
(park et al 1992).
4.3.1.3 Shelf life estimation
The stability data obtained from the analysis of polymer samples at regular intervals
were used to plot stability curves, according to ICH and pharmacopoeial guidelines.
Extension of the plots can be used to assess and estimate the shelf life of the polymers.
a) Poly(glycerol adipate) (PGA)
Figure 4.13 summarises the effect of simulated storage conditions and environmental
factors on PGA and clearly indicates that 4°C is the best storage condition for this
polymer, with a maximum decrease of molecular weight of only 4%. Hence, storage of
PGA at higher temperature is not advisable as it can lead to a 10-60% reduction in
molecular eight 0 er 6 months. Extended graphs for shelf life determination (Figure
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4.l3) show that at 4°C (at all humidity ranges tested) PGA can remain stable for more
than 12 months while retaining to 90% of its molecular weight. It is also evident that
polymer degradation reached its maximum within 60 days at higher temperature and
humidity.
b) Poly(glyceroladipate-co-pentadecalactone) (PGA-co-PDL)
The percentage decrease in molecular weight of PGA-co-PDL, under different
environmental conditions is presented in figure 4.14. This information enables the
selection of suitable storage conditions for this particular type of polymer. It is clear that
storage at 4°C and room temperature caused up to 20% variation in molecular weight of
the polymer under all relative humidities tested, whilst approximately a 60% decrease in
molecular weight was observed at 40°C at 25% and 75% RH only. Extended plots of
the stability data (Figure 4.l4), showed that PGA-co-PDL degraded by 25% within 6
months and this may extend to 30-35% by the end of 12 months at 0% RH over all
temperature ranges. At 25% RH the polymer remained in a similar range of 30%
degradation at both room temperature and 4°C, but at 40°C, the polymer had already
degraded by more than 60%. Hence the PGA-co-PDL should be stored at either 4°C or
room temperature, over drying sieves to avoid any physical and compositional changes.
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Figure 4.13: Shelf life determination of PGA via extrapolation of decrease in molecular
weight curve up to a year, under various storage conditions
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Figure 4.14: Shelf life determination of PGA-co-P DL via extrapolation of decrease in
molecular weight curves up to a year, under various storage conditions
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c) Poly(1,4-butanediol adipate) (PBA)
Figure 4.15, summarises the effects of humidity and temperature on the molecular
weight of PBA. PBA can be stored at 4°C and room temperature without any major
decrease «5%) in molecular weight for 12 months, while storage at higher temperatures
(~40°C) is not advisable because of compositional changes in the polymer. Polymer
samples stored at 40°C degraded by 60% within 6 months of their storage, hence storage
of the polymers at 4°C or room temperature over drying sieves is advised.
d) Poly(1,4-butanediol adfpate-ce-peetadeealaetene) (PBA-~o-PDL)
Figure 4.16, identifies the best conditions for the storage of the PBA-co-PDL copolymer.
It is clear that room temperature or 4°C with ambient humidity is also the better option
to store PBA-co-PDL. Furthermore, melting of the polymer at 40°C introduces another
limitation on the storage of the polymer; hence storage at room temperature or below is
essential for longer shelf life (nearly 2 years). From the data shown it can be observed
that within 12 months the molecular weight of the polymer may decrease only by 20%
at room temperature and 4°C, thus confirming that this polymer can stay stable for
longer than 1 year, if stored appropriately.
In conclusion, 4°C or room temperatures (25°C) under dry conditions are the best
storage conditions for all these polymers.
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Figure 4.15: 'helf life determination ofPBA via extrapolation of decrease in molecular
weight curve up to a year, under various storage conditions
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Figure 4.16: helflife determination of PBA-co-PDL via extrapolation of decrease in
molecular weight curve up to a year, under various storage conditions
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4.3.2 In vitro degradation
Along with a longer shelf life, another much desired property of the polymers for drug
delivery applications is biodegradability. PGA-co-PDL was previously investigated for
pulmonary drug and protein delivery by Gaskell et al (2008) and Thompson et al (2007).
Regardless of the route of administration the polymeric matrix should degrade
completely into non-toxic components and be excreted by the body via the
physiological pathways. As the human body provides a range of physiological
conditions, from very acidic (gastric juices) to neutral (blood) to very alkaline
(intestinal juices), this highlights the importance of in vitro degradation studies under
simulated physiological conditions. Phosphate-buffered saline (PBS), pH 7.4, is
commonly considered the medium of choice for in vitro degradation studies, and most
researchers report biodegradation in this buffer (Wang et al 1990). This buffer contains
150 mM sodium phosphate (dibasic) and 0.9% (w/v) sodium chloride. Although the
final pH of this buffer is 7.4, equal to lung pH, the ionic strength and concentrations do
not represent lung fluids. Gamble's solution is considered as the true representative of
interstitial lung fluids, pleural fluid or simulated lung fluid (SLF) (Gamble 1967). The
composition of SLF is summarised in table 4.2. As there are higher numbers of ions and
higher ionic strength (with the same pH of 7.3-7.6, as pleural fluid) it was presumed
that depending on polymer chemistry these materials would degrade to different extents.
This is why there was a need to study the comparative polymer degradation in PBS and
SLF, both of which provide 100% relative humidity (aqueous environment), pH 7.4±O.l
and physiological temperature (37°C). The results of polymer degradation under these
conditions are discussed below.
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4.3.2.1 Effect of polymer chemistry in simulated physiological fluids
For the in vitro degradation studies, the oxoester-containing PGA-co-PDL and the
thioester-containing PDTTA-co-PDL were compared. Both polymers were in direct
contact with the aqueous media (SLF and PBS), hence, all labile ester bonds on the
polymer backbone had the potential to degrade via hydrolysis in a short time. It is well
established that the thioester link is more readily hydrolysable than the oxoester,
because of its high reactivity due to the polarity of the bonds (Figure 4.17) and
delocalisation of electrons. Thioesters show high reactivity in base and enzyme
catalysed hydrolysis (Aarsman & Den Bosch 1979).
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Figure 4.17: Bond polarities in oxoester (left) and thioester (right)
Figures 4.18 and 4.19 summarise the results of the in vitro degradation of PGA-co-PDL
(powder) and PDTTA-co-PDL (powder) in two different physiological fluids. PDTTA-
co-PDL degraded more rapidly and to a greater extent than PGA-co-PDL. This is in
accordance with the hypothesis (chapter 2, section 2.3.3.4) that thioesters can degrade
more quickly and more completely in vitro and, hence, are potentially more suitable
candidates for drug delivery applications. Moreover, the degradation of thioester-based
polymers is in accordance with observations reported by Aarsman & Den Bosch (1979)
that the hydrolysis rate of thioesters is 2-5 times higher than that of the corresponding
oxoesters.
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Figure 4.18: In vitro degradationprojile ofPGA-co-PDL and PDTTA-co-PDL at 370(;
in SLF buffer during six weeks
It is clear from figures 4.18 and 4.19 that the molecular weight of the PDTTA-co-PDL
continuously decreased but the PGA-co-PDL did not show a consistent trend in the
change of molecular weight. However, this non-consistent trend can be explained by
the fact that both SLF and PBS contain various ions, but the ionic strength is higher in
SLF than in PBS (although the pH is the same). In such cases there is a possibility of
interaction between metal ions and electron rich functional groups which may lead to
chelation where highly electropositive metal ions (from buffers) can form a complex or
chelate with electronegative oxygen atoms in the carbonyl groups of the oxoester-based
polymer.
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Figure 4.19: In vitro degradation profile of PGA-co-PDL and PDTTA-co-PDL at 370C
in PBS buffer during six weeks
Figure 4.17 illustrate the electron densities around the carbonyl group, as oxygen is
more electron rich than the sulphur in the corresponding thioesters. Hence, it provides a
base for a hypothesis that the proposed metal-polymer chelation (which would result in
higher molecular weight products) and polymer degradation via hydrolysis (resulting in
decrease in polymer molecular weight) would proceed at the same time. An example in
support of this assumption is the work done by Chung et al (2004), where TiCI4, a
Lewis acid, chelates with the ester carbonyl moiety in non-aqueous media. This
hypothesis may explain the varying trends in molecular weight of oxoester-based
polymer, but thorough investigations are required to confirm any such interaction in
polymers discussed in presented work.
The implication of these results can further be seen from the OPC chromatograms of
both polymers after six months in PBS and SLF (Figure 4.20 and 4.21). It is evident
that peaks corresponding to POA-co-PDL after six months storage are broader when
compared to the starting polymers in both fluids indicating an increase in polydispersity.
Shifting of the peaks towards the right hand side indicates an increase in molecular
weight of the polymer after six months (Figure 4.20).
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Figure 4.20: GPC chromatogram of PGA-co-PDL (black) after six weeks storage in
PBS (green) and in SLF (red) at 370('
On the other hand, PDTTA-co-PDL peaks moved towards the right hand side (higher
retention volume) along with considerable peak broadening. This indicates higher
degradation in both fluids, but in SLF the degradation is much greater than in PBS
(Figure 4.21). These results prove that thioesters are more biodegradable than oxoesters.
They also suggest that for in vitro degradation studies of materials for pulmonary drug
delivery, the use of PBS can give misleading trends and observations. Hence, for
pulmonary applications, SLF should be used instead of PBS as the simulated
physiological fluid. While for other applications, such as oral delivery or intravenous
delivery, the actual simulated fluid should be use instead of a model buffer, PBS.
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Figure 4.21: GPC chromatogram oJPDTTA-co-PDL (black) after six weeks storage in
PBS (red) and in SLF (green) at 370('
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4.3.2.2 Effect of surface area/particle sizes
Another very important factor which usually is often neglected while studying in vitro
polymer degradation is the fmal dosage form of the biomaterial. Depending upon
application, these materials are usually formulated either as microparticles or
nanoparticles, but researchers often only use the raw polymeric material for degradation
studies (Gopferich & Langer 1993). This is a source of misleading data on the
biodegradability of polymeric materials, because after formulating into micro- and
nanoparticles the surface area of these materials increases several fold. Hence, this
could lead to further increases in the rate and extent of degradation. Based on this
hypothesis, PGA-co-PDL matrix and microparticles were subjected to degradation
studies under SLF and PBS conditions. The obtained results confirmed the hypothesis
that smaller particles with a larger surface area; degrade more quickly and to a greater
extent.
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Figure 4.22: In vitro degradation profile of PGA-co-PDL and its microparticles at
37 OCin SLF during six months
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Figures 4.22 and 4.23 represent the degradation of two forms of the PGA-co-PDL
material in the two simulated fluids. It is very interesting to see that PGA-co-PDL,
which exhibited an inconsistent degradation trend in its normal matrix form, completely
degraded within six weeks when formulated into microparticles. This proves that PGA-
co-PDL (oxoester) can completely degrade in its final dosage forms, hence making it a
good candidate for drug delivery applications.
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Figure 4.23: In vitro degradation profile of PGA -co-PDL and its microparticles at
37°C in PBS during six months
One more important point to note here is the complete degradation of the micro-
particles in both fluids. This further helps to conclude that by increasing the surface area,
hydrolysis is promoted and this is why the polymer degrades completely, instead of
increasing in molecular weight. The GPC chromatograms of microparticle degradation
(Figure 4.24) further prove the degradation of the particles in two simulated
physiological fluids.
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Figure 4.24: GPC chromatogram oj PGA-co-PDL microparticies (black) after six
weeks storage in PBS (green) and in SLF (red) at 37 OC
The results discussed in this chapter provide an understanding of the in vitro
degradation of polymers bearing varying chemistry and physical forms under different
simulated physiological fluids. The hydrolytic degradation of these polymers proceed
predominantly via random chain scissions (Wang et al 1990). The other major step
which is involved in later stages of hydrolytic degradation is conversion back to
monomeric units; a schematic representation of this is given in chapter 1 (Figure 1.9).
However, the GPC traces of polymer degradation did not show any small molecular
fragments or monomeric peaks, instead the whole peak had shifted to a lower molecular
weight scale along with peak broadening (indicated by an increase in PDI). Hence, it
was concluded that the predominant step in this polymer degradation is random chain
SCISSion.
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An additional aspect of polymer degradation under in vitro conditions is the
biodegradability of these polymers. The polymers are potential drug carriers and their
complete biodegradation under physiological conditions is a prime concern for
formulation developers, hence polymers with varying biodegradation rates are
synthesised for specific drug delivery applications. For example, PLGA is rapidly
biodegradable, which makes it useful in vaccine delivery applications (Wang et al 1990),
and it degrades rapidly via "self-catalysis" while polycaprolactone (peL), another FDA-
approved biomaterial, needs an external catalyst or initiator for degradation, resulting in
relatively slower degradation. Hence, peL is mainly used in tissue scaffolds, but also
has uses as drug delivery devices (for example as sutures, marketed under the brand
name Monocrylf) (Bezwada et al 1995).
The results obtained for PGA-co-PDL indicated its slower degradation (over 6 weeks)
compared to PLGA under in vitro conditions. Under similar conditions to those in this
study, Lu et al (1999) reported that 94% PLGA (matrix) degraded in 4 weeks, while
data obtained in the current work showed that no significant decrease in PGA-co-PDL
molecular weight was observed. Hence, it can be concluded that although PGA-co-PDL
is biodegradable like peL, it does not degrade as rapidly as PLGA in its matrix form.
The degradation of PGA-co-PDL can be altered not only by formulating it into various
particle sizes but also by changing the monomer composition, molecular weight and
copolymer ratio. In addition, if the type of ester link is changed from oxoester to
thioester, it would increase the degradation rate, hence providing a solution for delayed
degradation in the lung environment. PBS should be avoided for use as a simulated fluid
for pulmonary drug delivery applications, because pH is not the only factor/criteria for a
fluid to be representative of physiological environment. The presence of different ions
and ionic strengths should be considered while formulating a simulated fluid. For
degradation studies the final dosage forms should be used instead of raw material.
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These results not only help to understand the various physical and chemical factors
affecting in vitro degradation behaviour but also inform the design of biomaterials with
desired degradation rates. These results indicate that polymer degradation ends in
monomeric species which are non toxic in nature and can easily be excreted via various
physiological pathways.
4.4 CONCLUSION
In conclusion, these results clearly indicate that these polymers can be stable if stored
under appropriate conditions but are also biodegradable. Their degradation is affected
by both their chemistry (hydrophilicity, molecular weight, carbon chain length,
functional groups and type of ester link) and storage factors (temperature, humidity and
light).
a) Recommended storage conditions
To achieve stable polymers with long shelf lives, they should be stored in dark
containers at temperatures near or below 4°C, under drying conditions. Although all the
polymers studied under the suggested conditions will remain stable for more than 1 year,
they need to be re-analysed at 6 monthly intervals, to check their stability and
degradation indications. For drug delivery applications polymers with longer shelf-lives
(4-5 years) are desired, hence, there is a need for stability testing of such polymers for
longer durations.
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b) Chemistry of the polymers
Depending upon the application of these biomaterials, the degradation and stability of
the polymers can be controlled by altering the chain length, presence of functional
groups, molecular weight and the type ofhydrolysable ester link.
c) In vitro degradation
These polymers are biodegradable under simulated physiological conditions. However,
the in vitro degradation studies for pulmonary applications should be carried out in SLF
rather than commonly used simulated physiological fluid, PBS, using the final dosage
form of the biomaterials.
Although only five polymers of varying chemistries were studied here, the degradation
processes and trends are applicable for many other polymer-based drug delivery
systems studied in this research. The obtained data provide an understanding of the
degradation process and enables selection of appropriate chemical parameters for the
development of stable and biodegradable polymers. These studies also help draw basic
guidelines for recommended storage conditions and shelf lives of the synthesised library
of polyesters. This information can be used to achieve a longer shelf life and increased
stability of the particles prepared from these polymers. This should provide better
control of shelf life and in vitro degradation of the formulations. Based on these results,
these particles can be further explored for in vivo applications.
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5.0 General conclusion and future work
The aim of developing an effective polymeric drug delivery system via the enzyme
catalysed synthesis of a series of polymers, possessing a range of physicochemical
properties, was successfully achieved and subsequently investigated for drug delivery
and degradation in vitro.
To develop effective candidates for drug delivery applications, novel polymeric
materials were synthesised using simple, biocompatible and FDA-approved monomeric
units and formulated into stable microparticles containing a range of drugs of various
solubilities and molecular sizes. The devised polymeric systems released the drugs at
various rates depending on the polymer/drug chemistry and interactions. Hence, drug
release was varied by altering a range of physicochemical properties of the polymeric
materials including molecular weight, melting temperature, hydrophilicity, availability
of free functional groups and post-synthetic modifications.
The range of synthesised polymers showed varying rates of release of poorly water-
soluble drugs from microparticles as compared to PLGA-based systems, depending on
the hydrophilicity of polymers, indicating the successful development of new polymeric
drug delivery systems compared to existing FDA-approved materials. The materials'
physical properties played a vital role in controlling drug encapsulation and drug
release. A polymer with a lower Tg value (near physiological temperature) released
drugs at higher rates. However, making the polymer more hydrophobic, by attaching a
non-polar chemical moiety to the backbone, resulted in considerably slower drug
release. These two factors, Tg and hydrophilicity, might therefore be ''tuned'' to control
the drug release at a required rate.
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The developed polymeric systems can not only encapsulate drugs with a range of water
solubilities. However, drugs with very high water solubilities could not be encapsulated
via solvent emulsion techniques. To solve this issue, the use of alternative techniques
such as spray drying, interfacial deposition and/or conjugation to the functionalised
polymer backbone could be explored in future.
Altering the polymer chemistry by introducing monomers, such as PEG or thioesters
was also shown to affect the drug encapsulation and rate of release. There is a need for
further studies to exploit the use of such monomers for the improvement of
micropartic1e formulation. For example, the synthesis of copolymers with increased
PEG content may enable the formulation of particles via the solvent emulsion technique
without requiring an external surfactant or emulsion stabilizer. Although, polythioesters
were synthesised successfully and showed improved degradation rates and better
thermo-chemical properties, these materials failed to encapsulate drugs. However,
because of the much improved physicochemical properties there is a need to investigate
these materials further for successful micropartic1e formulation, either via spray drying,
interfacical deposition or by altering the chemistry of the polymer backbone to afford
better mechanical strength.
PBS is the most commonly used buffer for in vitro drug-release studies, hence it was
used to obtain drug-release profiles. However, because the polymer degradation rates
were different in PBS and SLF, this indicates the need for the use of SLF as a
"physiological fluid", especially for pulmonary drug delivery studies. SLF would be a
better and more realistic physiological fluid because it contains the same ionic strength
as the lung environment. The difference of true ionic strength between PBS and SLF
can affect the polymer-medium interaction and can give realistic drug release profiles.
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Overall these studies have been explorative in nature for the development of novel
biodegradable polyesters with longer shelf-lives for a broad range of colloidal drug-
delivery applications. The devised systems showed promising results in in vitro
environments and hence, need to be further investigated in vivo.
Suggestions for future work
Based on the observations in this project, further work could be carried out to obtain a
better understanding of different variables for improvement in the developed drug-
delivery system. It was observed that small incremental changes in polymer chemistry
did not show significant effects on drug encapsulation and release. Hence, there is a
need for altering the polymer properties by evaluating a range of new monomers to
extend the library of polymers, which can be tailored according to the application. In
addition, to further prove and understand the efficacy of the developed polymeric
system, these polymers should be evaluated for the delivery of a range of therapeutic
agents, such as drugs, enzymes and genes. The obtained feedback can then be used to
understand and improve the design of the drug delivery system by tuning the polymer-
drug chemistry. To achieve these aims, some of the suggested studies are as follows;
1. Synthesis of polymers with new pendant functional groups such as amine and
carboxylate for attachment of a range of drug molecules. This can be achieved
by use of functionalised monomers via enzyme catalysis.
2. Synthesis of PEG copolymers with higher PEG content to assist the drug
loaded microparticulate formulation.
3. Synthesis of polythioesters with better physico-mechanical properties, such as
higher Tm and crystallinity. This can be achieved by either using higher lactone
contents during synthesis or by conjugating non-polar chemical moieties to the
functionalised polymer backbone.
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4. Use of various other techniques, such as spray-drying and interfacial
disposition for the encapsulation of freely water-soluble drugs into
microparticles. This also allows the use of viscous polymers for drug delivery
applications.
5. Use of better particle characterisation techniques, such as;
a. Zetasizer: for surface charges, zeta potential measurement
b. Laser diffraction particle sizer: for actual particle sizes and fine particle
fraction measurement
c. Transmission electron microscopy
d. Confocal microscopy
6. Use of SLF for release studies in pulmonary drug delivery, instead of using
PBS.
7. Detailed qualitative analysis of polymer degradation to estimate the toxicity of
the by-products.
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